bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Paxillin, GST, SH2, Grb2, SH2	1.0alpha7.train.59_task2	Sentence: Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules. Instructions: please extract entity words from the input sentence	[ "B-protein", "O", "O", "O", "B-experiment-tag", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O" ]	Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules.	[ "Paxillin", "failed", "to", "bind", "GST", "alone", "or", "the", "SH2", "domain", "of", "Grb2", "that", "belongs", "to", "the", "family", "of", "SH2", "/", "SH3-containing", "signaling", "molecules", "." ]	[ "protein", "protein-domain", "experiment-tag" ]
germline TaqI restriction fragment length polymorphism is a DNA_domain_or_region, progesterone receptor gene is a DNA_domain_or_region, ovarian carcinoma is an other_name	8248_task0	Sentence: A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name	[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "O", "O", "O", "O" ]	A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments]	[ "A", "germline", "TaqI", "restriction", "fragment", "length", "polymorphism", "in", "the", "progesterone", "receptor", "gene", "in", "ovarian", "carcinoma", "[", "see", "comments", "]" ]	[ "DNA_domain_or_region", "DNA_molecule", "DNA_family_or_group", "other_name", "protein_family_or_group", "multi_cell", "DNA_N/A" ]
germline TaqI restriction fragment length polymorphism is a DNA_domain_or_region, progesterone receptor gene is a DNA_domain_or_region, ovarian carcinoma is an other_name	8248_task1	Sentence: A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments] Instructions: please typing these entity words according to sentence: germline TaqI restriction fragment length polymorphism, progesterone receptor gene, ovarian carcinoma Options: DNA_domain_or_region, other_name	[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "O", "O", "O", "O" ]	A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments]	[ "A", "germline", "TaqI", "restriction", "fragment", "length", "polymorphism", "in", "the", "progesterone", "receptor", "gene", "in", "ovarian", "carcinoma", "[", "see", "comments", "]" ]	[ "DNA_domain_or_region", "DNA_molecule", "DNA_family_or_group", "other_name", "protein_family_or_group", "multi_cell", "DNA_N/A" ]
germline TaqI restriction fragment length polymorphism, progesterone receptor gene, ovarian carcinoma	8248_task2	Sentence: A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments] Instructions: please extract entity words from the input sentence	[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "O", "O", "O", "O" ]	A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments]	[ "A", "germline", "TaqI", "restriction", "fragment", "length", "polymorphism", "in", "the", "progesterone", "receptor", "gene", "in", "ovarian", "carcinoma", "[", "see", "comments", "]" ]	[ "DNA_domain_or_region", "DNA_molecule", "DNA_family_or_group", "other_name", "protein_family_or_group", "multi_cell", "DNA_N/A" ]
imaging is an umlsterm, MRI is an umlsterm, role is an umlsterm, endoscopy is an umlsterm, laryngeal neoplasms is an umlsterm, knowledge is an umlsterm, familiarity is an umlsterm, diagnostic is an umlsterm, signs is an umlsterm, imaging is an umlsterm, treatment is an umlsterm, imaging is an umlsterm, cartilage is an umlsterm, value is an umlsterm, MRI is an umlsterm, cartilage is an umlsterm, specificity is an umlsterm, MRI is an umlsterm, methods is an umlsterm, tumor is an umlsterm, imaging is an umlsterm, methods is an umlsterm, tumors is an umlsterm, clinical examination is an umlsterm, biopsy is an umlsterm, MRI is an umlsterm, role is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, diagnosis is an umlsterm	DerRadiologe.80380093.eng.abstr_task0	Sentence: Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis .	[ "Cross", "-", "sectional", "imaging", "with", "CT", "and", "MRI", "plays", "an", "indispensable", "complementary", "role", "to", "endoscopy", "in", "the", "pretherapeutic", "workup", "and", "staging", "of", "laryngeal", "neoplasms", ".", "Adequate", "interpretation", "of", "the", "CT", "and", "MR", "images", "requires", "a", "thorough", "knowledge", "of", "the", "patterns", "of", "submucosal", "spread", "and", "familiarity", "with", "the", "diagnostic", "signs", "of", "neoplastic", "invasion", "as", "seen", "with", "each", "modality", ".", "In", "addition", ",", "the", "radiologist", "should", "be", "aware", "of", "the", "implications", "of", "imaging", "for", "staging", "and", "treatment", ".", "Both", "CT", "and", "MR", "imaging", "are", "highly", "sensitive", "for", "the", "detection", "of", "neoplastic", "invasion", "of", "the", "pre", "-", "epiglottic", "space", ",", "paraglottic", "space", ",", "subglottic", "region", "and", "cartilage", ".", "The", "high", "negative", "predictive", "value", "of", "both", "CT", "and", "MRI", "allows", "exclusion", "of", "neoplastic", "cartilage", "invasion", "quite", "reliably", ".", "The", "specificity", "of", "both", "CT", "and", "MRI", "is", ",", "however", ",", "limited", "and", "both", "methods", "may", "therefore", "overestimate", "the", "extent", "of", "tumor", "spread", ".", "Nevertheless", ",", "both", "cross", "-", "sectional", "imaging", "methods", "significantly", "improve", "the", "pretherapeutic", "staging", "accuracy", "of", "laryngeal", "tumors", "if", "used", "in", "addition", "to", "clinical", "examination", "and", "endoscopic", "biopsy", ".", "In", "the", "presence", "of", "a", "submucosal", "mass", ",", "CT", "and", "MRI", "play", "a", "key", "role", "for", "the", "diagnosis", ",", "as", "they", "may", "characterize", "the", "lesion", ",", "reliably", "depict", "its", "submucosal", "extent", ",", "and", "guide", "the", "endoscopist", "to", "perform", "deep", "biopsies", "that", "allow", "a", "definitive", "histological", "diagnosis", "." ]	[ "umlsterm" ]
imaging is an umlsterm, MRI is an umlsterm, role is an umlsterm, endoscopy is an umlsterm, laryngeal neoplasms is an umlsterm, knowledge is an umlsterm, familiarity is an umlsterm, diagnostic is an umlsterm, signs is an umlsterm, imaging is an umlsterm, treatment is an umlsterm, imaging is an umlsterm, cartilage is an umlsterm, value is an umlsterm, MRI is an umlsterm, cartilage is an umlsterm, specificity is an umlsterm, MRI is an umlsterm, methods is an umlsterm, tumor is an umlsterm, imaging is an umlsterm, methods is an umlsterm, tumors is an umlsterm, clinical examination is an umlsterm, biopsy is an umlsterm, MRI is an umlsterm, role is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, diagnosis is an umlsterm	DerRadiologe.80380093.eng.abstr_task1	Sentence: Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis . Instructions: please typing these entity words according to sentence: imaging, MRI, role, endoscopy, laryngeal neoplasms, knowledge, familiarity, diagnostic, signs, imaging, treatment, imaging, cartilage, value, MRI, cartilage, specificity, MRI, methods, tumor, imaging, methods, tumors, clinical examination, biopsy, MRI, role, diagnosis, biopsies, diagnosis Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis .	[ "Cross", "-", "sectional", "imaging", "with", "CT", "and", "MRI", "plays", "an", "indispensable", "complementary", "role", "to", "endoscopy", "in", "the", "pretherapeutic", "workup", "and", "staging", "of", "laryngeal", "neoplasms", ".", "Adequate", "interpretation", "of", "the", "CT", "and", "MR", "images", "requires", "a", "thorough", "knowledge", "of", "the", "patterns", "of", "submucosal", "spread", "and", "familiarity", "with", "the", "diagnostic", "signs", "of", "neoplastic", "invasion", "as", "seen", "with", "each", "modality", ".", "In", "addition", ",", "the", "radiologist", "should", "be", "aware", "of", "the", "implications", "of", "imaging", "for", "staging", "and", "treatment", ".", "Both", "CT", "and", "MR", "imaging", "are", "highly", "sensitive", "for", "the", "detection", "of", "neoplastic", "invasion", "of", "the", "pre", "-", "epiglottic", "space", ",", "paraglottic", "space", ",", "subglottic", "region", "and", "cartilage", ".", "The", "high", "negative", "predictive", "value", "of", "both", "CT", "and", "MRI", "allows", "exclusion", "of", "neoplastic", "cartilage", "invasion", "quite", "reliably", ".", "The", "specificity", "of", "both", "CT", "and", "MRI", "is", ",", "however", ",", "limited", "and", "both", "methods", "may", "therefore", "overestimate", "the", "extent", "of", "tumor", "spread", ".", "Nevertheless", ",", "both", "cross", "-", "sectional", "imaging", "methods", "significantly", "improve", "the", "pretherapeutic", "staging", "accuracy", "of", "laryngeal", "tumors", "if", "used", "in", "addition", "to", "clinical", "examination", "and", "endoscopic", "biopsy", ".", "In", "the", "presence", "of", "a", "submucosal", "mass", ",", "CT", "and", "MRI", "play", "a", "key", "role", "for", "the", "diagnosis", ",", "as", "they", "may", "characterize", "the", "lesion", ",", "reliably", "depict", "its", "submucosal", "extent", ",", "and", "guide", "the", "endoscopist", "to", "perform", "deep", "biopsies", "that", "allow", "a", "definitive", "histological", "diagnosis", "." ]	[ "umlsterm" ]
imaging, MRI, role, endoscopy, laryngeal neoplasms, knowledge, familiarity, diagnostic, signs, imaging, treatment, imaging, cartilage, value, MRI, cartilage, specificity, MRI, methods, tumor, imaging, methods, tumors, clinical examination, biopsy, MRI, role, diagnosis, biopsies, diagnosis	DerRadiologe.80380093.eng.abstr_task2	Sentence: Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis .	[ "Cross", "-", "sectional", "imaging", "with", "CT", "and", "MRI", "plays", "an", "indispensable", "complementary", "role", "to", "endoscopy", "in", "the", "pretherapeutic", "workup", "and", "staging", "of", "laryngeal", "neoplasms", ".", "Adequate", "interpretation", "of", "the", "CT", "and", "MR", "images", "requires", "a", "thorough", "knowledge", "of", "the", "patterns", "of", "submucosal", "spread", "and", "familiarity", "with", "the", "diagnostic", "signs", "of", "neoplastic", "invasion", "as", "seen", "with", "each", "modality", ".", "In", "addition", ",", "the", "radiologist", "should", "be", "aware", "of", "the", "implications", "of", "imaging", "for", "staging", "and", "treatment", ".", "Both", "CT", "and", "MR", "imaging", "are", "highly", "sensitive", "for", "the", "detection", "of", "neoplastic", "invasion", "of", "the", "pre", "-", "epiglottic", "space", ",", "paraglottic", "space", ",", "subglottic", "region", "and", "cartilage", ".", "The", "high", "negative", "predictive", "value", "of", "both", "CT", "and", "MRI", "allows", "exclusion", "of", "neoplastic", "cartilage", "invasion", "quite", "reliably", ".", "The", "specificity", "of", "both", "CT", "and", "MRI", "is", ",", "however", ",", "limited", "and", "both", "methods", "may", "therefore", "overestimate", "the", "extent", "of", "tumor", "spread", ".", "Nevertheless", ",", "both", "cross", "-", "sectional", "imaging", "methods", "significantly", "improve", "the", "pretherapeutic", "staging", "accuracy", "of", "laryngeal", "tumors", "if", "used", "in", "addition", "to", "clinical", "examination", "and", "endoscopic", "biopsy", ".", "In", "the", "presence", "of", "a", "submucosal", "mass", ",", "CT", "and", "MRI", "play", "a", "key", "role", "for", "the", "diagnosis", ",", "as", "they", "may", "characterize", "the", "lesion", ",", "reliably", "depict", "its", "submucosal", "extent", ",", "and", "guide", "the", "endoscopist", "to", "perform", "deep", "biopsies", "that", "allow", "a", "definitive", "histological", "diagnosis", "." ]	[ "umlsterm" ]
PTCA is an umlsterm, patients is an umlsterm, staff 's is an umlsterm, hospital costs is an umlsterm, length of stay is an umlsterm, safety is an umlsterm, hemostatic is an umlsterm, collagen is an umlsterm, device is an umlsterm, complications is an umlsterm, device is an umlsterm, old is an umlsterm, female is an umlsterm, patient is an umlsterm, weight is an umlsterm, PTCA is an umlsterm, anterior is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm, device is an umlsterm, standard is an umlsterm, technique is an umlsterm, device is an umlsterm, device is an umlsterm, hemostasis is an umlsterm, heparin is an umlsterm, protamine is an umlsterm, complications is an umlsterm, hemostasis is an umlsterm, patient is an umlsterm, symptoms is an umlsterm, right is an umlsterm, femoral artery is an umlsterm, patient is an umlsterm, vascular surgery is an umlsterm, collagen is an umlsterm, surgery is an umlsterm	ZfuerKardiologie.80870051.eng.abstr_task0	Sentence: Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery .	[ "Removal", "of", "the", "arterial", "sheath", "immediately", "after", "PTCA", "is", "desirable", "for", "patients", ",", "reduces", "the", "medical", "staff", "'s", "workload", ",", "and", "may", "decrease", "hospital", "costs", "due", "to", "a", "shortened", "length", "of", "stay", ".", "Although", "the", "safety", "and", "efficacy", "of", "the", "hemostatic", "systems", "used", "especially", "for", "the", "above", "purpose", "have", "been", "sufficiently", "documented", ",", "inadvertent", "intraluminal", "vascular", "occlusion", "is", "theoretically", "possible", ".", "While", "partial", "or", "complete", "arterial", "occlusion", "in", "conjunction", "with", "the", "VasoSeal", "collagen", "prototype", "device", "has", "been", "previously", "reported", ",", "similar", "complications", "occurring", "with", "the", "Angio", "-", "SealTM", "device", "were", "not", "published", ".", "In", "this", "report", ",", "we", "describe", "a", "54-year", "old", "female", "patient", "(", "height", ":", "150", "cm", ",", "weight", ":", "42.5", "kg", ")", "who", "was", "transferred", "for", "PTCA", "following", "an", "acute", "anterior", "wall", "myocardial", "infarction", ".", "Immediately", "after", "PTCA", ",", "the", "Angio", "-", "SealTM", "device", "was", "deployed", "utilizing", "standard", "technique", ".", "No", "difficulties", "were", "encountered", "during", "device", "deployment", ",", "however", ",", "immediately", "following", "device", "placement", "active", "arterial", "bleeding", "occurred", ".", "Due", "to", "the", "inadequacy", "of", "hemostasis", ",", "heparin", "was", "reversed", "with", "protamine", "to", "avoid", "further", "hemorrhagic", "complications", ".", "Following", "this", ",", "the", "desired", "hemostasis", "quickly", "occurred", ",", "but", "the", "patient", "soon", "complained", "about", "symptoms", "suggestive", "of", "an", "acute", "occlusion", "of", "the", "right", "femoral", "artery", ".", "Unsatisfactory", "attempts", "as", "lysis", "resulted", "in", "the", "patient", "being", "transferred", "to", "vascular", "surgery", ".", "The", "complete", "Angio", "-", "SealTM", "system", "(", "anchor", "including", "collagen", ")", "was", "located", "intravasculary", ",", "and", "removed", "during", "surgery", "." ]	[ "umlsterm" ]
PTCA is an umlsterm, patients is an umlsterm, staff 's is an umlsterm, hospital costs is an umlsterm, length of stay is an umlsterm, safety is an umlsterm, hemostatic is an umlsterm, collagen is an umlsterm, device is an umlsterm, complications is an umlsterm, device is an umlsterm, old is an umlsterm, female is an umlsterm, patient is an umlsterm, weight is an umlsterm, PTCA is an umlsterm, anterior is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm, device is an umlsterm, standard is an umlsterm, technique is an umlsterm, device is an umlsterm, device is an umlsterm, hemostasis is an umlsterm, heparin is an umlsterm, protamine is an umlsterm, complications is an umlsterm, hemostasis is an umlsterm, patient is an umlsterm, symptoms is an umlsterm, right is an umlsterm, femoral artery is an umlsterm, patient is an umlsterm, vascular surgery is an umlsterm, collagen is an umlsterm, surgery is an umlsterm	ZfuerKardiologie.80870051.eng.abstr_task1	Sentence: Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery . Instructions: please typing these entity words according to sentence: PTCA, patients, staff 's, hospital costs, length of stay, safety, hemostatic, collagen, device, complications, device, old, female, patient, weight, PTCA, anterior, myocardial infarction, PTCA, device, standard, technique, device, device, hemostasis, heparin, protamine, complications, hemostasis, patient, symptoms, right, femoral artery, patient, vascular surgery, collagen, surgery Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery .	[ "Removal", "of", "the", "arterial", "sheath", "immediately", "after", "PTCA", "is", "desirable", "for", "patients", ",", "reduces", "the", "medical", "staff", "'s", "workload", ",", "and", "may", "decrease", "hospital", "costs", "due", "to", "a", "shortened", "length", "of", "stay", ".", "Although", "the", "safety", "and", "efficacy", "of", "the", "hemostatic", "systems", "used", "especially", "for", "the", "above", "purpose", "have", "been", "sufficiently", "documented", ",", "inadvertent", "intraluminal", "vascular", "occlusion", "is", "theoretically", "possible", ".", "While", "partial", "or", "complete", "arterial", "occlusion", "in", "conjunction", "with", "the", "VasoSeal", "collagen", "prototype", "device", "has", "been", "previously", "reported", ",", "similar", "complications", "occurring", "with", "the", "Angio", "-", "SealTM", "device", "were", "not", "published", ".", "In", "this", "report", ",", "we", "describe", "a", "54-year", "old", "female", "patient", "(", "height", ":", "150", "cm", ",", "weight", ":", "42.5", "kg", ")", "who", "was", "transferred", "for", "PTCA", "following", "an", "acute", "anterior", "wall", "myocardial", "infarction", ".", "Immediately", "after", "PTCA", ",", "the", "Angio", "-", "SealTM", "device", "was", "deployed", "utilizing", "standard", "technique", ".", "No", "difficulties", "were", "encountered", "during", "device", "deployment", ",", "however", ",", "immediately", "following", "device", "placement", "active", "arterial", "bleeding", "occurred", ".", "Due", "to", "the", "inadequacy", "of", "hemostasis", ",", "heparin", "was", "reversed", "with", "protamine", "to", "avoid", "further", "hemorrhagic", "complications", ".", "Following", "this", ",", "the", "desired", "hemostasis", "quickly", "occurred", ",", "but", "the", "patient", "soon", "complained", "about", "symptoms", "suggestive", "of", "an", "acute", "occlusion", "of", "the", "right", "femoral", "artery", ".", "Unsatisfactory", "attempts", "as", "lysis", "resulted", "in", "the", "patient", "being", "transferred", "to", "vascular", "surgery", ".", "The", "complete", "Angio", "-", "SealTM", "system", "(", "anchor", "including", "collagen", ")", "was", "located", "intravasculary", ",", "and", "removed", "during", "surgery", "." ]	[ "umlsterm" ]
PTCA, patients, staff 's, hospital costs, length of stay, safety, hemostatic, collagen, device, complications, device, old, female, patient, weight, PTCA, anterior, myocardial infarction, PTCA, device, standard, technique, device, device, hemostasis, heparin, protamine, complications, hemostasis, patient, symptoms, right, femoral artery, patient, vascular surgery, collagen, surgery	ZfuerKardiologie.80870051.eng.abstr_task2	Sentence: Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery .	[ "Removal", "of", "the", "arterial", "sheath", "immediately", "after", "PTCA", "is", "desirable", "for", "patients", ",", "reduces", "the", "medical", "staff", "'s", "workload", ",", "and", "may", "decrease", "hospital", "costs", "due", "to", "a", "shortened", "length", "of", "stay", ".", "Although", "the", "safety", "and", "efficacy", "of", "the", "hemostatic", "systems", "used", "especially", "for", "the", "above", "purpose", "have", "been", "sufficiently", "documented", ",", "inadvertent", "intraluminal", "vascular", "occlusion", "is", "theoretically", "possible", ".", "While", "partial", "or", "complete", "arterial", "occlusion", "in", "conjunction", "with", "the", "VasoSeal", "collagen", "prototype", "device", "has", "been", "previously", "reported", ",", "similar", "complications", "occurring", "with", "the", "Angio", "-", "SealTM", "device", "were", "not", "published", ".", "In", "this", "report", ",", "we", "describe", "a", "54-year", "old", "female", "patient", "(", "height", ":", "150", "cm", ",", "weight", ":", "42.5", "kg", ")", "who", "was", "transferred", "for", "PTCA", "following", "an", "acute", "anterior", "wall", "myocardial", "infarction", ".", "Immediately", "after", "PTCA", ",", "the", "Angio", "-", "SealTM", "device", "was", "deployed", "utilizing", "standard", "technique", ".", "No", "difficulties", "were", "encountered", "during", "device", "deployment", ",", "however", ",", "immediately", "following", "device", "placement", "active", "arterial", "bleeding", "occurred", ".", "Due", "to", "the", "inadequacy", "of", "hemostasis", ",", "heparin", "was", "reversed", "with", "protamine", "to", "avoid", "further", "hemorrhagic", "complications", ".", "Following", "this", ",", "the", "desired", "hemostasis", "quickly", "occurred", ",", "but", "the", "patient", "soon", "complained", "about", "symptoms", "suggestive", "of", "an", "acute", "occlusion", "of", "the", "right", "femoral", "artery", ".", "Unsatisfactory", "attempts", "as", "lysis", "resulted", "in", "the", "patient", "being", "transferred", "to", "vascular", "surgery", ".", "The", "complete", "Angio", "-", "SealTM", "system", "(", "anchor", "including", "collagen", ")", "was", "located", "intravasculary", ",", "and", "removed", "during", "surgery", "." ]	[ "umlsterm" ]
active is a Qualifier, respiratory , cardiovascular or other disease is a Scope, requiring is a Mood, treatment is a Procedure, relevant is a Mood, tolerance is a Condition, hypoxia or altitude exposure is a Scope, heavy smoking is a Condition, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years is a Scope, regular use of alcohol is a Condition, Allergy is a Condition, acetazolamide and other sulfonamides is a Scope	NCT03537924_exc_task0	Sentence: Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Procedure, Scope, Mood	[ "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Mood", "O", "B-Procedure", "O", "O", "O", "B-Mood", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides.	[ "Any", "active", "respiratory", ",", "cardiovascular", "or", "other", "disease", "requiring", "regular", "treatment", "or", "being", "otherwise", "relevant", "for", "tolerance", "of", "hypoxia", "or", "altitude", "exposure", ".", "\n", "Any", "condition", "that", "may", "interfere", "with", "protocol", "compliance", "including", "current", "heavy", "smoking", "(", ">", "20", "cigarettes", "per", "day", "or", ">", "20", "pack", "-", "years", "with", "active", "smoking", "during", "the", "last", "10", "years", ")", ",", "regular", "use", "of", "alcohol", ".", "\n", "Allergy", "to", "acetazolamide", "and", "other", "sulfonamides", ".", "\n" ]	[ "Scope", "Temporal", "Condition", "Measurement", "Drug", "Mood", "Procedure", "Qualifier", "Value" ]
active is a Qualifier, respiratory , cardiovascular or other disease is a Scope, requiring is a Mood, treatment is a Procedure, relevant is a Mood, tolerance is a Condition, hypoxia or altitude exposure is a Scope, heavy smoking is a Condition, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years is a Scope, regular use of alcohol is a Condition, Allergy is a Condition, acetazolamide and other sulfonamides is a Scope	NCT03537924_exc_task1	Sentence: Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides. Instructions: please typing these entity words according to sentence: active, respiratory , cardiovascular or other disease, requiring, treatment, relevant, tolerance, hypoxia or altitude exposure, heavy smoking, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years, regular use of alcohol, Allergy, acetazolamide and other sulfonamides Options: Condition, Qualifier, Procedure, Scope, Mood	[ "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Mood", "O", "B-Procedure", "O", "O", "O", "B-Mood", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides.	[ "Any", "active", "respiratory", ",", "cardiovascular", "or", "other", "disease", "requiring", "regular", "treatment", "or", "being", "otherwise", "relevant", "for", "tolerance", "of", "hypoxia", "or", "altitude", "exposure", ".", "\n", "Any", "condition", "that", "may", "interfere", "with", "protocol", "compliance", "including", "current", "heavy", "smoking", "(", ">", "20", "cigarettes", "per", "day", "or", ">", "20", "pack", "-", "years", "with", "active", "smoking", "during", "the", "last", "10", "years", ")", ",", "regular", "use", "of", "alcohol", ".", "\n", "Allergy", "to", "acetazolamide", "and", "other", "sulfonamides", ".", "\n" ]	[ "Scope", "Temporal", "Condition", "Measurement", "Drug", "Mood", "Procedure", "Qualifier", "Value" ]
active, respiratory , cardiovascular or other disease, requiring, treatment, relevant, tolerance, hypoxia or altitude exposure, heavy smoking, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years, regular use of alcohol, Allergy, acetazolamide and other sulfonamides	NCT03537924_exc_task2	Sentence: Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides. Instructions: please extract entity words from the input sentence	[ "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Mood", "O", "B-Procedure", "O", "O", "O", "B-Mood", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides.	[ "Any", "active", "respiratory", ",", "cardiovascular", "or", "other", "disease", "requiring", "regular", "treatment", "or", "being", "otherwise", "relevant", "for", "tolerance", "of", "hypoxia", "or", "altitude", "exposure", ".", "\n", "Any", "condition", "that", "may", "interfere", "with", "protocol", "compliance", "including", "current", "heavy", "smoking", "(", ">", "20", "cigarettes", "per", "day", "or", ">", "20", "pack", "-", "years", "with", "active", "smoking", "during", "the", "last", "10", "years", ")", ",", "regular", "use", "of", "alcohol", ".", "\n", "Allergy", "to", "acetazolamide", "and", "other", "sulfonamides", ".", "\n" ]	[ "Scope", "Temporal", "Condition", "Measurement", "Drug", "Mood", "Procedure", "Qualifier", "Value" ]
development is an umlsterm, Australia is an umlsterm, Oregon is an umlsterm, assisted suicide is an umlsterm, Netherlands is an umlsterm, suicide is an umlsterm, psychiatrist is an umlsterm	DerNervenarzt.70680878.eng.abstr_task0	Sentence: The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view .	[ "The", "international", "discussion", "on", "physician", "-", "assisted", "dying", "as", "well", "as", "the", "recent", "development", "in", "North", "Australia", "and", "Oregon", "point", "to", "a", "growing", "tendency", "to", "favour", "assisted", "suicide", "as", "against", "killing", "on", "request", "-", "last", "not", "least", "for", "reasons", "of", "public", "acceptance", ".", "The", "decision", "of", "the", "Supreme", "Court", "of", "the", "Netherlands", "in", "a", "case", "of", "suicide", "assisted", "by", "a", "psychiatrist", "gives", "the", "opportunity", "to", "discuss", "the", "problem", "from", "the", "psychiatric", "point", "of", "view", "." ]	[ "umlsterm" ]
development is an umlsterm, Australia is an umlsterm, Oregon is an umlsterm, assisted suicide is an umlsterm, Netherlands is an umlsterm, suicide is an umlsterm, psychiatrist is an umlsterm	DerNervenarzt.70680878.eng.abstr_task1	Sentence: The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view . Instructions: please typing these entity words according to sentence: development, Australia, Oregon, assisted suicide, Netherlands, suicide, psychiatrist Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view .	[ "The", "international", "discussion", "on", "physician", "-", "assisted", "dying", "as", "well", "as", "the", "recent", "development", "in", "North", "Australia", "and", "Oregon", "point", "to", "a", "growing", "tendency", "to", "favour", "assisted", "suicide", "as", "against", "killing", "on", "request", "-", "last", "not", "least", "for", "reasons", "of", "public", "acceptance", ".", "The", "decision", "of", "the", "Supreme", "Court", "of", "the", "Netherlands", "in", "a", "case", "of", "suicide", "assisted", "by", "a", "psychiatrist", "gives", "the", "opportunity", "to", "discuss", "the", "problem", "from", "the", "psychiatric", "point", "of", "view", "." ]	[ "umlsterm" ]
development, Australia, Oregon, assisted suicide, Netherlands, suicide, psychiatrist	DerNervenarzt.70680878.eng.abstr_task2	Sentence: The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view .	[ "The", "international", "discussion", "on", "physician", "-", "assisted", "dying", "as", "well", "as", "the", "recent", "development", "in", "North", "Australia", "and", "Oregon", "point", "to", "a", "growing", "tendency", "to", "favour", "assisted", "suicide", "as", "against", "killing", "on", "request", "-", "last", "not", "least", "for", "reasons", "of", "public", "acceptance", ".", "The", "decision", "of", "the", "Supreme", "Court", "of", "the", "Netherlands", "in", "a", "case", "of", "suicide", "assisted", "by", "a", "psychiatrist", "gives", "the", "opportunity", "to", "discuss", "the", "problem", "from", "the", "psychiatric", "point", "of", "view", "." ]	[ "umlsterm" ]
Pollex is an umlsterm, Bewegungseinschraenkung is an umlsterm, Diagnostik is an umlsterm, Tendovaginitis is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Daumens is an umlsterm, passive Gelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Ringbandspaltung is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Operationstechnik is an umlsterm, Hand is an umlsterm, Tendovaginitis is an umlsterm, Kind is an umlsterm	DerChirurg.70681190.ger.abstr_task0	Sentence: Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten .	[ "Zusammenfassung", ".", "Die", "eigene", "Behandlungsmethode", "bei", "Pollex", "flexus", "congenitus", "wird", "vorgestellt", ".", "Leitsymptome", "sind", "die", "fixierte", "Beugefehlstellung", ",", "eine", "schmerzhafte", ")", "Bewegungseinschraenkung", "(", "(", "mit", "Klick", "-", "Phaenomen", ")", "oder", "eine", "persistierende", "Streckfehlstellung", ".", "Obwohl", "es", "sich", "um", "ein", "einfaches", "Krankheitsbild", "handelt", ",", "ist", "eine", "sorgfaeltige", "Diagnostik", "mit", "Ausschluss", "seltener", "Ursachen", ",", "welche", "eine", "Tendovaginitis", "stenosans", "imitieren", "koennen", ",", "notwendig", ",", "da", "gerade", "diese", "Faelle", "zu", "schwerwiegenden", "Komplikationen", "fuehren", "koennen", ".", "26", "Patienten", "mit", "persistierenden", "Beschwerden", "wurde", "operativ", "das", "A1-Ringband", "des", "Daumens", "gespalten", ".", "Eine", "freie", "aktive", "und", "passive", "Gelenkbeweglichkeit", "im", "Seitenvergleich", "trat", "bei", "92,7", "%", "der", "Patienten", "auf", ",", "wobei", "aufgrund", "einer", "inkompletten", "Ringbandspaltung", "bei", "2", "Patienten", "eine", "erneute", "Operation", "durchgefuehrt", "wurde", ".", "Bei", "adaequater", "Diagnostik", ",", "fruehzeitiger", "Indikationsstellung", "und", "exakter", "Operationstechnik", "sollten", "heutzutage", "aesthetische", "und", "funktionelle", "Beeintraechtigungen", "der", "Hand", "aufgrund", "einer", "Tendovaginitis", "stenosans", "beim", "Kind", "nicht", "mehr", "auftreten", "." ]	[ "umlsterm" ]
Pollex is an umlsterm, Bewegungseinschraenkung is an umlsterm, Diagnostik is an umlsterm, Tendovaginitis is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Daumens is an umlsterm, passive Gelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Ringbandspaltung is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Operationstechnik is an umlsterm, Hand is an umlsterm, Tendovaginitis is an umlsterm, Kind is an umlsterm	DerChirurg.70681190.ger.abstr_task1	Sentence: Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten . Instructions: please typing these entity words according to sentence: Pollex, Bewegungseinschraenkung, Diagnostik, Tendovaginitis, Komplikationen, Patienten, Daumens, passive Gelenkbeweglichkeit, Patienten, Ringbandspaltung, Patienten, Diagnostik, Operationstechnik, Hand, Tendovaginitis, Kind Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten .	[ "Zusammenfassung", ".", "Die", "eigene", "Behandlungsmethode", "bei", "Pollex", "flexus", "congenitus", "wird", "vorgestellt", ".", "Leitsymptome", "sind", "die", "fixierte", "Beugefehlstellung", ",", "eine", "schmerzhafte", ")", "Bewegungseinschraenkung", "(", "(", "mit", "Klick", "-", "Phaenomen", ")", "oder", "eine", "persistierende", "Streckfehlstellung", ".", "Obwohl", "es", "sich", "um", "ein", "einfaches", "Krankheitsbild", "handelt", ",", "ist", "eine", "sorgfaeltige", "Diagnostik", "mit", "Ausschluss", "seltener", "Ursachen", ",", "welche", "eine", "Tendovaginitis", "stenosans", "imitieren", "koennen", ",", "notwendig", ",", "da", "gerade", "diese", "Faelle", "zu", "schwerwiegenden", "Komplikationen", "fuehren", "koennen", ".", "26", "Patienten", "mit", "persistierenden", "Beschwerden", "wurde", "operativ", "das", "A1-Ringband", "des", "Daumens", "gespalten", ".", "Eine", "freie", "aktive", "und", "passive", "Gelenkbeweglichkeit", "im", "Seitenvergleich", "trat", "bei", "92,7", "%", "der", "Patienten", "auf", ",", "wobei", "aufgrund", "einer", "inkompletten", "Ringbandspaltung", "bei", "2", "Patienten", "eine", "erneute", "Operation", "durchgefuehrt", "wurde", ".", "Bei", "adaequater", "Diagnostik", ",", "fruehzeitiger", "Indikationsstellung", "und", "exakter", "Operationstechnik", "sollten", "heutzutage", "aesthetische", "und", "funktionelle", "Beeintraechtigungen", "der", "Hand", "aufgrund", "einer", "Tendovaginitis", "stenosans", "beim", "Kind", "nicht", "mehr", "auftreten", "." ]	[ "umlsterm" ]
Pollex, Bewegungseinschraenkung, Diagnostik, Tendovaginitis, Komplikationen, Patienten, Daumens, passive Gelenkbeweglichkeit, Patienten, Ringbandspaltung, Patienten, Diagnostik, Operationstechnik, Hand, Tendovaginitis, Kind	DerChirurg.70681190.ger.abstr_task2	Sentence: Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten .	[ "Zusammenfassung", ".", "Die", "eigene", "Behandlungsmethode", "bei", "Pollex", "flexus", "congenitus", "wird", "vorgestellt", ".", "Leitsymptome", "sind", "die", "fixierte", "Beugefehlstellung", ",", "eine", "schmerzhafte", ")", "Bewegungseinschraenkung", "(", "(", "mit", "Klick", "-", "Phaenomen", ")", "oder", "eine", "persistierende", "Streckfehlstellung", ".", "Obwohl", "es", "sich", "um", "ein", "einfaches", "Krankheitsbild", "handelt", ",", "ist", "eine", "sorgfaeltige", "Diagnostik", "mit", "Ausschluss", "seltener", "Ursachen", ",", "welche", "eine", "Tendovaginitis", "stenosans", "imitieren", "koennen", ",", "notwendig", ",", "da", "gerade", "diese", "Faelle", "zu", "schwerwiegenden", "Komplikationen", "fuehren", "koennen", ".", "26", "Patienten", "mit", "persistierenden", "Beschwerden", "wurde", "operativ", "das", "A1-Ringband", "des", "Daumens", "gespalten", ".", "Eine", "freie", "aktive", "und", "passive", "Gelenkbeweglichkeit", "im", "Seitenvergleich", "trat", "bei", "92,7", "%", "der", "Patienten", "auf", ",", "wobei", "aufgrund", "einer", "inkompletten", "Ringbandspaltung", "bei", "2", "Patienten", "eine", "erneute", "Operation", "durchgefuehrt", "wurde", ".", "Bei", "adaequater", "Diagnostik", ",", "fruehzeitiger", "Indikationsstellung", "und", "exakter", "Operationstechnik", "sollten", "heutzutage", "aesthetische", "und", "funktionelle", "Beeintraechtigungen", "der", "Hand", "aufgrund", "einer", "Tendovaginitis", "stenosans", "beim", "Kind", "nicht", "mehr", "auftreten", "." ]	[ "umlsterm" ]
Fas ligand is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bax is a Protein, Bad is a Protein, microtubule is a Entity, Fas is a Protein, Fas ligand is a Protein, FasL is a Protein, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, microtubule is a Entity, FasL is a Protein, microtubule is a Entity, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, calcineurin is a Protein, FasL is a Protein, Bcl-2 is a Protein	687_task0	Sentence: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.	[ "Bcl-2-mediated", "drug", "resistance", ":", "inhibition", "of", "apoptosis", "by", "blocking", "nuclear", "factor", "of", "activated", "T", "lymphocytes", "(", "NFAT)-induced", "Fas", "ligand", "transcription", ".", "\n", "Bcl-2", "inhibits", "apoptosis", "induced", "by", "a", "variety", "of", "stimuli", ",", "including", "chemotherapy", "drugs", "and", "glucocorticoids", ".", "It", "is", "generally", "accepted", "that", "Bcl-2", "exerts", "its", "antiapoptotic", "effects", "mainly", "by", "dimerizing", "with", "proapoptotic", "members", "of", "the", "Bcl-2", "family", "such", "as", "Bax", "and", "Bad", ".", "However", ",", "the", "mechanism", "of", "the", "antiapoptotic", "effects", "is", "unclear", ".", "Paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "dynamics", "kill", "cells", "in", "a", "Fas", "/", "Fas", "ligand", "(", "FasL)-dependent", "manner", ";", "antibody", "to", "FasL", "inhibits", "paclitaxel", "-", "induced", "apoptosis", ".", "We", "have", "found", "that", "Bcl-2", "overexpression", "leads", "to", "the", "prevention", "of", "chemotherapy", "(", "paclitaxel)-induced", "expression", "of", "FasL", "and", "blocks", "paclitaxel", "-", "induced", "apoptosis", ".", "The", "mechanism", "of", "this", "effect", "is", "that", "Bcl-2", "prevents", "the", "nuclear", "translocation", "of", "NFAT", "(", "nuclear", "factor", "of", "activated", "T", "lymphocytes", ",", "a", "transcription", "factor", "activated", "by", "microtubule", "damage", ")", "by", "binding", "and", "sequestering", "calcineurin", ",", "a", "calcium", "-", "dependent", "phosphatase", "that", "must", "dephosphorylate", "NFAT", "to", "move", "to", "the", "nucleus", ".", "Without", "NFAT", "nuclear", "translocation", ",", "the", "FasL", "gene", "is", "not", "transcribed", ".", "Thus", ",", "it", "appears", "that", "paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "function", "kill", "cells", "at", "least", "in", "part", "through", "the", "induction", "of", "FasL.", "Furthermore", ",", "Bcl-2", "antagonizes", "drug", "-", "induced", "apoptosis", "by", "inhibiting", "calcineurin", "activation", ",", "blocking", "NFAT", "nuclear", "translocation", ",", "and", "preventing", "FasL", "expression", ".", "The", "effects", "of", "Bcl-2", "can", "be", "overcome", ",", "at", "least", "partially", ",", "through", "phosphorylation", "of", "Bcl-2", ".", "Phosphorylated", "Bcl-2", "cannot", "bind", "calcineurin", ",", "and", "NFAT", "activation", ",", "FasL", "expression", ",", "and", "apoptosis", "can", "occur", "after", "Bcl-2", "phosphorylation", ".", "\n" ]	[ "Protein", "Entity" ]
Fas ligand is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bax is a Protein, Bad is a Protein, microtubule is a Entity, Fas is a Protein, Fas ligand is a Protein, FasL is a Protein, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, microtubule is a Entity, FasL is a Protein, microtubule is a Entity, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, calcineurin is a Protein, FasL is a Protein, Bcl-2 is a Protein	687_task1	Sentence: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation. Instructions: please typing these entity words according to sentence: Fas ligand, Bcl-2, Bcl-2, Bax, Bad, microtubule, Fas, Fas ligand, FasL, Bcl-2, FasL, Bcl-2, microtubule, FasL, microtubule, Bcl-2, FasL, Bcl-2, Bcl-2, Bcl-2, calcineurin, FasL, Bcl-2 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.	[ "Bcl-2-mediated", "drug", "resistance", ":", "inhibition", "of", "apoptosis", "by", "blocking", "nuclear", "factor", "of", "activated", "T", "lymphocytes", "(", "NFAT)-induced", "Fas", "ligand", "transcription", ".", "\n", "Bcl-2", "inhibits", "apoptosis", "induced", "by", "a", "variety", "of", "stimuli", ",", "including", "chemotherapy", "drugs", "and", "glucocorticoids", ".", "It", "is", "generally", "accepted", "that", "Bcl-2", "exerts", "its", "antiapoptotic", "effects", "mainly", "by", "dimerizing", "with", "proapoptotic", "members", "of", "the", "Bcl-2", "family", "such", "as", "Bax", "and", "Bad", ".", "However", ",", "the", "mechanism", "of", "the", "antiapoptotic", "effects", "is", "unclear", ".", "Paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "dynamics", "kill", "cells", "in", "a", "Fas", "/", "Fas", "ligand", "(", "FasL)-dependent", "manner", ";", "antibody", "to", "FasL", "inhibits", "paclitaxel", "-", "induced", "apoptosis", ".", "We", "have", "found", "that", "Bcl-2", "overexpression", "leads", "to", "the", "prevention", "of", "chemotherapy", "(", "paclitaxel)-induced", "expression", "of", "FasL", "and", "blocks", "paclitaxel", "-", "induced", "apoptosis", ".", "The", "mechanism", "of", "this", "effect", "is", "that", "Bcl-2", "prevents", "the", "nuclear", "translocation", "of", "NFAT", "(", "nuclear", "factor", "of", "activated", "T", "lymphocytes", ",", "a", "transcription", "factor", "activated", "by", "microtubule", "damage", ")", "by", "binding", "and", "sequestering", "calcineurin", ",", "a", "calcium", "-", "dependent", "phosphatase", "that", "must", "dephosphorylate", "NFAT", "to", "move", "to", "the", "nucleus", ".", "Without", "NFAT", "nuclear", "translocation", ",", "the", "FasL", "gene", "is", "not", "transcribed", ".", "Thus", ",", "it", "appears", "that", "paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "function", "kill", "cells", "at", "least", "in", "part", "through", "the", "induction", "of", "FasL.", "Furthermore", ",", "Bcl-2", "antagonizes", "drug", "-", "induced", "apoptosis", "by", "inhibiting", "calcineurin", "activation", ",", "blocking", "NFAT", "nuclear", "translocation", ",", "and", "preventing", "FasL", "expression", ".", "The", "effects", "of", "Bcl-2", "can", "be", "overcome", ",", "at", "least", "partially", ",", "through", "phosphorylation", "of", "Bcl-2", ".", "Phosphorylated", "Bcl-2", "cannot", "bind", "calcineurin", ",", "and", "NFAT", "activation", ",", "FasL", "expression", ",", "and", "apoptosis", "can", "occur", "after", "Bcl-2", "phosphorylation", ".", "\n" ]	[ "Protein", "Entity" ]
Fas ligand, Bcl-2, Bcl-2, Bax, Bad, microtubule, Fas, Fas ligand, FasL, Bcl-2, FasL, Bcl-2, microtubule, FasL, microtubule, Bcl-2, FasL, Bcl-2, Bcl-2, Bcl-2, calcineurin, FasL, Bcl-2	687_task2	Sentence: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.	[ "Bcl-2-mediated", "drug", "resistance", ":", "inhibition", "of", "apoptosis", "by", "blocking", "nuclear", "factor", "of", "activated", "T", "lymphocytes", "(", "NFAT)-induced", "Fas", "ligand", "transcription", ".", "\n", "Bcl-2", "inhibits", "apoptosis", "induced", "by", "a", "variety", "of", "stimuli", ",", "including", "chemotherapy", "drugs", "and", "glucocorticoids", ".", "It", "is", "generally", "accepted", "that", "Bcl-2", "exerts", "its", "antiapoptotic", "effects", "mainly", "by", "dimerizing", "with", "proapoptotic", "members", "of", "the", "Bcl-2", "family", "such", "as", "Bax", "and", "Bad", ".", "However", ",", "the", "mechanism", "of", "the", "antiapoptotic", "effects", "is", "unclear", ".", "Paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "dynamics", "kill", "cells", "in", "a", "Fas", "/", "Fas", "ligand", "(", "FasL)-dependent", "manner", ";", "antibody", "to", "FasL", "inhibits", "paclitaxel", "-", "induced", "apoptosis", ".", "We", "have", "found", "that", "Bcl-2", "overexpression", "leads", "to", "the", "prevention", "of", "chemotherapy", "(", "paclitaxel)-induced", "expression", "of", "FasL", "and", "blocks", "paclitaxel", "-", "induced", "apoptosis", ".", "The", "mechanism", "of", "this", "effect", "is", "that", "Bcl-2", "prevents", "the", "nuclear", "translocation", "of", "NFAT", "(", "nuclear", "factor", "of", "activated", "T", "lymphocytes", ",", "a", "transcription", "factor", "activated", "by", "microtubule", "damage", ")", "by", "binding", "and", "sequestering", "calcineurin", ",", "a", "calcium", "-", "dependent", "phosphatase", "that", "must", "dephosphorylate", "NFAT", "to", "move", "to", "the", "nucleus", ".", "Without", "NFAT", "nuclear", "translocation", ",", "the", "FasL", "gene", "is", "not", "transcribed", ".", "Thus", ",", "it", "appears", "that", "paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "function", "kill", "cells", "at", "least", "in", "part", "through", "the", "induction", "of", "FasL.", "Furthermore", ",", "Bcl-2", "antagonizes", "drug", "-", "induced", "apoptosis", "by", "inhibiting", "calcineurin", "activation", ",", "blocking", "NFAT", "nuclear", "translocation", ",", "and", "preventing", "FasL", "expression", ".", "The", "effects", "of", "Bcl-2", "can", "be", "overcome", ",", "at", "least", "partially", ",", "through", "phosphorylation", "of", "Bcl-2", ".", "Phosphorylated", "Bcl-2", "cannot", "bind", "calcineurin", ",", "and", "NFAT", "activation", ",", "FasL", "expression", ",", "and", "apoptosis", "can", "occur", "after", "Bcl-2", "phosphorylation", ".", "\n" ]	[ "Protein", "Entity" ]
placenta pathology is a Condition, praevia , acreta , pre - eclampsia is a Scope, bleeding disorders is a Condition, intolerance is a Condition, one of the two is a Multiplier, drugs is a Drug, prolonged QT - time is a Condition, other is a Qualifier, serious cardiac diseases is a Condition, kidney failure is a Condition, Epilepsy is a Condition	NCT02528136_exc_task0	Sentence: Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Multiplier, Scope, Drug	[ "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate	[ "Patients", "with", "placenta", "pathology", "such", "as", "praevia", ",", "acreta", ",", "pre", "-", "eclampsia", "\n", "Patients", "with", "bleeding", "disorders", "including", "vonWillebrand", "disease", "type", "I.", "\n", "Known", "intolerance", "to", "one", "of", "the", "two", "drugs", ".", "\n", "Patients", "with", "prolonged", "QT", "-", "time", "or", "other", "serious", "cardiac", "diseases", ".", "\n", "Liver", "or", "kidney", "failure", ".", "\n", "Epilepsy", ".", "\n", "Any", "medical", "reason", "why", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "the", "patient", "should", "not", "participate", "\n" ]	[ "Scope", "Condition", "Multiplier", "Drug", "Qualifier" ]
placenta pathology is a Condition, praevia , acreta , pre - eclampsia is a Scope, bleeding disorders is a Condition, intolerance is a Condition, one of the two is a Multiplier, drugs is a Drug, prolonged QT - time is a Condition, other is a Qualifier, serious cardiac diseases is a Condition, kidney failure is a Condition, Epilepsy is a Condition	NCT02528136_exc_task1	Sentence: Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate Instructions: please typing these entity words according to sentence: placenta pathology, praevia , acreta , pre - eclampsia, bleeding disorders, intolerance, one of the two, drugs, prolonged QT - time, other, serious cardiac diseases, kidney failure, Epilepsy Options: Condition, Qualifier, Multiplier, Scope, Drug	[ "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate	[ "Patients", "with", "placenta", "pathology", "such", "as", "praevia", ",", "acreta", ",", "pre", "-", "eclampsia", "\n", "Patients", "with", "bleeding", "disorders", "including", "vonWillebrand", "disease", "type", "I.", "\n", "Known", "intolerance", "to", "one", "of", "the", "two", "drugs", ".", "\n", "Patients", "with", "prolonged", "QT", "-", "time", "or", "other", "serious", "cardiac", "diseases", ".", "\n", "Liver", "or", "kidney", "failure", ".", "\n", "Epilepsy", ".", "\n", "Any", "medical", "reason", "why", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "the", "patient", "should", "not", "participate", "\n" ]	[ "Scope", "Condition", "Multiplier", "Drug", "Qualifier" ]
placenta pathology, praevia , acreta , pre - eclampsia, bleeding disorders, intolerance, one of the two, drugs, prolonged QT - time, other, serious cardiac diseases, kidney failure, Epilepsy	NCT02528136_exc_task2	Sentence: Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate	[ "Patients", "with", "placenta", "pathology", "such", "as", "praevia", ",", "acreta", ",", "pre", "-", "eclampsia", "\n", "Patients", "with", "bleeding", "disorders", "including", "vonWillebrand", "disease", "type", "I.", "\n", "Known", "intolerance", "to", "one", "of", "the", "two", "drugs", ".", "\n", "Patients", "with", "prolonged", "QT", "-", "time", "or", "other", "serious", "cardiac", "diseases", ".", "\n", "Liver", "or", "kidney", "failure", ".", "\n", "Epilepsy", ".", "\n", "Any", "medical", "reason", "why", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "the", "patient", "should", "not", "participate", "\n" ]	[ "Scope", "Condition", "Multiplier", "Drug", "Qualifier" ]
Minor is an umlsterm, fistula is an umlsterm, syndrome is an umlsterm, syndrome is an umlsterm, vertigo is an umlsterm, noises is an umlsterm, middle ear is an umlsterm, pressure is an umlsterm, bone is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm, oval windows is an umlsterm, pressure is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm	DerNervenarzt.00710138.eng.abstr_task0	Sentence: In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O" ]	In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal .	[ "In", "1998", "Minor", "et", "al", ".", "described", "a", "new", "variant", "of", "perilymphatic", "fistula", ":", "the", "\"", "superior", "canal", "dehiscence", "syndrome", "\"", ".", "This", "syndrome", "is", "clinically", "characterized", "by", "recurrent", "attacks", "of", "vertigo", "and", "oscillopsia", "induced", "by", "loud", "noises", "or", "stimuli", "that", "result", "in", "changes", "in", "intracranial", "or", "middle", "ear", "pressure", ".", "It", "is", "caused", "by", "a", "dehiscence", "of", "bone", "overlying", "the", "superior", "(", "anterior", ")", "semicircular", "canal", ".", "Due", "to", "this", "dehiscence", ",", "a", "third", ",", "mobile", "window", "(", "in", "addition", "to", "the", "round", "and", "oval", "windows", ")", "is", "formed", ",", "and", "changes", "in", "pressure", "are", "pathologically", "transduced", "to", "the", "anterior", "semicircular", "canal", "." ]	[ "umlsterm" ]
Minor is an umlsterm, fistula is an umlsterm, syndrome is an umlsterm, syndrome is an umlsterm, vertigo is an umlsterm, noises is an umlsterm, middle ear is an umlsterm, pressure is an umlsterm, bone is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm, oval windows is an umlsterm, pressure is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm	DerNervenarzt.00710138.eng.abstr_task1	Sentence: In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal . Instructions: please typing these entity words according to sentence: Minor, fistula, syndrome, syndrome, vertigo, noises, middle ear, pressure, bone, anterior, semicircular canal, oval windows, pressure, anterior, semicircular canal Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O" ]	In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal .	[ "In", "1998", "Minor", "et", "al", ".", "described", "a", "new", "variant", "of", "perilymphatic", "fistula", ":", "the", "\"", "superior", "canal", "dehiscence", "syndrome", "\"", ".", "This", "syndrome", "is", "clinically", "characterized", "by", "recurrent", "attacks", "of", "vertigo", "and", "oscillopsia", "induced", "by", "loud", "noises", "or", "stimuli", "that", "result", "in", "changes", "in", "intracranial", "or", "middle", "ear", "pressure", ".", "It", "is", "caused", "by", "a", "dehiscence", "of", "bone", "overlying", "the", "superior", "(", "anterior", ")", "semicircular", "canal", ".", "Due", "to", "this", "dehiscence", ",", "a", "third", ",", "mobile", "window", "(", "in", "addition", "to", "the", "round", "and", "oval", "windows", ")", "is", "formed", ",", "and", "changes", "in", "pressure", "are", "pathologically", "transduced", "to", "the", "anterior", "semicircular", "canal", "." ]	[ "umlsterm" ]
Minor, fistula, syndrome, syndrome, vertigo, noises, middle ear, pressure, bone, anterior, semicircular canal, oval windows, pressure, anterior, semicircular canal	DerNervenarzt.00710138.eng.abstr_task2	Sentence: In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O" ]	In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal .	[ "In", "1998", "Minor", "et", "al", ".", "described", "a", "new", "variant", "of", "perilymphatic", "fistula", ":", "the", "\"", "superior", "canal", "dehiscence", "syndrome", "\"", ".", "This", "syndrome", "is", "clinically", "characterized", "by", "recurrent", "attacks", "of", "vertigo", "and", "oscillopsia", "induced", "by", "loud", "noises", "or", "stimuli", "that", "result", "in", "changes", "in", "intracranial", "or", "middle", "ear", "pressure", ".", "It", "is", "caused", "by", "a", "dehiscence", "of", "bone", "overlying", "the", "superior", "(", "anterior", ")", "semicircular", "canal", ".", "Due", "to", "this", "dehiscence", ",", "a", "third", ",", "mobile", "window", "(", "in", "addition", "to", "the", "round", "and", "oval", "windows", ")", "is", "formed", ",", "and", "changes", "in", "pressure", "are", "pathologically", "transduced", "to", "the", "anterior", "semicircular", "canal", "." ]	[ "umlsterm" ]
generic warfarin is a Intervention_Pharmacological, Warfarin is a Intervention_Pharmacological, safety is a Outcome_Other, efficacy is a Outcome_Other, Coumadin is a Intervention_Pharmacological, ( N = 7 ) is a Participant_Sample-size, generic warfarin formulation ( Apo - warfarin ) is a Intervention_Pharmacological, Coumadin over 30 weeks is a Intervention_Pharmacological, Study patients took each drug for five 3-week periods is a Participant_Condition, with international normalized ratio ( INR ) measurements taken twice per period is a Participant_Condition, INR results is a Outcome_Other, safely and effectively switch is a Outcome_Other	21881_task0	Sentence: Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Participant_Sample-size	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O" ]	Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin .	[ "Are", "brand", "-", "name", "and", "generic", "warfarin", "interchangeable", "?", "Multiple", "n", "-", "of-1", "randomized", ",", "crossover", "trials", ".", "BACKGROUND", "Warfarin", "is", "a", "commonly", "used", "anticoagulant", "in", "North", "America", ".", "Several", "generic", "formulations", "have", "been", "approved", ",", "raising", "concern", "over", "the", "safety", "and", "efficacy", "of", "these", "products", "compared", "with", "brand", "-", "name", "Coumadin", ".", "OBJECTIVE", "To", "ensure", "that", "generic", "warfarin", "products", "can", "be", "safely", "interchanged", "with", "Coumadin", ".", "METHODS", "Multiple", "n", "-", "of-1", "randomized", ",", "double", "-", "blind", ",", "crossover", "trials", "switched", "outpatients", "(", "N", "=", "7", ")", "between", "a", "generic", "warfarin", "formulation", "(", "Apo", "-", "warfarin", ")", "and", "Coumadin", "over", "30", "weeks", ".", "Study", "patients", "took", "each", "drug", "for", "five", "3-week", "periods", ",", "with", "international", "normalized", "ratio", "(", "INR", ")", "measurements", "taken", "twice", "per", "period", ".", "Inter-", "and", "intrapatient", "differences", "between", "generic", "warfarin", "and", "Coumadin", "were", "compared", ",", "and", "overall", "study", "patient", "results", "were", "compared", "with", "those", "of", "a", "Coumadin", "control", "group", ".", "RESULTS", "There", "were", "no", "differences", "between", "warfarin", "products", "in", "terms", "of", "mean", "INR", "results", "or", "number", "of", "dosage", "adjustments", "required", ".", "There", "also", "was", "no", "difference", "in", "INR", "variation", "based", "on", "warfarin", "formulation", "(", "p", ">", "0.69", ")", ",", "nor", "was", "a", "patient", "and", "warfarin", "interaction", "found", "(", "p", ">", "0.81", ")", ".", "The", "INR", "results", "were", "not", "influenced", "by", "whether", "patients", "were", "maintained", "on", "Coumadin", "only", "(", "control", "group", ")", "or", "interchanged", "between", "Coumadin", "and", "generic", "warfarin", "(", "p", "=", "0.98", ")", ".", "CONCLUSIONS", "It", "appears", "that", "patients", "can", "safely", "and", "effectively", "switch", "between", "generic", "warfarin", "and", "Coumadin", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
generic warfarin is a Intervention_Pharmacological, Warfarin is a Intervention_Pharmacological, safety is a Outcome_Other, efficacy is a Outcome_Other, Coumadin is a Intervention_Pharmacological, ( N = 7 ) is a Participant_Sample-size, generic warfarin formulation ( Apo - warfarin ) is a Intervention_Pharmacological, Coumadin over 30 weeks is a Intervention_Pharmacological, Study patients took each drug for five 3-week periods is a Participant_Condition, with international normalized ratio ( INR ) measurements taken twice per period is a Participant_Condition, INR results is a Outcome_Other, safely and effectively switch is a Outcome_Other	21881_task1	Sentence: Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin . Instructions: please typing these entity words according to sentence: generic warfarin, Warfarin, safety, efficacy, Coumadin, ( N = 7 ), generic warfarin formulation ( Apo - warfarin ), Coumadin over 30 weeks, Study patients took each drug for five 3-week periods, with international normalized ratio ( INR ) measurements taken twice per period, INR results, safely and effectively switch Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Participant_Sample-size	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O" ]	Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin .	[ "Are", "brand", "-", "name", "and", "generic", "warfarin", "interchangeable", "?", "Multiple", "n", "-", "of-1", "randomized", ",", "crossover", "trials", ".", "BACKGROUND", "Warfarin", "is", "a", "commonly", "used", "anticoagulant", "in", "North", "America", ".", "Several", "generic", "formulations", "have", "been", "approved", ",", "raising", "concern", "over", "the", "safety", "and", "efficacy", "of", "these", "products", "compared", "with", "brand", "-", "name", "Coumadin", ".", "OBJECTIVE", "To", "ensure", "that", "generic", "warfarin", "products", "can", "be", "safely", "interchanged", "with", "Coumadin", ".", "METHODS", "Multiple", "n", "-", "of-1", "randomized", ",", "double", "-", "blind", ",", "crossover", "trials", "switched", "outpatients", "(", "N", "=", "7", ")", "between", "a", "generic", "warfarin", "formulation", "(", "Apo", "-", "warfarin", ")", "and", "Coumadin", "over", "30", "weeks", ".", "Study", "patients", "took", "each", "drug", "for", "five", "3-week", "periods", ",", "with", "international", "normalized", "ratio", "(", "INR", ")", "measurements", "taken", "twice", "per", "period", ".", "Inter-", "and", "intrapatient", "differences", "between", "generic", "warfarin", "and", "Coumadin", "were", "compared", ",", "and", "overall", "study", "patient", "results", "were", "compared", "with", "those", "of", "a", "Coumadin", "control", "group", ".", "RESULTS", "There", "were", "no", "differences", "between", "warfarin", "products", "in", "terms", "of", "mean", "INR", "results", "or", "number", "of", "dosage", "adjustments", "required", ".", "There", "also", "was", "no", "difference", "in", "INR", "variation", "based", "on", "warfarin", "formulation", "(", "p", ">", "0.69", ")", ",", "nor", "was", "a", "patient", "and", "warfarin", "interaction", "found", "(", "p", ">", "0.81", ")", ".", "The", "INR", "results", "were", "not", "influenced", "by", "whether", "patients", "were", "maintained", "on", "Coumadin", "only", "(", "control", "group", ")", "or", "interchanged", "between", "Coumadin", "and", "generic", "warfarin", "(", "p", "=", "0.98", ")", ".", "CONCLUSIONS", "It", "appears", "that", "patients", "can", "safely", "and", "effectively", "switch", "between", "generic", "warfarin", "and", "Coumadin", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
generic warfarin, Warfarin, safety, efficacy, Coumadin, ( N = 7 ), generic warfarin formulation ( Apo - warfarin ), Coumadin over 30 weeks, Study patients took each drug for five 3-week periods, with international normalized ratio ( INR ) measurements taken twice per period, INR results, safely and effectively switch	21881_task2	Sentence: Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O" ]	Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin .	[ "Are", "brand", "-", "name", "and", "generic", "warfarin", "interchangeable", "?", "Multiple", "n", "-", "of-1", "randomized", ",", "crossover", "trials", ".", "BACKGROUND", "Warfarin", "is", "a", "commonly", "used", "anticoagulant", "in", "North", "America", ".", "Several", "generic", "formulations", "have", "been", "approved", ",", "raising", "concern", "over", "the", "safety", "and", "efficacy", "of", "these", "products", "compared", "with", "brand", "-", "name", "Coumadin", ".", "OBJECTIVE", "To", "ensure", "that", "generic", "warfarin", "products", "can", "be", "safely", "interchanged", "with", "Coumadin", ".", "METHODS", "Multiple", "n", "-", "of-1", "randomized", ",", "double", "-", "blind", ",", "crossover", "trials", "switched", "outpatients", "(", "N", "=", "7", ")", "between", "a", "generic", "warfarin", "formulation", "(", "Apo", "-", "warfarin", ")", "and", "Coumadin", "over", "30", "weeks", ".", "Study", "patients", "took", "each", "drug", "for", "five", "3-week", "periods", ",", "with", "international", "normalized", "ratio", "(", "INR", ")", "measurements", "taken", "twice", "per", "period", ".", "Inter-", "and", "intrapatient", "differences", "between", "generic", "warfarin", "and", "Coumadin", "were", "compared", ",", "and", "overall", "study", "patient", "results", "were", "compared", "with", "those", "of", "a", "Coumadin", "control", "group", ".", "RESULTS", "There", "were", "no", "differences", "between", "warfarin", "products", "in", "terms", "of", "mean", "INR", "results", "or", "number", "of", "dosage", "adjustments", "required", ".", "There", "also", "was", "no", "difference", "in", "INR", "variation", "based", "on", "warfarin", "formulation", "(", "p", ">", "0.69", ")", ",", "nor", "was", "a", "patient", "and", "warfarin", "interaction", "found", "(", "p", ">", "0.81", ")", ".", "The", "INR", "results", "were", "not", "influenced", "by", "whether", "patients", "were", "maintained", "on", "Coumadin", "only", "(", "control", "group", ")", "or", "interchanged", "between", "Coumadin", "and", "generic", "warfarin", "(", "p", "=", "0.98", ")", ".", "CONCLUSIONS", "It", "appears", "that", "patients", "can", "safely", "and", "effectively", "switch", "between", "generic", "warfarin", "and", "Coumadin", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
glucocorticoid receptor is a GENE-Y, ERK is a GENE-N, ginsenoside Rg1 is a CHEMICAL, β - amyloid peptide is a GENE-Y, β - amyloid is a GENE-Y, Aβ is a GENE-Y, Ginsenoside Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, Aβ is a GENE-Y, Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, HIF-1α is a GENE-Y, nitrogen is a CHEMICAL, glucocorticoid receptor is a GENE-Y, GR is a GENE-Y, RU486 is a CHEMICAL, p - ERK is a GENE-N, U0126 is a CHEMICAL, estrogen receptor α is a GENE-Y, ICI 82,780 is a CHEMICAL, Rg1 is a CHEMICAL, GR is a GENE-Y, ERK is a GENE-N, HIF-1α is a GENE-Y, GR is a GENE-Y, ERK is a GENE-N	14269_task0	Sentence: Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N	[ "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.	[ "Activating", "glucocorticoid", "receptor", "-", "ERK", "signaling", "pathway", "contributes", "to", "ginsenoside", "Rg1", "protection", "against", "β", "-", "amyloid", "peptide", "-", "induced", "human", "endothelial", "cells", "apoptosis", ".", "\n", "The", "deposition", "of", "β", "-", "amyloid", "(", "Aβ", ")", "in", "neurons", "and", "vascular", "cells", "of", "the", "brain", "has", "been", "characterized", "in", "Alzheimer", "'s", "disease", ".", "Ginsenoside", "Rg1", "(", "Rg1", ")", "is", "an", "active", "components", "in", "Panax", "ginseng", ",", "a", "famous", "traditional", "Chinese", "medicines", "recorded", "in", "Compendium", "of", "Materia", "Medica", ".", "Present", "study", "attempted", "to", "evaluate", "the", "potential", "mechanisms", "of", "Aβ", "-", "mediated", "insult", "and", "the", "protective", "effects", "of", "Rg1", "on", "human", "endothelial", "cells", ".", "Rg1", "attenuated", "the", "Aβ25", "-", "35-associated", "mitochondrial", "apoptotic", "events", ",", "accompanied", "by", "inhibiting", "HIF-1α", "expression", "followed", "by", "intracellular", "reactive", "nitrogen", "species", "generation", ",", "and", "protein", "nitrotyrosination", ".", "These", "protective", "effects", "were", "abolished", "by", "glucocorticoid", "receptor", "(", "GR", ")", "antagonist", "RU486", "or", "p", "-", "ERK", "inhibitor", "U0126", "rather", "than", "estrogen", "receptor", "α", "antagonist", "ICI", "82,780", ".", "Taken", "together", ",", "our", "results", "suggested", "that", "Rg1", "protected", "against", "Aβ25", "-", "35-induced", "apoptosis", "at", "least", "in", "part", "by", "two", "complementary", "GR", "-", "dependent", "ERK", "phosphorylation", "pathways", ":", "(", "1", ")", "down", "-", "regulating", "HIF-1α", "initiated", "protein", "nitrotyrosination", ",", "and", "(", "2", ")", "inhibiting", "mitochondrial", "apoptotic", "cascades", ".", "These", "data", "provided", "a", "novel", "insight", "to", "the", "mechanisms", "of", "Rg1protective", "effects", "on", "Aβ25", "-", "35-induced", "endothelial", "cells", "apoptosis", ",", "suggesting", "that", "GR", "-", "ERK", "signaling", "pathway", "might", "play", "an", "important", "role", "in", "it", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
glucocorticoid receptor is a GENE-Y, ERK is a GENE-N, ginsenoside Rg1 is a CHEMICAL, β - amyloid peptide is a GENE-Y, β - amyloid is a GENE-Y, Aβ is a GENE-Y, Ginsenoside Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, Aβ is a GENE-Y, Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, HIF-1α is a GENE-Y, nitrogen is a CHEMICAL, glucocorticoid receptor is a GENE-Y, GR is a GENE-Y, RU486 is a CHEMICAL, p - ERK is a GENE-N, U0126 is a CHEMICAL, estrogen receptor α is a GENE-Y, ICI 82,780 is a CHEMICAL, Rg1 is a CHEMICAL, GR is a GENE-Y, ERK is a GENE-N, HIF-1α is a GENE-Y, GR is a GENE-Y, ERK is a GENE-N	14269_task1	Sentence: Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it. Instructions: please typing these entity words according to sentence: glucocorticoid receptor, ERK, ginsenoside Rg1, β - amyloid peptide, β - amyloid, Aβ, Ginsenoside Rg1, Rg1, Aβ, Rg1, Rg1, HIF-1α, nitrogen, glucocorticoid receptor, GR, RU486, p - ERK, U0126, estrogen receptor α, ICI 82,780, Rg1, GR, ERK, HIF-1α, GR, ERK Options: CHEMICAL, GENE-Y, GENE-N	[ "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.	[ "Activating", "glucocorticoid", "receptor", "-", "ERK", "signaling", "pathway", "contributes", "to", "ginsenoside", "Rg1", "protection", "against", "β", "-", "amyloid", "peptide", "-", "induced", "human", "endothelial", "cells", "apoptosis", ".", "\n", "The", "deposition", "of", "β", "-", "amyloid", "(", "Aβ", ")", "in", "neurons", "and", "vascular", "cells", "of", "the", "brain", "has", "been", "characterized", "in", "Alzheimer", "'s", "disease", ".", "Ginsenoside", "Rg1", "(", "Rg1", ")", "is", "an", "active", "components", "in", "Panax", "ginseng", ",", "a", "famous", "traditional", "Chinese", "medicines", "recorded", "in", "Compendium", "of", "Materia", "Medica", ".", "Present", "study", "attempted", "to", "evaluate", "the", "potential", "mechanisms", "of", "Aβ", "-", "mediated", "insult", "and", "the", "protective", "effects", "of", "Rg1", "on", "human", "endothelial", "cells", ".", "Rg1", "attenuated", "the", "Aβ25", "-", "35-associated", "mitochondrial", "apoptotic", "events", ",", "accompanied", "by", "inhibiting", "HIF-1α", "expression", "followed", "by", "intracellular", "reactive", "nitrogen", "species", "generation", ",", "and", "protein", "nitrotyrosination", ".", "These", "protective", "effects", "were", "abolished", "by", "glucocorticoid", "receptor", "(", "GR", ")", "antagonist", "RU486", "or", "p", "-", "ERK", "inhibitor", "U0126", "rather", "than", "estrogen", "receptor", "α", "antagonist", "ICI", "82,780", ".", "Taken", "together", ",", "our", "results", "suggested", "that", "Rg1", "protected", "against", "Aβ25", "-", "35-induced", "apoptosis", "at", "least", "in", "part", "by", "two", "complementary", "GR", "-", "dependent", "ERK", "phosphorylation", "pathways", ":", "(", "1", ")", "down", "-", "regulating", "HIF-1α", "initiated", "protein", "nitrotyrosination", ",", "and", "(", "2", ")", "inhibiting", "mitochondrial", "apoptotic", "cascades", ".", "These", "data", "provided", "a", "novel", "insight", "to", "the", "mechanisms", "of", "Rg1protective", "effects", "on", "Aβ25", "-", "35-induced", "endothelial", "cells", "apoptosis", ",", "suggesting", "that", "GR", "-", "ERK", "signaling", "pathway", "might", "play", "an", "important", "role", "in", "it", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
glucocorticoid receptor, ERK, ginsenoside Rg1, β - amyloid peptide, β - amyloid, Aβ, Ginsenoside Rg1, Rg1, Aβ, Rg1, Rg1, HIF-1α, nitrogen, glucocorticoid receptor, GR, RU486, p - ERK, U0126, estrogen receptor α, ICI 82,780, Rg1, GR, ERK, HIF-1α, GR, ERK	14269_task2	Sentence: Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it. Instructions: please extract entity words from the input sentence	[ "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.	[ "Activating", "glucocorticoid", "receptor", "-", "ERK", "signaling", "pathway", "contributes", "to", "ginsenoside", "Rg1", "protection", "against", "β", "-", "amyloid", "peptide", "-", "induced", "human", "endothelial", "cells", "apoptosis", ".", "\n", "The", "deposition", "of", "β", "-", "amyloid", "(", "Aβ", ")", "in", "neurons", "and", "vascular", "cells", "of", "the", "brain", "has", "been", "characterized", "in", "Alzheimer", "'s", "disease", ".", "Ginsenoside", "Rg1", "(", "Rg1", ")", "is", "an", "active", "components", "in", "Panax", "ginseng", ",", "a", "famous", "traditional", "Chinese", "medicines", "recorded", "in", "Compendium", "of", "Materia", "Medica", ".", "Present", "study", "attempted", "to", "evaluate", "the", "potential", "mechanisms", "of", "Aβ", "-", "mediated", "insult", "and", "the", "protective", "effects", "of", "Rg1", "on", "human", "endothelial", "cells", ".", "Rg1", "attenuated", "the", "Aβ25", "-", "35-associated", "mitochondrial", "apoptotic", "events", ",", "accompanied", "by", "inhibiting", "HIF-1α", "expression", "followed", "by", "intracellular", "reactive", "nitrogen", "species", "generation", ",", "and", "protein", "nitrotyrosination", ".", "These", "protective", "effects", "were", "abolished", "by", "glucocorticoid", "receptor", "(", "GR", ")", "antagonist", "RU486", "or", "p", "-", "ERK", "inhibitor", "U0126", "rather", "than", "estrogen", "receptor", "α", "antagonist", "ICI", "82,780", ".", "Taken", "together", ",", "our", "results", "suggested", "that", "Rg1", "protected", "against", "Aβ25", "-", "35-induced", "apoptosis", "at", "least", "in", "part", "by", "two", "complementary", "GR", "-", "dependent", "ERK", "phosphorylation", "pathways", ":", "(", "1", ")", "down", "-", "regulating", "HIF-1α", "initiated", "protein", "nitrotyrosination", ",", "and", "(", "2", ")", "inhibiting", "mitochondrial", "apoptotic", "cascades", ".", "These", "data", "provided", "a", "novel", "insight", "to", "the", "mechanisms", "of", "Rg1protective", "effects", "on", "Aβ25", "-", "35-induced", "endothelial", "cells", "apoptosis", ",", "suggesting", "that", "GR", "-", "ERK", "signaling", "pathway", "might", "play", "an", "important", "role", "in", "it", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, Neg-1 is a Protein, Neg-2 is a Protein, IL-4 is a Protein, promoter is a Entity, IL-4 is a Protein	1541828_task0	Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]	T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells.	[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", ".", "\n", "IL-4", "secreted", "by", "activated", "T", "cells", "is", "a", "pleiotropic", "cytokine", "affecting", "growth", "and", "differentiation", "of", "diverse", "cell", "types", "such", "as", "T", "cells", ",", "B", "cells", ",", "and", "mast", "cells", ".", "We", "investigated", "the", "upstream", "regulatory", "elements", "of", "the", "human", "IL-4", "promoter", ".", "A", "novel", "T", "cell", "-", "specific", "negative", "regulatory", "element", "(", "NRE", ")", "composed", "of", "two", "protein", "-", "binding", "sites", "were", "mapped", "in", "the", "5", "'", "flanking", "region", "of", "the", "IL-4", "gene", ":", "-311CTCCCTTCT-303", "(", "NRE", "-", "I", ")", "and", "-288CTTTTTGCTT", "-", "TGC-300", "(", "NRE", "-", "II", ")", ".", "A", "T", "cell", "-", "specific", "protein", "Neg-1", "and", "a", "ubiquitous", "protein", "Neg-2", "binding", "to", "NRE", "-", "I", "and", "NRE", "-", "II", ",", "respectively", ",", "were", "identified", ".", "Furthermore", ",", "a", "positive", "regulatory", "element", "was", "found", "45", "bp", "downstream", "of", "the", "NRE", ".", "The", "enhancer", "activity", "of", "the", "PRE", "was", "completely", "suppressed", "when", "the", "NRE", "was", "present", ".", "These", "data", "suggest", "that", "IL-4", "promoter", "activity", "is", "normally", "down", "-", "regulated", "by", "an", "NRE", "via", "repression", "of", "the", "enhancer", "positive", "regulatory", "element", ".", "These", "data", "may", "have", "implications", "for", "the", "stringent", "control", "of", "IL-4", "expression", "in", "T", "cells", "." ]	[ "Entity", "Protein" ]
IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, Neg-1 is a Protein, Neg-2 is a Protein, IL-4 is a Protein, promoter is a Entity, IL-4 is a Protein	1541828_task1	Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells. Instructions: please typing these entity words according to sentence: IL-4, IL-4, IL-4, IL-4, Neg-1, Neg-2, IL-4, promoter, IL-4 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]	T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells.	[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", ".", "\n", "IL-4", "secreted", "by", "activated", "T", "cells", "is", "a", "pleiotropic", "cytokine", "affecting", "growth", "and", "differentiation", "of", "diverse", "cell", "types", "such", "as", "T", "cells", ",", "B", "cells", ",", "and", "mast", "cells", ".", "We", "investigated", "the", "upstream", "regulatory", "elements", "of", "the", "human", "IL-4", "promoter", ".", "A", "novel", "T", "cell", "-", "specific", "negative", "regulatory", "element", "(", "NRE", ")", "composed", "of", "two", "protein", "-", "binding", "sites", "were", "mapped", "in", "the", "5", "'", "flanking", "region", "of", "the", "IL-4", "gene", ":", "-311CTCCCTTCT-303", "(", "NRE", "-", "I", ")", "and", "-288CTTTTTGCTT", "-", "TGC-300", "(", "NRE", "-", "II", ")", ".", "A", "T", "cell", "-", "specific", "protein", "Neg-1", "and", "a", "ubiquitous", "protein", "Neg-2", "binding", "to", "NRE", "-", "I", "and", "NRE", "-", "II", ",", "respectively", ",", "were", "identified", ".", "Furthermore", ",", "a", "positive", "regulatory", "element", "was", "found", "45", "bp", "downstream", "of", "the", "NRE", ".", "The", "enhancer", "activity", "of", "the", "PRE", "was", "completely", "suppressed", "when", "the", "NRE", "was", "present", ".", "These", "data", "suggest", "that", "IL-4", "promoter", "activity", "is", "normally", "down", "-", "regulated", "by", "an", "NRE", "via", "repression", "of", "the", "enhancer", "positive", "regulatory", "element", ".", "These", "data", "may", "have", "implications", "for", "the", "stringent", "control", "of", "IL-4", "expression", "in", "T", "cells", "." ]	[ "Entity", "Protein" ]
IL-4, IL-4, IL-4, IL-4, Neg-1, Neg-2, IL-4, promoter, IL-4	1541828_task2	Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]	T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells.	[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", ".", "\n", "IL-4", "secreted", "by", "activated", "T", "cells", "is", "a", "pleiotropic", "cytokine", "affecting", "growth", "and", "differentiation", "of", "diverse", "cell", "types", "such", "as", "T", "cells", ",", "B", "cells", ",", "and", "mast", "cells", ".", "We", "investigated", "the", "upstream", "regulatory", "elements", "of", "the", "human", "IL-4", "promoter", ".", "A", "novel", "T", "cell", "-", "specific", "negative", "regulatory", "element", "(", "NRE", ")", "composed", "of", "two", "protein", "-", "binding", "sites", "were", "mapped", "in", "the", "5", "'", "flanking", "region", "of", "the", "IL-4", "gene", ":", "-311CTCCCTTCT-303", "(", "NRE", "-", "I", ")", "and", "-288CTTTTTGCTT", "-", "TGC-300", "(", "NRE", "-", "II", ")", ".", "A", "T", "cell", "-", "specific", "protein", "Neg-1", "and", "a", "ubiquitous", "protein", "Neg-2", "binding", "to", "NRE", "-", "I", "and", "NRE", "-", "II", ",", "respectively", ",", "were", "identified", ".", "Furthermore", ",", "a", "positive", "regulatory", "element", "was", "found", "45", "bp", "downstream", "of", "the", "NRE", ".", "The", "enhancer", "activity", "of", "the", "PRE", "was", "completely", "suppressed", "when", "the", "NRE", "was", "present", ".", "These", "data", "suggest", "that", "IL-4", "promoter", "activity", "is", "normally", "down", "-", "regulated", "by", "an", "NRE", "via", "repression", "of", "the", "enhancer", "positive", "regulatory", "element", ".", "These", "data", "may", "have", "implications", "for", "the", "stringent", "control", "of", "IL-4", "expression", "in", "T", "cells", "." ]	[ "Entity", "Protein" ]
SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, mac is a Protein, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, mouse is a Organism, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, horses is a Organism, mice is a Organism, S. equi is a Organism, SeMac is a Protein, SeMac is a Protein	103_task0	Sentence: Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Protein	[ "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Organism", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection.	[ "Recombinant", "SeMac", "and", "In", "Vitro", "and", "In", "Vivo", "Expression", "of", "SeMac", "\n", "To", "characterize", "SeMac", ",", "the", "fragment", "of", "S.", "equi", "mac", "gene", "encoding", "mature", "SeMac", "was", "cloned", ",", "and", "recombinant", "SeMac", "was", "purified", "to", ">", "95", "%", "purity", "as", "assessed", "by", "SDS", "-", "PAGE", "(", "Fig", ".", "3A", ")", ".", "To", "assess", "the", "in", "vitro", "production", "of", "SeMac", ",", "culture", "supernatant", "of", "the", "10", "S.", "equi", "strains", "was", "prepared", "by", "the", "method", "of", "Lei", "et", "al", ".", "[", "16", "]", ",", "resolved", "by", "SDS", "-", "PAGE", ",", "and", "probed", "by", "Western", "immunoblot", "with", "anti", "-", "SeMac", "mouse", "antisera", ".", "No", "SeMac", "was", "detected", "in", "all", "the", "samples", "(", "data", "not", "shown", ")", ",", "suggesting", "that", "SeMac", "is", "not", "produced", "in", "vitro", ".", "To", "test", "whether", "SeMac", "is", "produced", "in", "vivo", "during", "S.", "equi", "infection", ",", "the", "presence", "of", "SeMac", "-", "specific", "antibody", "was", "assessed", "by", "Western", "immunoblot", "analysis", "with", "convalescent", "sera", "from", "3", "horses", "suffered", "from", "strangles", "and", "mice", "with", "experimental", "S.", "equi", "infection", ".", "All", "the", "convalescent", "sera", "tested", "had", "SeMac", "-", "specific", "antibody", "(", "Fig", ".", "3B", ")", ",", "indicating", "that", "SeMac", "is", "produced", "in", "vivo", "during", "infection", ".", "\n" ]	[ "Organism", "Protein" ]
SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, mac is a Protein, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, mouse is a Organism, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, horses is a Organism, mice is a Organism, S. equi is a Organism, SeMac is a Protein, SeMac is a Protein	103_task1	Sentence: Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection. Instructions: please typing these entity words according to sentence: SeMac, SeMac, SeMac, S. equi, mac, SeMac, SeMac, SeMac, S. equi, SeMac, mouse, SeMac, SeMac, SeMac, S. equi, SeMac, horses, mice, S. equi, SeMac, SeMac Options: Organism, Protein	[ "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Organism", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection.	[ "Recombinant", "SeMac", "and", "In", "Vitro", "and", "In", "Vivo", "Expression", "of", "SeMac", "\n", "To", "characterize", "SeMac", ",", "the", "fragment", "of", "S.", "equi", "mac", "gene", "encoding", "mature", "SeMac", "was", "cloned", ",", "and", "recombinant", "SeMac", "was", "purified", "to", ">", "95", "%", "purity", "as", "assessed", "by", "SDS", "-", "PAGE", "(", "Fig", ".", "3A", ")", ".", "To", "assess", "the", "in", "vitro", "production", "of", "SeMac", ",", "culture", "supernatant", "of", "the", "10", "S.", "equi", "strains", "was", "prepared", "by", "the", "method", "of", "Lei", "et", "al", ".", "[", "16", "]", ",", "resolved", "by", "SDS", "-", "PAGE", ",", "and", "probed", "by", "Western", "immunoblot", "with", "anti", "-", "SeMac", "mouse", "antisera", ".", "No", "SeMac", "was", "detected", "in", "all", "the", "samples", "(", "data", "not", "shown", ")", ",", "suggesting", "that", "SeMac", "is", "not", "produced", "in", "vitro", ".", "To", "test", "whether", "SeMac", "is", "produced", "in", "vivo", "during", "S.", "equi", "infection", ",", "the", "presence", "of", "SeMac", "-", "specific", "antibody", "was", "assessed", "by", "Western", "immunoblot", "analysis", "with", "convalescent", "sera", "from", "3", "horses", "suffered", "from", "strangles", "and", "mice", "with", "experimental", "S.", "equi", "infection", ".", "All", "the", "convalescent", "sera", "tested", "had", "SeMac", "-", "specific", "antibody", "(", "Fig", ".", "3B", ")", ",", "indicating", "that", "SeMac", "is", "produced", "in", "vivo", "during", "infection", ".", "\n" ]	[ "Organism", "Protein" ]
SeMac, SeMac, SeMac, S. equi, mac, SeMac, SeMac, SeMac, S. equi, SeMac, mouse, SeMac, SeMac, SeMac, S. equi, SeMac, horses, mice, S. equi, SeMac, SeMac	103_task2	Sentence: Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection. Instructions: please extract entity words from the input sentence	[ "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Organism", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection.	[ "Recombinant", "SeMac", "and", "In", "Vitro", "and", "In", "Vivo", "Expression", "of", "SeMac", "\n", "To", "characterize", "SeMac", ",", "the", "fragment", "of", "S.", "equi", "mac", "gene", "encoding", "mature", "SeMac", "was", "cloned", ",", "and", "recombinant", "SeMac", "was", "purified", "to", ">", "95", "%", "purity", "as", "assessed", "by", "SDS", "-", "PAGE", "(", "Fig", ".", "3A", ")", ".", "To", "assess", "the", "in", "vitro", "production", "of", "SeMac", ",", "culture", "supernatant", "of", "the", "10", "S.", "equi", "strains", "was", "prepared", "by", "the", "method", "of", "Lei", "et", "al", ".", "[", "16", "]", ",", "resolved", "by", "SDS", "-", "PAGE", ",", "and", "probed", "by", "Western", "immunoblot", "with", "anti", "-", "SeMac", "mouse", "antisera", ".", "No", "SeMac", "was", "detected", "in", "all", "the", "samples", "(", "data", "not", "shown", ")", ",", "suggesting", "that", "SeMac", "is", "not", "produced", "in", "vitro", ".", "To", "test", "whether", "SeMac", "is", "produced", "in", "vivo", "during", "S.", "equi", "infection", ",", "the", "presence", "of", "SeMac", "-", "specific", "antibody", "was", "assessed", "by", "Western", "immunoblot", "analysis", "with", "convalescent", "sera", "from", "3", "horses", "suffered", "from", "strangles", "and", "mice", "with", "experimental", "S.", "equi", "infection", ".", "All", "the", "convalescent", "sera", "tested", "had", "SeMac", "-", "specific", "antibody", "(", "Fig", ".", "3B", ")", ",", "indicating", "that", "SeMac", "is", "produced", "in", "vivo", "during", "infection", ".", "\n" ]	[ "Organism", "Protein" ]
Hydralazine is a compound, APC is a protein	DS.d281_task0	Sentence: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]	Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.	[ "Hydralazine", "inhibits", "human", "cervical", "cancer", "cell", "growth", "in", "vitro", "in", "association", "with", "APC", "demethylation", "and", "re", "-", "expression", "." ]	[ "compound", "protein" ]
Hydralazine is a compound, APC is a protein	DS.d281_task1	Sentence: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Instructions: please typing these entity words according to sentence: Hydralazine, APC Options: compound, protein	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]	Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.	[ "Hydralazine", "inhibits", "human", "cervical", "cancer", "cell", "growth", "in", "vitro", "in", "association", "with", "APC", "demethylation", "and", "re", "-", "expression", "." ]	[ "compound", "protein" ]
Hydralazine, APC	DS.d281_task2	Sentence: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Instructions: please extract entity words from the input sentence	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]	Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.	[ "Hydralazine", "inhibits", "human", "cervical", "cancer", "cell", "growth", "in", "vitro", "in", "association", "with", "APC", "demethylation", "and", "re", "-", "expression", "." ]	[ "compound", "protein" ]
Effectiveness is an outcome, hygienic - dietary recommendations is an intervention, patients with depression is a participant	105_task0	Sentence: Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome, participant	[ "B-outcome", "O", "B-intervention", "I-intervention", "I-intervention", "I-intervention", "O", "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .	[ "Effectiveness", "of", "hygienic", "-", "dietary", "recommendations", "as", "enhancers", "of", "antidepressant", "treatment", "in", "patients", "with", "depression", ":", "study", "protocol", "of", "a", "randomized", "controlled", "trial", "." ]	[ "intervention", "participant", "outcome" ]
Effectiveness is an outcome, hygienic - dietary recommendations is an intervention, patients with depression is a participant	105_task1	Sentence: Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial . Instructions: please typing these entity words according to sentence: Effectiveness, hygienic - dietary recommendations, patients with depression Options: intervention, outcome, participant	[ "B-outcome", "O", "B-intervention", "I-intervention", "I-intervention", "I-intervention", "O", "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .	[ "Effectiveness", "of", "hygienic", "-", "dietary", "recommendations", "as", "enhancers", "of", "antidepressant", "treatment", "in", "patients", "with", "depression", ":", "study", "protocol", "of", "a", "randomized", "controlled", "trial", "." ]	[ "intervention", "participant", "outcome" ]
Effectiveness, hygienic - dietary recommendations, patients with depression	105_task2	Sentence: Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial . Instructions: please extract entity words from the input sentence	[ "B-outcome", "O", "B-intervention", "I-intervention", "I-intervention", "I-intervention", "O", "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .	[ "Effectiveness", "of", "hygienic", "-", "dietary", "recommendations", "as", "enhancers", "of", "antidepressant", "treatment", "in", "patients", "with", "depression", ":", "study", "protocol", "of", "a", "randomized", "controlled", "trial", "." ]	[ "intervention", "participant", "outcome" ]
Human Cytochromes P450 2A13 , 2A6 , and 1B1 is a GENE-N	23432429_task0	Sentence: Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N	[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]	Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.	[ "Binding", "of", "Diverse", "Environmental", "Chemicals", "with", "Human", "Cytochromes", "P450", "2A13", ",", "2A6", ",", "and", "1B1", "and", "Enzyme", "Inhibition", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Human Cytochromes P450 2A13 , 2A6 , and 1B1 is a GENE-N	23432429_task1	Sentence: Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Instructions: please typing these entity words according to sentence: Human Cytochromes P450 2A13 , 2A6 , and 1B1 Options: GENE-N	[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]	Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.	[ "Binding", "of", "Diverse", "Environmental", "Chemicals", "with", "Human", "Cytochromes", "P450", "2A13", ",", "2A6", ",", "and", "1B1", "and", "Enzyme", "Inhibition", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Human Cytochromes P450 2A13 , 2A6 , and 1B1	23432429_task2	Sentence: Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]	Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.	[ "Binding", "of", "Diverse", "Environmental", "Chemicals", "with", "Human", "Cytochromes", "P450", "2A13", ",", "2A6", ",", "and", "1B1", "and", "Enzyme", "Inhibition", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
woman is an umlsterm, syndrome is an umlsterm, blood pressure is an umlsterm, relaxation is an umlsterm, baclofen is an umlsterm, regulation is an umlsterm, cardiovascular system is an umlsterm	DerNervenarzt.60671027.eng.abstr_task0	Sentence: A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system .	[ "A", "woman", "with", "severe", "stiff", "-", "man", "syndrome", "showed", "periodic", "cardiovascular", "dysregulation", ".", "The", "blood", "pressure", "changed", "spontaneously", "every", "5", "-", "10", "min", ".", "This", "rhythm", "was", "also", "maintained", "after", "relaxation", ".", "However", ",", "the", "vegetative", "and", "motoric", "disturbances", "disappeared", "after", "intrathecal", "application", "of", "baclofen", ".", "It", "is", "speculated", "that", "spinal", "GABAergic", "mechanisms", "are", "responsible", "for", "the", "tonic", "regulation", "of", "the", "cardiovascular", "system", "." ]	[ "umlsterm" ]
woman is an umlsterm, syndrome is an umlsterm, blood pressure is an umlsterm, relaxation is an umlsterm, baclofen is an umlsterm, regulation is an umlsterm, cardiovascular system is an umlsterm	DerNervenarzt.60671027.eng.abstr_task1	Sentence: A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system . Instructions: please typing these entity words according to sentence: woman, syndrome, blood pressure, relaxation, baclofen, regulation, cardiovascular system Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system .	[ "A", "woman", "with", "severe", "stiff", "-", "man", "syndrome", "showed", "periodic", "cardiovascular", "dysregulation", ".", "The", "blood", "pressure", "changed", "spontaneously", "every", "5", "-", "10", "min", ".", "This", "rhythm", "was", "also", "maintained", "after", "relaxation", ".", "However", ",", "the", "vegetative", "and", "motoric", "disturbances", "disappeared", "after", "intrathecal", "application", "of", "baclofen", ".", "It", "is", "speculated", "that", "spinal", "GABAergic", "mechanisms", "are", "responsible", "for", "the", "tonic", "regulation", "of", "the", "cardiovascular", "system", "." ]	[ "umlsterm" ]
woman, syndrome, blood pressure, relaxation, baclofen, regulation, cardiovascular system	DerNervenarzt.60671027.eng.abstr_task2	Sentence: A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system .	[ "A", "woman", "with", "severe", "stiff", "-", "man", "syndrome", "showed", "periodic", "cardiovascular", "dysregulation", ".", "The", "blood", "pressure", "changed", "spontaneously", "every", "5", "-", "10", "min", ".", "This", "rhythm", "was", "also", "maintained", "after", "relaxation", ".", "However", ",", "the", "vegetative", "and", "motoric", "disturbances", "disappeared", "after", "intrathecal", "application", "of", "baclofen", ".", "It", "is", "speculated", "that", "spinal", "GABAergic", "mechanisms", "are", "responsible", "for", "the", "tonic", "regulation", "of", "the", "cardiovascular", "system", "." ]	[ "umlsterm" ]
myocardial infarction is an umlsterm, PTCA is an umlsterm, occurrence is an umlsterm, function is an umlsterm, function is an umlsterm, patients is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm	ZfuerKardiologie.00890330.eng.abstr_task0	Sentence: In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) .	[ "In", "acute", "myocardial", "infarction", "intracoronary", "stenting", "is", "superior", "to", "PTCA", "regarding", "interventional", "success", "and", "occurrence", "of", "cardiac", "events", ".", "It", "is", ",", "however", ",", "uncertain", "whether", "myocardial", "function", "also", "improves", "with", "stenting", ".", "We", ",", "therefore", ",", "assessed", "angiographic", "parameters", "of", "myocardial", "function", "in", "patients", "with", "acute", "myocardial", "infarction", "who", "were", "treated", "with", "primary", "PTCA", "and", "received", "additional", "stenting", "in", "case", "of", "an", "unsatisfactory", "angiographic", "result", "(", "provisional", "stenting", ")", "." ]	[ "umlsterm" ]
myocardial infarction is an umlsterm, PTCA is an umlsterm, occurrence is an umlsterm, function is an umlsterm, function is an umlsterm, patients is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm	ZfuerKardiologie.00890330.eng.abstr_task1	Sentence: In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) . Instructions: please typing these entity words according to sentence: myocardial infarction, PTCA, occurrence, function, function, patients, myocardial infarction, PTCA Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) .	[ "In", "acute", "myocardial", "infarction", "intracoronary", "stenting", "is", "superior", "to", "PTCA", "regarding", "interventional", "success", "and", "occurrence", "of", "cardiac", "events", ".", "It", "is", ",", "however", ",", "uncertain", "whether", "myocardial", "function", "also", "improves", "with", "stenting", ".", "We", ",", "therefore", ",", "assessed", "angiographic", "parameters", "of", "myocardial", "function", "in", "patients", "with", "acute", "myocardial", "infarction", "who", "were", "treated", "with", "primary", "PTCA", "and", "received", "additional", "stenting", "in", "case", "of", "an", "unsatisfactory", "angiographic", "result", "(", "provisional", "stenting", ")", "." ]	[ "umlsterm" ]
myocardial infarction, PTCA, occurrence, function, function, patients, myocardial infarction, PTCA	ZfuerKardiologie.00890330.eng.abstr_task2	Sentence: In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) .	[ "In", "acute", "myocardial", "infarction", "intracoronary", "stenting", "is", "superior", "to", "PTCA", "regarding", "interventional", "success", "and", "occurrence", "of", "cardiac", "events", ".", "It", "is", ",", "however", ",", "uncertain", "whether", "myocardial", "function", "also", "improves", "with", "stenting", ".", "We", ",", "therefore", ",", "assessed", "angiographic", "parameters", "of", "myocardial", "function", "in", "patients", "with", "acute", "myocardial", "infarction", "who", "were", "treated", "with", "primary", "PTCA", "and", "received", "additional", "stenting", "in", "case", "of", "an", "unsatisfactory", "angiographic", "result", "(", "provisional", "stenting", ")", "." ]	[ "umlsterm" ]
Movements is an umlsterm, vibrations is an umlsterm, vitrectomy is an umlsterm, motion is an umlsterm, artifacts is an umlsterm, erbium is an umlsterm, laser is an umlsterm, vitrectomy is an umlsterm	DerOpthalmologe.00970615.eng.abstr_task0	Sentence: Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy .	[ "Background", ".", "Movements", "and", "vibrations", "of", "intraocular", "structures", "can", "be", "observed", "during", "vitrectomy", "with", "mechanical", "cutting", "systems", ".", "We", "experimentally", "compared", "these", "intraocular", "motion", "artifacts", "between", "mechanical", "and", "erbium", ":", "YAG", "laser", "vitrectomy", "." ]	[ "umlsterm" ]
Movements is an umlsterm, vibrations is an umlsterm, vitrectomy is an umlsterm, motion is an umlsterm, artifacts is an umlsterm, erbium is an umlsterm, laser is an umlsterm, vitrectomy is an umlsterm	DerOpthalmologe.00970615.eng.abstr_task1	Sentence: Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy . Instructions: please typing these entity words according to sentence: Movements, vibrations, vitrectomy, motion, artifacts, erbium, laser, vitrectomy Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy .	[ "Background", ".", "Movements", "and", "vibrations", "of", "intraocular", "structures", "can", "be", "observed", "during", "vitrectomy", "with", "mechanical", "cutting", "systems", ".", "We", "experimentally", "compared", "these", "intraocular", "motion", "artifacts", "between", "mechanical", "and", "erbium", ":", "YAG", "laser", "vitrectomy", "." ]	[ "umlsterm" ]
Movements, vibrations, vitrectomy, motion, artifacts, erbium, laser, vitrectomy	DerOpthalmologe.00970615.eng.abstr_task2	Sentence: Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy .	[ "Background", ".", "Movements", "and", "vibrations", "of", "intraocular", "structures", "can", "be", "observed", "during", "vitrectomy", "with", "mechanical", "cutting", "systems", ".", "We", "experimentally", "compared", "these", "intraocular", "motion", "artifacts", "between", "mechanical", "and", "erbium", ":", "YAG", "laser", "vitrectomy", "." ]	[ "umlsterm" ]
p300deltaSRC is a protein, p300 is a protein, SRC/ p160 is a protein-family	1.0alpha7.train.1037_task0	Sentence: In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O" ]	In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins.	[ "In", " ", "p300deltaSRC", ",", "there", "is", "a", "deletion", "of", "the", "C", "-", "terminal", "segment", "of", " ", "p300", "that", "binds", "to", "the", " ", "SRC/", "p160", "family", "of", "coactivator", "proteins", "." ]	[ "protein", "protein-family" ]
p300deltaSRC is a protein, p300 is a protein, SRC/ p160 is a protein-family	1.0alpha7.train.1037_task1	Sentence: In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins. Instructions: please typing these entity words according to sentence: p300deltaSRC, p300, SRC/ p160 Options: protein-family, protein	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O" ]	In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins.	[ "In", " ", "p300deltaSRC", ",", "there", "is", "a", "deletion", "of", "the", "C", "-", "terminal", "segment", "of", " ", "p300", "that", "binds", "to", "the", " ", "SRC/", "p160", "family", "of", "coactivator", "proteins", "." ]	[ "protein", "protein-family" ]
p300deltaSRC, p300, SRC/ p160	1.0alpha7.train.1037_task2	Sentence: In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O" ]	In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins.	[ "In", " ", "p300deltaSRC", ",", "there", "is", "a", "deletion", "of", "the", "C", "-", "terminal", "segment", "of", " ", "p300", "that", "binds", "to", "the", " ", "SRC/", "p160", "family", "of", "coactivator", "proteins", "." ]	[ "protein", "protein-family" ]
DNA is a Entity, Epstein - Barr virus nuclear antigen 2 is a Protein, EBNA-2 is a Protein, Epstein - Barr virus ( EBV ) nuclear antigen 2 is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, genes is a Entity, CD23 is a Protein, c - fgr is a Protein, latent membrane protein 1 is a Protein, LMP1 is a Protein, terminal protein 1 is a Protein, TP1 is a Protein, TP1 is a Protein, promoter is a Entity, BamHI C is a Protein, promoter is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2 is a Protein, LMP is a Protein, cis - acting elements is a Entity, LMP is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, promoter is a Entity, LMP is a Protein, protein - binding region is a Entity, LMP is a Protein, promoter is a Entity, 42 bp fragment is a Entity, nucleotides -135 to -176 is a Entity, LMP transcriptional start site is a Entity, DNA fragments is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2A is a Protein, TP1 is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity, specific complexes is a Entity, LMP is a Protein, promoter is a Entity	467_task0	Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.	[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", ".", "\n" ]	[ "Protein", "Entity" ]
DNA is a Entity, Epstein - Barr virus nuclear antigen 2 is a Protein, EBNA-2 is a Protein, Epstein - Barr virus ( EBV ) nuclear antigen 2 is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, genes is a Entity, CD23 is a Protein, c - fgr is a Protein, latent membrane protein 1 is a Protein, LMP1 is a Protein, terminal protein 1 is a Protein, TP1 is a Protein, TP1 is a Protein, promoter is a Entity, BamHI C is a Protein, promoter is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2 is a Protein, LMP is a Protein, cis - acting elements is a Entity, LMP is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, promoter is a Entity, LMP is a Protein, protein - binding region is a Entity, LMP is a Protein, promoter is a Entity, 42 bp fragment is a Entity, nucleotides -135 to -176 is a Entity, LMP transcriptional start site is a Entity, DNA fragments is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2A is a Protein, TP1 is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity, specific complexes is a Entity, LMP is a Protein, promoter is a Entity	467_task1	Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please typing these entity words according to sentence: DNA, Epstein - Barr virus nuclear antigen 2, EBNA-2, Epstein - Barr virus ( EBV ) nuclear antigen 2, EBNA-2, EBNA-2, genes, CD23, c - fgr, latent membrane protein 1, LMP1, terminal protein 1, TP1, TP1, promoter, BamHI C, promoter, EBNA-2, DNA, EBNA-2, LMP, cis - acting elements, LMP, promoter, EBNA-2, EBNA-2, LMP, promoter, LMP, protein - binding region, LMP, promoter, 42 bp fragment, nucleotides -135 to -176, LMP transcriptional start site, DNA fragments, EBNA-2, DNA, EBNA-2A, TP1, promoter, LMP, promoter, specific complexes, LMP, promoter Options: Entity, Protein	[ "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.	[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", ".", "\n" ]	[ "Protein", "Entity" ]
DNA, Epstein - Barr virus nuclear antigen 2, EBNA-2, Epstein - Barr virus ( EBV ) nuclear antigen 2, EBNA-2, EBNA-2, genes, CD23, c - fgr, latent membrane protein 1, LMP1, terminal protein 1, TP1, TP1, promoter, BamHI C, promoter, EBNA-2, DNA, EBNA-2, LMP, cis - acting elements, LMP, promoter, EBNA-2, EBNA-2, LMP, promoter, LMP, protein - binding region, LMP, promoter, 42 bp fragment, nucleotides -135 to -176, LMP transcriptional start site, DNA fragments, EBNA-2, DNA, EBNA-2A, TP1, promoter, LMP, promoter, specific complexes, LMP, promoter	467_task2	Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please extract entity words from the input sentence	[ "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.	[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", ".", "\n" ]	[ "Protein", "Entity" ]
patient is an umlsterm, measurements is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, radiation is an umlsterm, patient is an umlsterm, measurements is an umlsterm, patient is an umlsterm, use is an umlsterm, art is an umlsterm	DerRadiologe.80380993.eng.abstr_task0	Sentence: To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution .	[ "To", "compare", "patient", "dose", "and", "image", "quality", "of", "electron", "-", "beam", "-", "CT", "vs", ".", "spiral", "-", "CT", "by", "means", "of", "phantom", "measurements", ".", "An", "EBCT", "scanner", "(", "C-150", "XP", ")", "and", "a", "spiral", "-", "CT", "scanner", "(", "GE", "HiSpeed", "Advantage", ")", "were", "used", "to", "scan", "three", "different", "phantoms", ".", "Administered", "dose", ",", "high", "contrast", "(", "HC", ")", "resolution", ",", "low", "contrast", "(", "LC", ")", "lesion", "detectability", "and", "the", "width", "of", "the", "radiation", "beams", "were", "measured", ".", "EBCT", "showed", "25", "-", "35", "%", "lower", "HC", "resolution", "in", "comparison", "to", "spiral", "-", "CT", ".", "LC", "lesion", "detectability", "showed", "equivalent", "results", "for", "S", "/", "N", "vs", ".", "patient", "dose", "using", "3", "mm", "collimation", "with", "EBCT", "and", "spiral", "-", "CT", ",", "whereas", "spiral", "-", "CT", "was", "superior", "for", "1,5", "and", "6", "mm", "collimation", ".", "Dose", "measurements", "revealed", "a", "2", "fold", "higher", "patient", "dose", "using", "EBCT", "with", "1,5", "mm", "or", "6", "mm", "collimation", "compared", "to", "spiral", "-", "CT", "using", "equivalent", "scan", "parameters", ".", "No", "differences", "were", "seen", "using", "3", "mm", "collimation", ".", "Differences", "were", "due", "to", "insufficient", "beamside", "collimation", "of", "the", "EBCT", ".", "The", "use", "of", "EBCT", "with", "6", "mm", "collimation", "should", "be", "avoided", ",", "because", "of", "impaired", "performance", ".", "Using", "3", "mm", "collimation", ",", "EBCT", "showed", "comparable", "performance", "like", "state", "of", "the", "art", "spiral", "-", "CT", "despite", "lower", "HC", "resolution", "." ]	[ "umlsterm" ]
patient is an umlsterm, measurements is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, radiation is an umlsterm, patient is an umlsterm, measurements is an umlsterm, patient is an umlsterm, use is an umlsterm, art is an umlsterm	DerRadiologe.80380993.eng.abstr_task1	Sentence: To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution . Instructions: please typing these entity words according to sentence: patient, measurements, contrast, contrast, radiation, patient, measurements, patient, use, art Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution .	[ "To", "compare", "patient", "dose", "and", "image", "quality", "of", "electron", "-", "beam", "-", "CT", "vs", ".", "spiral", "-", "CT", "by", "means", "of", "phantom", "measurements", ".", "An", "EBCT", "scanner", "(", "C-150", "XP", ")", "and", "a", "spiral", "-", "CT", "scanner", "(", "GE", "HiSpeed", "Advantage", ")", "were", "used", "to", "scan", "three", "different", "phantoms", ".", "Administered", "dose", ",", "high", "contrast", "(", "HC", ")", "resolution", ",", "low", "contrast", "(", "LC", ")", "lesion", "detectability", "and", "the", "width", "of", "the", "radiation", "beams", "were", "measured", ".", "EBCT", "showed", "25", "-", "35", "%", "lower", "HC", "resolution", "in", "comparison", "to", "spiral", "-", "CT", ".", "LC", "lesion", "detectability", "showed", "equivalent", "results", "for", "S", "/", "N", "vs", ".", "patient", "dose", "using", "3", "mm", "collimation", "with", "EBCT", "and", "spiral", "-", "CT", ",", "whereas", "spiral", "-", "CT", "was", "superior", "for", "1,5", "and", "6", "mm", "collimation", ".", "Dose", "measurements", "revealed", "a", "2", "fold", "higher", "patient", "dose", "using", "EBCT", "with", "1,5", "mm", "or", "6", "mm", "collimation", "compared", "to", "spiral", "-", "CT", "using", "equivalent", "scan", "parameters", ".", "No", "differences", "were", "seen", "using", "3", "mm", "collimation", ".", "Differences", "were", "due", "to", "insufficient", "beamside", "collimation", "of", "the", "EBCT", ".", "The", "use", "of", "EBCT", "with", "6", "mm", "collimation", "should", "be", "avoided", ",", "because", "of", "impaired", "performance", ".", "Using", "3", "mm", "collimation", ",", "EBCT", "showed", "comparable", "performance", "like", "state", "of", "the", "art", "spiral", "-", "CT", "despite", "lower", "HC", "resolution", "." ]	[ "umlsterm" ]
patient, measurements, contrast, contrast, radiation, patient, measurements, patient, use, art	DerRadiologe.80380993.eng.abstr_task2	Sentence: To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution .	[ "To", "compare", "patient", "dose", "and", "image", "quality", "of", "electron", "-", "beam", "-", "CT", "vs", ".", "spiral", "-", "CT", "by", "means", "of", "phantom", "measurements", ".", "An", "EBCT", "scanner", "(", "C-150", "XP", ")", "and", "a", "spiral", "-", "CT", "scanner", "(", "GE", "HiSpeed", "Advantage", ")", "were", "used", "to", "scan", "three", "different", "phantoms", ".", "Administered", "dose", ",", "high", "contrast", "(", "HC", ")", "resolution", ",", "low", "contrast", "(", "LC", ")", "lesion", "detectability", "and", "the", "width", "of", "the", "radiation", "beams", "were", "measured", ".", "EBCT", "showed", "25", "-", "35", "%", "lower", "HC", "resolution", "in", "comparison", "to", "spiral", "-", "CT", ".", "LC", "lesion", "detectability", "showed", "equivalent", "results", "for", "S", "/", "N", "vs", ".", "patient", "dose", "using", "3", "mm", "collimation", "with", "EBCT", "and", "spiral", "-", "CT", ",", "whereas", "spiral", "-", "CT", "was", "superior", "for", "1,5", "and", "6", "mm", "collimation", ".", "Dose", "measurements", "revealed", "a", "2", "fold", "higher", "patient", "dose", "using", "EBCT", "with", "1,5", "mm", "or", "6", "mm", "collimation", "compared", "to", "spiral", "-", "CT", "using", "equivalent", "scan", "parameters", ".", "No", "differences", "were", "seen", "using", "3", "mm", "collimation", ".", "Differences", "were", "due", "to", "insufficient", "beamside", "collimation", "of", "the", "EBCT", ".", "The", "use", "of", "EBCT", "with", "6", "mm", "collimation", "should", "be", "avoided", ",", "because", "of", "impaired", "performance", ".", "Using", "3", "mm", "collimation", ",", "EBCT", "showed", "comparable", "performance", "like", "state", "of", "the", "art", "spiral", "-", "CT", "despite", "lower", "HC", "resolution", "." ]	[ "umlsterm" ]
polytetrafluorethylene is an umlsterm, aim is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, elements is an umlsterm, incorporation is an umlsterm, prostheses is an umlsterm, high density polyethylene is an umlsterm, neck muscle is an umlsterm, pigs is an umlsterm, prostheses is an umlsterm, cell is an umlsterm, technique is an umlsterm, defect is an umlsterm, endoscopy is an umlsterm, light is an umlsterm, scanning electron microscopy is an umlsterm, prostheses is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, ability is an umlsterm, prosthesis is an umlsterm, cell differentiation is an umlsterm, prostheses is an umlsterm, epitheliums is an umlsterm, solution is an umlsterm, defects is an umlsterm	HNO.70450453.eng.abstr_task0	Sentence: Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects .	[ "Replacement", "of", "the", "tracheal", "conduit", "remains", "an", "unresolved", "problem", ".", "The", "microporous", "material", "expanded", "polytetrafluorethylene", "(", "ePTFE", ")", "is", "suitable", "for", "tracheal", "reconstruction", ".", "The", "aim", "of", "our", "study", "was", "to", "improve", "the", "limited", "mechanical", "properties", "of", "this", "material", "by", "incorporating", "reinforcement", "elements", "and", "to", "examine", "the", "influence", "of", "these", "elements", "on", "host", "incorporation", "and", "epithelialization", ".", "In", "so", "dours", "ePTFE", "prostheses", "were", "reinforced", "with", "Ionomer", "cement", "and", "porous", "high", "density", "polyethylene", "(", "pHDPE", ")", "rings", "and", "implanted", "into", "the", "neck", "muscle", "of", "miniature", "pigs", ".", "One", "of", "these", "prostheses", "was", "epithelialized", "by", "a", "cell", "seeding", "technique", "and", "was", "thus", "placed", "into", "a", "tracheal", "defect", ".", "Results", "were", "examined", "grossly", "by", "endoscopy", "and", "than", "by", "light", "and", "scanning", "electron", "microscopy", ".", "The", "shapes", "of", "both", "types", "of", "prostheses", "showed", "a", "high", "stability", ".", "The", "reinforcement", "elements", "did", "not", "impair", "bioincorporation", "or", "the", "ability", "to", "epithelialize", ".", "In", "vivo", "interposition", "of", "an", "incorporated", "and", "epithelialized", "prosthesis", "to", "a", "host", "led", "to", "cell", "differentiation", ".", "The", "improved", "biomechanical", "properties", "of", "the", "prostheses", "waid", "and", "the", "reproducible", "formation", "of", "epitheliums", "are", "important", "advances", "in", "the", "solution", "of", "effectively", "correcting", "tracheal", "defects", "." ]	[ "umlsterm" ]
polytetrafluorethylene is an umlsterm, aim is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, elements is an umlsterm, incorporation is an umlsterm, prostheses is an umlsterm, high density polyethylene is an umlsterm, neck muscle is an umlsterm, pigs is an umlsterm, prostheses is an umlsterm, cell is an umlsterm, technique is an umlsterm, defect is an umlsterm, endoscopy is an umlsterm, light is an umlsterm, scanning electron microscopy is an umlsterm, prostheses is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, ability is an umlsterm, prosthesis is an umlsterm, cell differentiation is an umlsterm, prostheses is an umlsterm, epitheliums is an umlsterm, solution is an umlsterm, defects is an umlsterm	HNO.70450453.eng.abstr_task1	Sentence: Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects . Instructions: please typing these entity words according to sentence: polytetrafluorethylene, aim, reinforcement, elements, elements, incorporation, prostheses, high density polyethylene, neck muscle, pigs, prostheses, cell, technique, defect, endoscopy, light, scanning electron microscopy, prostheses, reinforcement, elements, ability, prosthesis, cell differentiation, prostheses, epitheliums, solution, defects Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects .	[ "Replacement", "of", "the", "tracheal", "conduit", "remains", "an", "unresolved", "problem", ".", "The", "microporous", "material", "expanded", "polytetrafluorethylene", "(", "ePTFE", ")", "is", "suitable", "for", "tracheal", "reconstruction", ".", "The", "aim", "of", "our", "study", "was", "to", "improve", "the", "limited", "mechanical", "properties", "of", "this", "material", "by", "incorporating", "reinforcement", "elements", "and", "to", "examine", "the", "influence", "of", "these", "elements", "on", "host", "incorporation", "and", "epithelialization", ".", "In", "so", "dours", "ePTFE", "prostheses", "were", "reinforced", "with", "Ionomer", "cement", "and", "porous", "high", "density", "polyethylene", "(", "pHDPE", ")", "rings", "and", "implanted", "into", "the", "neck", "muscle", "of", "miniature", "pigs", ".", "One", "of", "these", "prostheses", "was", "epithelialized", "by", "a", "cell", "seeding", "technique", "and", "was", "thus", "placed", "into", "a", "tracheal", "defect", ".", "Results", "were", "examined", "grossly", "by", "endoscopy", "and", "than", "by", "light", "and", "scanning", "electron", "microscopy", ".", "The", "shapes", "of", "both", "types", "of", "prostheses", "showed", "a", "high", "stability", ".", "The", "reinforcement", "elements", "did", "not", "impair", "bioincorporation", "or", "the", "ability", "to", "epithelialize", ".", "In", "vivo", "interposition", "of", "an", "incorporated", "and", "epithelialized", "prosthesis", "to", "a", "host", "led", "to", "cell", "differentiation", ".", "The", "improved", "biomechanical", "properties", "of", "the", "prostheses", "waid", "and", "the", "reproducible", "formation", "of", "epitheliums", "are", "important", "advances", "in", "the", "solution", "of", "effectively", "correcting", "tracheal", "defects", "." ]	[ "umlsterm" ]
polytetrafluorethylene, aim, reinforcement, elements, elements, incorporation, prostheses, high density polyethylene, neck muscle, pigs, prostheses, cell, technique, defect, endoscopy, light, scanning electron microscopy, prostheses, reinforcement, elements, ability, prosthesis, cell differentiation, prostheses, epitheliums, solution, defects	HNO.70450453.eng.abstr_task2	Sentence: Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects .	[ "Replacement", "of", "the", "tracheal", "conduit", "remains", "an", "unresolved", "problem", ".", "The", "microporous", "material", "expanded", "polytetrafluorethylene", "(", "ePTFE", ")", "is", "suitable", "for", "tracheal", "reconstruction", ".", "The", "aim", "of", "our", "study", "was", "to", "improve", "the", "limited", "mechanical", "properties", "of", "this", "material", "by", "incorporating", "reinforcement", "elements", "and", "to", "examine", "the", "influence", "of", "these", "elements", "on", "host", "incorporation", "and", "epithelialization", ".", "In", "so", "dours", "ePTFE", "prostheses", "were", "reinforced", "with", "Ionomer", "cement", "and", "porous", "high", "density", "polyethylene", "(", "pHDPE", ")", "rings", "and", "implanted", "into", "the", "neck", "muscle", "of", "miniature", "pigs", ".", "One", "of", "these", "prostheses", "was", "epithelialized", "by", "a", "cell", "seeding", "technique", "and", "was", "thus", "placed", "into", "a", "tracheal", "defect", ".", "Results", "were", "examined", "grossly", "by", "endoscopy", "and", "than", "by", "light", "and", "scanning", "electron", "microscopy", ".", "The", "shapes", "of", "both", "types", "of", "prostheses", "showed", "a", "high", "stability", ".", "The", "reinforcement", "elements", "did", "not", "impair", "bioincorporation", "or", "the", "ability", "to", "epithelialize", ".", "In", "vivo", "interposition", "of", "an", "incorporated", "and", "epithelialized", "prosthesis", "to", "a", "host", "led", "to", "cell", "differentiation", ".", "The", "improved", "biomechanical", "properties", "of", "the", "prostheses", "waid", "and", "the", "reproducible", "formation", "of", "epitheliums", "are", "important", "advances", "in", "the", "solution", "of", "effectively", "correcting", "tracheal", "defects", "." ]	[ "umlsterm" ]
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a CHEMICAL, PhIP is a CHEMICAL, creatinine is a CHEMICAL, phenylalanine is a CHEMICAL, creatinine is a CHEMICAL	23265474_task0	Sentence: Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]	Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures.	[ "Comparative", "formation", "of", "2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine", "(", "PhIP", ")", "in", "creatinine", "/", "phenylalanine", "and", "creatinine", "/", "phenylalanine/4-oxo-2-nonenal", "reaction", "mixtures", "." ]	[ "CHEMICAL" ]
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a CHEMICAL, PhIP is a CHEMICAL, creatinine is a CHEMICAL, phenylalanine is a CHEMICAL, creatinine is a CHEMICAL	23265474_task1	Sentence: Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures. Instructions: please typing these entity words according to sentence: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, PhIP, creatinine, phenylalanine, creatinine Options: CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]	Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures.	[ "Comparative", "formation", "of", "2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine", "(", "PhIP", ")", "in", "creatinine", "/", "phenylalanine", "and", "creatinine", "/", "phenylalanine/4-oxo-2-nonenal", "reaction", "mixtures", "." ]	[ "CHEMICAL" ]
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, PhIP, creatinine, phenylalanine, creatinine	23265474_task2	Sentence: Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]	Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures.	[ "Comparative", "formation", "of", "2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine", "(", "PhIP", ")", "in", "creatinine", "/", "phenylalanine", "and", "creatinine", "/", "phenylalanine/4-oxo-2-nonenal", "reaction", "mixtures", "." ]	[ "CHEMICAL" ]
p50 is a Protein, p50 is a Protein, p65 is a Protein, Ets-1 is a Protein	690_task0	Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.	[ "Physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "play", "an", "important", "role", "in", "their", "cooperative", "activation", "of", "the", "human", "immunodeficiency", "virus", "enhancer", "in", "T", "cells", ".", "\n", "The", "transcriptional", "regulatory", "elements", "of", "many", "inducible", "T", "-", "cell", "genes", "contain", "adjacent", "or", "overlapping", "binding", "sites", "for", "the", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "families", "of", "transcription", "factors", ".", "Similar", "arrays", "of", "functionally", "important", "NF", "-", "kappaB", "/", "NFAT", "and", "Ets", "binding", "sites", "are", "present", "in", "the", "transcriptional", "enhancers", "of", "human", "immunodeficiency", "viruses", "types", "1", "and", "2", "(", "HIV-1", "and", "HIV-2", ")", ",", "suggesting", "that", "this", "pattern", "of", "nuclear", "protein", "binding", "sites", "reflects", "an", "evolutionarily", "conserved", "mechanism", "for", "regulating", "inducible", "T", "-", "cell", "gene", "expression", "that", "has", "been", "co", "-", "opted", "during", "HIV", "evolution", ".", "Despite", "these", "findings", ",", "the", "molecular", "mechanisms", "by", "which", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "cooperatively", "regulate", "inducible", "T", "-", "cell", "gene", "expression", "remained", "unknown", ".", "In", "the", "studies", "described", "in", "this", "report", ",", "we", "demonstrated", "a", "physical", "interaction", "between", "multiple", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "both", "in", "vitro", "and", "in", "activated", "normal", "human", "T", "cells", ".", "This", "interaction", "is", "mediated", "by", "the", "Ets", "domain", "of", "Ets", "proteins", "and", "the", "C", "-", "terminal", "region", "of", "the", "Rel", "homology", "domains", "of", "NF", "-", "kappaB", "/", "NFAT", "proteins", ".", "In", "addition", ",", "the", "Ets", "-", "NF", "-", "kappaB", "/", "NFAT", "interaction", "requires", "the", "presence", "of", "DNA", "binding", "sites", "for", "both", "proteins", ",", "as", "it", "is", "abolished", "by", "the", "DNA", "intercalating", "agents", "propidium", "iodide", "and", "ethidium", "bromide", "and", "enhanced", "by", "the", "presence", "of", "synthetic", "oligonucleotides", "containing", "binding", "sites", "for", "Ets", "and", "NF", "-", "kappaB", "proteins", ".", "A", "dominant", "-", "negative", "mutant", "of", "NF", "-", "kappaB", "p50", "that", "binds", "DNA", "but", "fails", "to", "interact", "with", "Ets", "proteins", "inhibits", "the", "synergistic", "activation", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", "by", "NF", "-", "kappaB", "(", "p50", "+", "p65", ")", "and", "Ets-1", ",", "suggesting", "that", "physical", "interaction", "between", "Ets", "and", "NF", "-", "kappaB", "proteins", "is", "required", "for", "the", "transcriptional", "activity", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", ".", "Taken", "together", ",", "these", "findings", "suggest", "that", "evolutionarily", "conserved", "physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "are", "important", "in", "regulating", "the", "inducible", "expression", "of", "T", "-", "cell", "genes", "and", "viruses", ".", "These", "interactions", "represent", "a", "potential", "target", "for", "the", "development", "of", "novel", "immunosuppressive", "and", "antiviral", "therapies", "." ]	[ "Protein" ]
p50 is a Protein, p50 is a Protein, p65 is a Protein, Ets-1 is a Protein	690_task1	Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies. Instructions: please typing these entity words according to sentence: p50, p50, p65, Ets-1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.	[ "Physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "play", "an", "important", "role", "in", "their", "cooperative", "activation", "of", "the", "human", "immunodeficiency", "virus", "enhancer", "in", "T", "cells", ".", "\n", "The", "transcriptional", "regulatory", "elements", "of", "many", "inducible", "T", "-", "cell", "genes", "contain", "adjacent", "or", "overlapping", "binding", "sites", "for", "the", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "families", "of", "transcription", "factors", ".", "Similar", "arrays", "of", "functionally", "important", "NF", "-", "kappaB", "/", "NFAT", "and", "Ets", "binding", "sites", "are", "present", "in", "the", "transcriptional", "enhancers", "of", "human", "immunodeficiency", "viruses", "types", "1", "and", "2", "(", "HIV-1", "and", "HIV-2", ")", ",", "suggesting", "that", "this", "pattern", "of", "nuclear", "protein", "binding", "sites", "reflects", "an", "evolutionarily", "conserved", "mechanism", "for", "regulating", "inducible", "T", "-", "cell", "gene", "expression", "that", "has", "been", "co", "-", "opted", "during", "HIV", "evolution", ".", "Despite", "these", "findings", ",", "the", "molecular", "mechanisms", "by", "which", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "cooperatively", "regulate", "inducible", "T", "-", "cell", "gene", "expression", "remained", "unknown", ".", "In", "the", "studies", "described", "in", "this", "report", ",", "we", "demonstrated", "a", "physical", "interaction", "between", "multiple", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "both", "in", "vitro", "and", "in", "activated", "normal", "human", "T", "cells", ".", "This", "interaction", "is", "mediated", "by", "the", "Ets", "domain", "of", "Ets", "proteins", "and", "the", "C", "-", "terminal", "region", "of", "the", "Rel", "homology", "domains", "of", "NF", "-", "kappaB", "/", "NFAT", "proteins", ".", "In", "addition", ",", "the", "Ets", "-", "NF", "-", "kappaB", "/", "NFAT", "interaction", "requires", "the", "presence", "of", "DNA", "binding", "sites", "for", "both", "proteins", ",", "as", "it", "is", "abolished", "by", "the", "DNA", "intercalating", "agents", "propidium", "iodide", "and", "ethidium", "bromide", "and", "enhanced", "by", "the", "presence", "of", "synthetic", "oligonucleotides", "containing", "binding", "sites", "for", "Ets", "and", "NF", "-", "kappaB", "proteins", ".", "A", "dominant", "-", "negative", "mutant", "of", "NF", "-", "kappaB", "p50", "that", "binds", "DNA", "but", "fails", "to", "interact", "with", "Ets", "proteins", "inhibits", "the", "synergistic", "activation", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", "by", "NF", "-", "kappaB", "(", "p50", "+", "p65", ")", "and", "Ets-1", ",", "suggesting", "that", "physical", "interaction", "between", "Ets", "and", "NF", "-", "kappaB", "proteins", "is", "required", "for", "the", "transcriptional", "activity", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", ".", "Taken", "together", ",", "these", "findings", "suggest", "that", "evolutionarily", "conserved", "physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "are", "important", "in", "regulating", "the", "inducible", "expression", "of", "T", "-", "cell", "genes", "and", "viruses", ".", "These", "interactions", "represent", "a", "potential", "target", "for", "the", "development", "of", "novel", "immunosuppressive", "and", "antiviral", "therapies", "." ]	[ "Protein" ]
p50, p50, p65, Ets-1	690_task2	Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.	[ "Physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "play", "an", "important", "role", "in", "their", "cooperative", "activation", "of", "the", "human", "immunodeficiency", "virus", "enhancer", "in", "T", "cells", ".", "\n", "The", "transcriptional", "regulatory", "elements", "of", "many", "inducible", "T", "-", "cell", "genes", "contain", "adjacent", "or", "overlapping", "binding", "sites", "for", "the", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "families", "of", "transcription", "factors", ".", "Similar", "arrays", "of", "functionally", "important", "NF", "-", "kappaB", "/", "NFAT", "and", "Ets", "binding", "sites", "are", "present", "in", "the", "transcriptional", "enhancers", "of", "human", "immunodeficiency", "viruses", "types", "1", "and", "2", "(", "HIV-1", "and", "HIV-2", ")", ",", "suggesting", "that", "this", "pattern", "of", "nuclear", "protein", "binding", "sites", "reflects", "an", "evolutionarily", "conserved", "mechanism", "for", "regulating", "inducible", "T", "-", "cell", "gene", "expression", "that", "has", "been", "co", "-", "opted", "during", "HIV", "evolution", ".", "Despite", "these", "findings", ",", "the", "molecular", "mechanisms", "by", "which", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "cooperatively", "regulate", "inducible", "T", "-", "cell", "gene", "expression", "remained", "unknown", ".", "In", "the", "studies", "described", "in", "this", "report", ",", "we", "demonstrated", "a", "physical", "interaction", "between", "multiple", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "both", "in", "vitro", "and", "in", "activated", "normal", "human", "T", "cells", ".", "This", "interaction", "is", "mediated", "by", "the", "Ets", "domain", "of", "Ets", "proteins", "and", "the", "C", "-", "terminal", "region", "of", "the", "Rel", "homology", "domains", "of", "NF", "-", "kappaB", "/", "NFAT", "proteins", ".", "In", "addition", ",", "the", "Ets", "-", "NF", "-", "kappaB", "/", "NFAT", "interaction", "requires", "the", "presence", "of", "DNA", "binding", "sites", "for", "both", "proteins", ",", "as", "it", "is", "abolished", "by", "the", "DNA", "intercalating", "agents", "propidium", "iodide", "and", "ethidium", "bromide", "and", "enhanced", "by", "the", "presence", "of", "synthetic", "oligonucleotides", "containing", "binding", "sites", "for", "Ets", "and", "NF", "-", "kappaB", "proteins", ".", "A", "dominant", "-", "negative", "mutant", "of", "NF", "-", "kappaB", "p50", "that", "binds", "DNA", "but", "fails", "to", "interact", "with", "Ets", "proteins", "inhibits", "the", "synergistic", "activation", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", "by", "NF", "-", "kappaB", "(", "p50", "+", "p65", ")", "and", "Ets-1", ",", "suggesting", "that", "physical", "interaction", "between", "Ets", "and", "NF", "-", "kappaB", "proteins", "is", "required", "for", "the", "transcriptional", "activity", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", ".", "Taken", "together", ",", "these", "findings", "suggest", "that", "evolutionarily", "conserved", "physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "are", "important", "in", "regulating", "the", "inducible", "expression", "of", "T", "-", "cell", "genes", "and", "viruses", ".", "These", "interactions", "represent", "a", "potential", "target", "for", "the", "development", "of", "novel", "immunosuppressive", "and", "antiviral", "therapies", "." ]	[ "Protein" ]
Retinal is a Multi-tissue_structure, patient is a Organism, vessels is a Multi-tissue_structure, retinal periphery is a Tissue, capillary is a Tissue, macula is a Tissue, eye is a Organ, vessels is a Multi-tissue_structure, vessels is a Multi-tissue_structure, retina is a Multi-tissue_structure, vessels is a Multi-tissue_structure	10_task0	Sentence: Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Tissue, Multi-tissue_structure, Organ	[ "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O" ]	Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels.	[ "Retinal", "revascularisation", "in", "diabetic", "retinopathy", ".", "\n\n", "The", "case", "history", "of", "a", "33-year", "-", "old", "diabetic", "patient", "who", "has", "had", "diabetes", "for", "24", "years", "is", "presented", ".", "When", "first", "seen", "in", "1975", "he", "had", "bilateral", "proliferative", "retinopathy", "with", "new", "vessels", "in", "the", "retinal", "periphery", ".", "He", "had", "large", "areas", "of", "capillary", "non", "-", "perfusion", "lateral", "to", "the", "macula", "in", "the", "right", "eye", "associated", "with", "the", "new", "vessels", ".", "Nine", "years", "later", ",", "after", "extensive", "repeated", "photocoagulation", ",", "revascularisation", "of", "large", "areas", "previously", "not", "perfused", "were", "seen", ".", "The", "vessels", "are", "in", "the", "plane", "of", "the", "retina", "and", "do", "not", "have", "the", "appearance", "of", "new", "vessels", ".", "\n" ]	[ "Tissue", "Multi-tissue_structure", "Organism", "Organ" ]
Retinal is a Multi-tissue_structure, patient is a Organism, vessels is a Multi-tissue_structure, retinal periphery is a Tissue, capillary is a Tissue, macula is a Tissue, eye is a Organ, vessels is a Multi-tissue_structure, vessels is a Multi-tissue_structure, retina is a Multi-tissue_structure, vessels is a Multi-tissue_structure	10_task1	Sentence: Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels. Instructions: please typing these entity words according to sentence: Retinal, patient, vessels, retinal periphery, capillary, macula, eye, vessels, vessels, retina, vessels Options: Organism, Tissue, Multi-tissue_structure, Organ	[ "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O" ]	Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels.	[ "Retinal", "revascularisation", "in", "diabetic", "retinopathy", ".", "\n\n", "The", "case", "history", "of", "a", "33-year", "-", "old", "diabetic", "patient", "who", "has", "had", "diabetes", "for", "24", "years", "is", "presented", ".", "When", "first", "seen", "in", "1975", "he", "had", "bilateral", "proliferative", "retinopathy", "with", "new", "vessels", "in", "the", "retinal", "periphery", ".", "He", "had", "large", "areas", "of", "capillary", "non", "-", "perfusion", "lateral", "to", "the", "macula", "in", "the", "right", "eye", "associated", "with", "the", "new", "vessels", ".", "Nine", "years", "later", ",", "after", "extensive", "repeated", "photocoagulation", ",", "revascularisation", "of", "large", "areas", "previously", "not", "perfused", "were", "seen", ".", "The", "vessels", "are", "in", "the", "plane", "of", "the", "retina", "and", "do", "not", "have", "the", "appearance", "of", "new", "vessels", ".", "\n" ]	[ "Tissue", "Multi-tissue_structure", "Organism", "Organ" ]
Retinal, patient, vessels, retinal periphery, capillary, macula, eye, vessels, vessels, retina, vessels	10_task2	Sentence: Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels. Instructions: please extract entity words from the input sentence	[ "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O" ]	Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels.	[ "Retinal", "revascularisation", "in", "diabetic", "retinopathy", ".", "\n\n", "The", "case", "history", "of", "a", "33-year", "-", "old", "diabetic", "patient", "who", "has", "had", "diabetes", "for", "24", "years", "is", "presented", ".", "When", "first", "seen", "in", "1975", "he", "had", "bilateral", "proliferative", "retinopathy", "with", "new", "vessels", "in", "the", "retinal", "periphery", ".", "He", "had", "large", "areas", "of", "capillary", "non", "-", "perfusion", "lateral", "to", "the", "macula", "in", "the", "right", "eye", "associated", "with", "the", "new", "vessels", ".", "Nine", "years", "later", ",", "after", "extensive", "repeated", "photocoagulation", ",", "revascularisation", "of", "large", "areas", "previously", "not", "perfused", "were", "seen", ".", "The", "vessels", "are", "in", "the", "plane", "of", "the", "retina", "and", "do", "not", "have", "the", "appearance", "of", "new", "vessels", ".", "\n" ]	[ "Tissue", "Multi-tissue_structure", "Organism", "Organ" ]
narcotics control is an umlsterm, therapeutic is an umlsterm, physician is an umlsterm, time is an umlsterm, use is an umlsterm, narcotics is an umlsterm, control is an umlsterm, use is an umlsterm, narcotics is an umlsterm, conflicts is an umlsterm, physicians is an umlsterm, use is an umlsterm, opioids is an umlsterm, pain therapy is an umlsterm, opioids is an umlsterm, Narcotics is an umlsterm, Drug is an umlsterm	DerSchmerz.60100302.eng.abstr_task0	Sentence: Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O" ]	Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act .	[ "Rules", "still", "valid", "today", "continue", "the", "tradition", "of", "state", "narcotics", "control", ",", "conceding", "therapeutic", "decisions", "to", "the", "physician", ",", "but", "at", "the", "same", "time", "allowing", "only", "restrictive", "use", "of", "narcotics", ".", "Legal", "control", "of", "medically", "indicated", "use", "of", "narcotics", "is", "burdened", "with", "conflicts", ".", "Recently", ",", "physicians", "have", "been", "given", "more", "scope", "in", "the", "use", "of", "strong", "opioids", "for", "pain", "therapy", ".", "Existing", "limits", "for", "a", "dose", "of", "opioids", "may", "be", "exceeded", "when", "necessary", ".", "However", ",", "there", "are", "still", "formal", "rules", "in", "the", "German", "Narcotics", "Drug", "Act", "." ]	[ "umlsterm" ]
narcotics control is an umlsterm, therapeutic is an umlsterm, physician is an umlsterm, time is an umlsterm, use is an umlsterm, narcotics is an umlsterm, control is an umlsterm, use is an umlsterm, narcotics is an umlsterm, conflicts is an umlsterm, physicians is an umlsterm, use is an umlsterm, opioids is an umlsterm, pain therapy is an umlsterm, opioids is an umlsterm, Narcotics is an umlsterm, Drug is an umlsterm	DerSchmerz.60100302.eng.abstr_task1	Sentence: Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act . Instructions: please typing these entity words according to sentence: narcotics control, therapeutic, physician, time, use, narcotics, control, use, narcotics, conflicts, physicians, use, opioids, pain therapy, opioids, Narcotics, Drug Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O" ]	Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act .	[ "Rules", "still", "valid", "today", "continue", "the", "tradition", "of", "state", "narcotics", "control", ",", "conceding", "therapeutic", "decisions", "to", "the", "physician", ",", "but", "at", "the", "same", "time", "allowing", "only", "restrictive", "use", "of", "narcotics", ".", "Legal", "control", "of", "medically", "indicated", "use", "of", "narcotics", "is", "burdened", "with", "conflicts", ".", "Recently", ",", "physicians", "have", "been", "given", "more", "scope", "in", "the", "use", "of", "strong", "opioids", "for", "pain", "therapy", ".", "Existing", "limits", "for", "a", "dose", "of", "opioids", "may", "be", "exceeded", "when", "necessary", ".", "However", ",", "there", "are", "still", "formal", "rules", "in", "the", "German", "Narcotics", "Drug", "Act", "." ]	[ "umlsterm" ]
narcotics control, therapeutic, physician, time, use, narcotics, control, use, narcotics, conflicts, physicians, use, opioids, pain therapy, opioids, Narcotics, Drug	DerSchmerz.60100302.eng.abstr_task2	Sentence: Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O" ]	Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act .	[ "Rules", "still", "valid", "today", "continue", "the", "tradition", "of", "state", "narcotics", "control", ",", "conceding", "therapeutic", "decisions", "to", "the", "physician", ",", "but", "at", "the", "same", "time", "allowing", "only", "restrictive", "use", "of", "narcotics", ".", "Legal", "control", "of", "medically", "indicated", "use", "of", "narcotics", "is", "burdened", "with", "conflicts", ".", "Recently", ",", "physicians", "have", "been", "given", "more", "scope", "in", "the", "use", "of", "strong", "opioids", "for", "pain", "therapy", ".", "Existing", "limits", "for", "a", "dose", "of", "opioids", "may", "be", "exceeded", "when", "necessary", ".", "However", ",", "there", "are", "still", "formal", "rules", "in", "the", "German", "Narcotics", "Drug", "Act", "." ]	[ "umlsterm" ]
Uterus is an umlsterm, Endometrium is an umlsterm, Myometrium is an umlsterm, Ovar is an umlsterm, Reproduktion is an umlsterm, Peristaltik is an umlsterm, Spermientransport is an umlsterm, Muskelschichten is an umlsterm, Geburt is an umlsterm, Endometriose is an umlsterm, Adenomyosis is an umlsterm, Frauen is an umlsterm, Endometriose is an umlsterm, Myometrium is an umlsterm, Adenomyosis is an umlsterm	Reproduktionsmedizin.90150356.ger.abstr_task0	Sentence: Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri .	[ "Der", "menschliche", "Uterus", "setzt", "sich", "aus", "einer", "inneren", "paramesonephrischen", "Archimetra", "und", "einer", "aeusseren", "nicht", "-", "paramesonephrischen", "Neometra", "zusammen", ".", "Die", "Archimetra", "besteht", "aus", "dem", "Endometrium", "und", "dem", "Stratum", "subvasculare", "des", "Myometrium", "und", "erfuellt", "verschiedene", "vom", "Ovar", "gesteuerte", "Funktionen", "im", "fruehen", "Prozess", "der", "Reproduktion", "wie", "Aufbau", "des", "Endometriums", "fuer", "die", "Implantation", ",", "uterine", "Peristaltik", "fuer", "den", "gerichteten", "Spermientransport", "und", "die", "hohe", "fundale", "Implantation", "sowie", "die", "Infektabwehr", ".", "Die", "Neometra", "besteht", "aus", "den", "beiden", "aeusseren", "Muskelschichten", ",", "dem", "Stratum", "vasculare", "und", "supravasculare", ".", "Die", "wesentliche", "Funktion", "besteht", "im", "Aufbringen", "der", "Kraefte", "fuer", "die", "Geburt", ".", "Die", "Endometriose", "wird", "als", "Folge", "einer", "Adenomyosis", "oder", "deren", "Fruehmanifestationen", "und", "somit", "als", "eine", "Erkrankung", "der", "Archimetra", "angesehen", ".", "Dieses", "Konzept", "stuetzt", "sich", "auf", "spezifische", "Veraenderungen", "des", "eutopen", "Endometriums", "bei", "Frauen", "mit", "Endometriose", ",", "auf", "archimetrale", "Funktionsstoerungen", "wie", "Hyper-", "und", "Dysperistaltik", "sowie", "auf", "eine", "archimetrale", "Infiltration", "in", "das", "darunter", "liegende", "Myometrium", "mit", "dem", "Bild", "einer", "Adenomyosis", "uteri", "." ]	[ "umlsterm" ]
Uterus is an umlsterm, Endometrium is an umlsterm, Myometrium is an umlsterm, Ovar is an umlsterm, Reproduktion is an umlsterm, Peristaltik is an umlsterm, Spermientransport is an umlsterm, Muskelschichten is an umlsterm, Geburt is an umlsterm, Endometriose is an umlsterm, Adenomyosis is an umlsterm, Frauen is an umlsterm, Endometriose is an umlsterm, Myometrium is an umlsterm, Adenomyosis is an umlsterm	Reproduktionsmedizin.90150356.ger.abstr_task1	Sentence: Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri . Instructions: please typing these entity words according to sentence: Uterus, Endometrium, Myometrium, Ovar, Reproduktion, Peristaltik, Spermientransport, Muskelschichten, Geburt, Endometriose, Adenomyosis, Frauen, Endometriose, Myometrium, Adenomyosis Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri .	[ "Der", "menschliche", "Uterus", "setzt", "sich", "aus", "einer", "inneren", "paramesonephrischen", "Archimetra", "und", "einer", "aeusseren", "nicht", "-", "paramesonephrischen", "Neometra", "zusammen", ".", "Die", "Archimetra", "besteht", "aus", "dem", "Endometrium", "und", "dem", "Stratum", "subvasculare", "des", "Myometrium", "und", "erfuellt", "verschiedene", "vom", "Ovar", "gesteuerte", "Funktionen", "im", "fruehen", "Prozess", "der", "Reproduktion", "wie", "Aufbau", "des", "Endometriums", "fuer", "die", "Implantation", ",", "uterine", "Peristaltik", "fuer", "den", "gerichteten", "Spermientransport", "und", "die", "hohe", "fundale", "Implantation", "sowie", "die", "Infektabwehr", ".", "Die", "Neometra", "besteht", "aus", "den", "beiden", "aeusseren", "Muskelschichten", ",", "dem", "Stratum", "vasculare", "und", "supravasculare", ".", "Die", "wesentliche", "Funktion", "besteht", "im", "Aufbringen", "der", "Kraefte", "fuer", "die", "Geburt", ".", "Die", "Endometriose", "wird", "als", "Folge", "einer", "Adenomyosis", "oder", "deren", "Fruehmanifestationen", "und", "somit", "als", "eine", "Erkrankung", "der", "Archimetra", "angesehen", ".", "Dieses", "Konzept", "stuetzt", "sich", "auf", "spezifische", "Veraenderungen", "des", "eutopen", "Endometriums", "bei", "Frauen", "mit", "Endometriose", ",", "auf", "archimetrale", "Funktionsstoerungen", "wie", "Hyper-", "und", "Dysperistaltik", "sowie", "auf", "eine", "archimetrale", "Infiltration", "in", "das", "darunter", "liegende", "Myometrium", "mit", "dem", "Bild", "einer", "Adenomyosis", "uteri", "." ]	[ "umlsterm" ]
Uterus, Endometrium, Myometrium, Ovar, Reproduktion, Peristaltik, Spermientransport, Muskelschichten, Geburt, Endometriose, Adenomyosis, Frauen, Endometriose, Myometrium, Adenomyosis	Reproduktionsmedizin.90150356.ger.abstr_task2	Sentence: Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri .	[ "Der", "menschliche", "Uterus", "setzt", "sich", "aus", "einer", "inneren", "paramesonephrischen", "Archimetra", "und", "einer", "aeusseren", "nicht", "-", "paramesonephrischen", "Neometra", "zusammen", ".", "Die", "Archimetra", "besteht", "aus", "dem", "Endometrium", "und", "dem", "Stratum", "subvasculare", "des", "Myometrium", "und", "erfuellt", "verschiedene", "vom", "Ovar", "gesteuerte", "Funktionen", "im", "fruehen", "Prozess", "der", "Reproduktion", "wie", "Aufbau", "des", "Endometriums", "fuer", "die", "Implantation", ",", "uterine", "Peristaltik", "fuer", "den", "gerichteten", "Spermientransport", "und", "die", "hohe", "fundale", "Implantation", "sowie", "die", "Infektabwehr", ".", "Die", "Neometra", "besteht", "aus", "den", "beiden", "aeusseren", "Muskelschichten", ",", "dem", "Stratum", "vasculare", "und", "supravasculare", ".", "Die", "wesentliche", "Funktion", "besteht", "im", "Aufbringen", "der", "Kraefte", "fuer", "die", "Geburt", ".", "Die", "Endometriose", "wird", "als", "Folge", "einer", "Adenomyosis", "oder", "deren", "Fruehmanifestationen", "und", "somit", "als", "eine", "Erkrankung", "der", "Archimetra", "angesehen", ".", "Dieses", "Konzept", "stuetzt", "sich", "auf", "spezifische", "Veraenderungen", "des", "eutopen", "Endometriums", "bei", "Frauen", "mit", "Endometriose", ",", "auf", "archimetrale", "Funktionsstoerungen", "wie", "Hyper-", "und", "Dysperistaltik", "sowie", "auf", "eine", "archimetrale", "Infiltration", "in", "das", "darunter", "liegende", "Myometrium", "mit", "dem", "Bild", "einer", "Adenomyosis", "uteri", "." ]	[ "umlsterm" ]
coproporphyrinogen oxidase gene is a DNA_domain_or_region, erythroid and nonerythroid cells is a (AND cell_type cell_type)	77322_task0	Sentence: Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, (AND cell_type cell_type)	[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O" ]	Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells.	[ "Differential", "regulation", "of", "coproporphyrinogen", "oxidase", "gene", "between", "erythroid", "and", "nonerythroid", "cells", "." ]	[ "cell_type", "(AND cell_type cell_type)", "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "DNA_family_or_group", "protein_complex", "(AND cell_line cell_line)", "" ]
coproporphyrinogen oxidase gene is a DNA_domain_or_region, erythroid and nonerythroid cells is a (AND cell_type cell_type)	77322_task1	Sentence: Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Instructions: please typing these entity words according to sentence: coproporphyrinogen oxidase gene, erythroid and nonerythroid cells Options: DNA_domain_or_region, (AND cell_type cell_type)	[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O" ]	Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells.	[ "Differential", "regulation", "of", "coproporphyrinogen", "oxidase", "gene", "between", "erythroid", "and", "nonerythroid", "cells", "." ]	[ "cell_type", "(AND cell_type cell_type)", "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "DNA_family_or_group", "protein_complex", "(AND cell_line cell_line)", "" ]
coproporphyrinogen oxidase gene, erythroid and nonerythroid cells	77322_task2	Sentence: Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O" ]	Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells.	[ "Differential", "regulation", "of", "coproporphyrinogen", "oxidase", "gene", "between", "erythroid", "and", "nonerythroid", "cells", "." ]	[ "cell_type", "(AND cell_type cell_type)", "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "DNA_family_or_group", "protein_complex", "(AND cell_line cell_line)", "" ]
Patienten is an umlsterm, Tumors is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lymphknoten is an umlsterm, Gesamtkrankengut is an umlsterm, multivariaten Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lokalrezidivrate is an umlsterm, Rezidivs is an umlsterm	DerChirurg.70681023.ger.abstr_task0	Sentence: Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin .	[ "Zusammenfassung", ".", "Vom", "1", ".", "1", ".", "1985", "bis", "zum", "31", ".", "12", ".", "1995", "wurde", "bei", "386", "Patienten", "mit", "einem", "Rectumcarcinom", "im", "UICC", "-", "Stadium", "I", "-", "III", "nach", "konventionell", "chirurgischen", "Eingriffen", "und", "R0-Resektion", "des", "Tumors", "der", "Einfluss", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "auf", "Tumorstaging", "und", "Lokalrezidivrate", "retrospektiv", "untersucht", ".", "In", "der", "univariaten", "Analyse", "fanden", "wir", "einen", "signifikanten", "Zusammenhang", "zwischen", "der", "Zahl", "der", "dissezierten", "und", "der", "Zahl", "der", "befallenen", "Lymphknoten", ",", "und", "damit", "einhergehend", "eine", "signifikante", "Zunahme", "des", "UICC", "-", "Stadiums", "III", "(", "p", "=", "0,013", ")", "und", "der", "pTxpN2-Kategorie", "(", "p", "=", "0,000", ")", ".", "Eine", "signifikante", "Senkung", "der", "Lokalrezidivrate", "in", "Abhaengigkeit", "von", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "konnte", "nur", "fuer", "das", "UICC", "-", "Stadium", "I", "und", "II", "nachgewiesen", "werden", ".", "Im", "Gesamtkrankengut", "und", "in", "der", "multivariaten", "Analyse", "hatte", "die", "Zahl", "der", "dissezierten", "Lymphknoten", "keinen", "Einfluss", "auf", "die", "Lokalrezidivrate", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "die", "Senkung", "der", "Lokalrezidivrate", "im", "UICC", "-", "Stadium", "I", "und", "II", "nicht", "auf", "einen", "therapeutischen", "Effekt", ",", "sondern", "auf", "eine", "Stadienverschiebung", "im", "Rahmen", "eines", "exakteren", "Tumorstagings", "zurueckzufuehren", "ist", ".", "Dies", "weist", "auf", "den", "Einfluss", "anderer", "chirurgisch", "beeinflussbarer", "Faktoren", ",", "insbesondere", "die", "totale", "mesorectale", "Excision", "fuer", "die", "Entstehung", "eines", "locoregionaeren", "Rezidivs", "hin", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Tumors is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lymphknoten is an umlsterm, Gesamtkrankengut is an umlsterm, multivariaten Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lokalrezidivrate is an umlsterm, Rezidivs is an umlsterm	DerChirurg.70681023.ger.abstr_task1	Sentence: Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin . Instructions: please typing these entity words according to sentence: Patienten, Tumors, Lymphknoten, Lokalrezidivrate, Analyse, Lymphknoten, Lokalrezidivrate, Lymphknoten, Gesamtkrankengut, multivariaten Analyse, Lymphknoten, Lokalrezidivrate, Lokalrezidivrate, Rezidivs Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin .	[ "Zusammenfassung", ".", "Vom", "1", ".", "1", ".", "1985", "bis", "zum", "31", ".", "12", ".", "1995", "wurde", "bei", "386", "Patienten", "mit", "einem", "Rectumcarcinom", "im", "UICC", "-", "Stadium", "I", "-", "III", "nach", "konventionell", "chirurgischen", "Eingriffen", "und", "R0-Resektion", "des", "Tumors", "der", "Einfluss", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "auf", "Tumorstaging", "und", "Lokalrezidivrate", "retrospektiv", "untersucht", ".", "In", "der", "univariaten", "Analyse", "fanden", "wir", "einen", "signifikanten", "Zusammenhang", "zwischen", "der", "Zahl", "der", "dissezierten", "und", "der", "Zahl", "der", "befallenen", "Lymphknoten", ",", "und", "damit", "einhergehend", "eine", "signifikante", "Zunahme", "des", "UICC", "-", "Stadiums", "III", "(", "p", "=", "0,013", ")", "und", "der", "pTxpN2-Kategorie", "(", "p", "=", "0,000", ")", ".", "Eine", "signifikante", "Senkung", "der", "Lokalrezidivrate", "in", "Abhaengigkeit", "von", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "konnte", "nur", "fuer", "das", "UICC", "-", "Stadium", "I", "und", "II", "nachgewiesen", "werden", ".", "Im", "Gesamtkrankengut", "und", "in", "der", "multivariaten", "Analyse", "hatte", "die", "Zahl", "der", "dissezierten", "Lymphknoten", "keinen", "Einfluss", "auf", "die", "Lokalrezidivrate", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "die", "Senkung", "der", "Lokalrezidivrate", "im", "UICC", "-", "Stadium", "I", "und", "II", "nicht", "auf", "einen", "therapeutischen", "Effekt", ",", "sondern", "auf", "eine", "Stadienverschiebung", "im", "Rahmen", "eines", "exakteren", "Tumorstagings", "zurueckzufuehren", "ist", ".", "Dies", "weist", "auf", "den", "Einfluss", "anderer", "chirurgisch", "beeinflussbarer", "Faktoren", ",", "insbesondere", "die", "totale", "mesorectale", "Excision", "fuer", "die", "Entstehung", "eines", "locoregionaeren", "Rezidivs", "hin", "." ]	[ "umlsterm" ]
Patienten, Tumors, Lymphknoten, Lokalrezidivrate, Analyse, Lymphknoten, Lokalrezidivrate, Lymphknoten, Gesamtkrankengut, multivariaten Analyse, Lymphknoten, Lokalrezidivrate, Lokalrezidivrate, Rezidivs	DerChirurg.70681023.ger.abstr_task2	Sentence: Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin .	[ "Zusammenfassung", ".", "Vom", "1", ".", "1", ".", "1985", "bis", "zum", "31", ".", "12", ".", "1995", "wurde", "bei", "386", "Patienten", "mit", "einem", "Rectumcarcinom", "im", "UICC", "-", "Stadium", "I", "-", "III", "nach", "konventionell", "chirurgischen", "Eingriffen", "und", "R0-Resektion", "des", "Tumors", "der", "Einfluss", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "auf", "Tumorstaging", "und", "Lokalrezidivrate", "retrospektiv", "untersucht", ".", "In", "der", "univariaten", "Analyse", "fanden", "wir", "einen", "signifikanten", "Zusammenhang", "zwischen", "der", "Zahl", "der", "dissezierten", "und", "der", "Zahl", "der", "befallenen", "Lymphknoten", ",", "und", "damit", "einhergehend", "eine", "signifikante", "Zunahme", "des", "UICC", "-", "Stadiums", "III", "(", "p", "=", "0,013", ")", "und", "der", "pTxpN2-Kategorie", "(", "p", "=", "0,000", ")", ".", "Eine", "signifikante", "Senkung", "der", "Lokalrezidivrate", "in", "Abhaengigkeit", "von", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "konnte", "nur", "fuer", "das", "UICC", "-", "Stadium", "I", "und", "II", "nachgewiesen", "werden", ".", "Im", "Gesamtkrankengut", "und", "in", "der", "multivariaten", "Analyse", "hatte", "die", "Zahl", "der", "dissezierten", "Lymphknoten", "keinen", "Einfluss", "auf", "die", "Lokalrezidivrate", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "die", "Senkung", "der", "Lokalrezidivrate", "im", "UICC", "-", "Stadium", "I", "und", "II", "nicht", "auf", "einen", "therapeutischen", "Effekt", ",", "sondern", "auf", "eine", "Stadienverschiebung", "im", "Rahmen", "eines", "exakteren", "Tumorstagings", "zurueckzufuehren", "ist", ".", "Dies", "weist", "auf", "den", "Einfluss", "anderer", "chirurgisch", "beeinflussbarer", "Faktoren", ",", "insbesondere", "die", "totale", "mesorectale", "Excision", "fuer", "die", "Entstehung", "eines", "locoregionaeren", "Rezidivs", "hin", "." ]	[ "umlsterm" ]
Group A streptococcus is a Organism, human is a Organism, emm49 GAS is a Organism, human is a Organism, GAS is a Organism, GAS is a Organism, human is a Organism, GAS is a Organism, non - invasive GAS is a Organism, invasive GAS is a Organism, human is a Organism, invasive GAS is a Organism, human is a Organism	67_task0	Sentence: Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism	[ "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O" ]	Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN.	[ "Results", "\n", "Group", "A", "streptococcus", "isolates", "from", "severe", "invasive", "infections", "is", "resistant", "to", "killing", "by", "human", "PMN", "To", "examine", "whether", "emm49", "GAS", "isolated", "from", "severe", "invasive", "infection", "might", "alter", "human", "PMN", "function", ",", "we", "performed", "phagocytosis", "assay", "in", "vitro", ".", "As", "non", "-", "opsonized", "GAS", "was", "resistant", "to", "the", "phagocytosis", "by", "PMN", "[", "14", "]", ",", "we", "opsonized", "GAS", "with", "human", "plasma", "in", "advance", "to", "the", "assay", ".", "As", "shown", "in", "Figure", "1A", ",", "there", "was", "no", "significant", "difference", "between", "GAS", "that", "were", "isolated", "from", "non", "-", "invasive", "and", "severe", "invasive", "infections", "in", "phagocytosis", "by", "PMN", "(", "p=0.5556", ")", ".", "However", ",", "as", "shown", "in", "Figure", "1B", ",", "in", "vitro", "killing", "assay", "revealed", "that", "PMN", "killed", "non", "-", "invasive", "GAS", ",", "resulting", "in", "15", "-", "42", "%", "of", "initial", "number", "of", "bacteria", ",", "but", "not", "invasive", "GAS", "(", "p=0.019", ")", ".", "The", "similar", "results", "were", "obtained", "when", "opsonized", "with", "either", "FCS", "or", "human", "serum", "regardless", "of", "complements", "immobilization", "(", "data", "not", "shown", ")", ".", "These", "results", "were", "common", "among", "all", "PMN", "donors", ".", "These", "data", "indicated", "that", "clinically", "isolated", "severe", "invasive", "GAS", "were", "phagocytosed", ",", "but", "escaped", "from", "killing", "by", "human", "PMN", ".", "\n" ]	[ "Organism", "Protein" ]
Group A streptococcus is a Organism, human is a Organism, emm49 GAS is a Organism, human is a Organism, GAS is a Organism, GAS is a Organism, human is a Organism, GAS is a Organism, non - invasive GAS is a Organism, invasive GAS is a Organism, human is a Organism, invasive GAS is a Organism, human is a Organism	67_task1	Sentence: Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN. Instructions: please typing these entity words according to sentence: Group A streptococcus, human, emm49 GAS, human, GAS, GAS, human, GAS, non - invasive GAS, invasive GAS, human, invasive GAS, human Options: Organism	[ "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O" ]	Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN.	[ "Results", "\n", "Group", "A", "streptococcus", "isolates", "from", "severe", "invasive", "infections", "is", "resistant", "to", "killing", "by", "human", "PMN", "To", "examine", "whether", "emm49", "GAS", "isolated", "from", "severe", "invasive", "infection", "might", "alter", "human", "PMN", "function", ",", "we", "performed", "phagocytosis", "assay", "in", "vitro", ".", "As", "non", "-", "opsonized", "GAS", "was", "resistant", "to", "the", "phagocytosis", "by", "PMN", "[", "14", "]", ",", "we", "opsonized", "GAS", "with", "human", "plasma", "in", "advance", "to", "the", "assay", ".", "As", "shown", "in", "Figure", "1A", ",", "there", "was", "no", "significant", "difference", "between", "GAS", "that", "were", "isolated", "from", "non", "-", "invasive", "and", "severe", "invasive", "infections", "in", "phagocytosis", "by", "PMN", "(", "p=0.5556", ")", ".", "However", ",", "as", "shown", "in", "Figure", "1B", ",", "in", "vitro", "killing", "assay", "revealed", "that", "PMN", "killed", "non", "-", "invasive", "GAS", ",", "resulting", "in", "15", "-", "42", "%", "of", "initial", "number", "of", "bacteria", ",", "but", "not", "invasive", "GAS", "(", "p=0.019", ")", ".", "The", "similar", "results", "were", "obtained", "when", "opsonized", "with", "either", "FCS", "or", "human", "serum", "regardless", "of", "complements", "immobilization", "(", "data", "not", "shown", ")", ".", "These", "results", "were", "common", "among", "all", "PMN", "donors", ".", "These", "data", "indicated", "that", "clinically", "isolated", "severe", "invasive", "GAS", "were", "phagocytosed", ",", "but", "escaped", "from", "killing", "by", "human", "PMN", ".", "\n" ]	[ "Organism", "Protein" ]
Group A streptococcus, human, emm49 GAS, human, GAS, GAS, human, GAS, non - invasive GAS, invasive GAS, human, invasive GAS, human	67_task2	Sentence: Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O" ]	Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN.	[ "Results", "\n", "Group", "A", "streptococcus", "isolates", "from", "severe", "invasive", "infections", "is", "resistant", "to", "killing", "by", "human", "PMN", "To", "examine", "whether", "emm49", "GAS", "isolated", "from", "severe", "invasive", "infection", "might", "alter", "human", "PMN", "function", ",", "we", "performed", "phagocytosis", "assay", "in", "vitro", ".", "As", "non", "-", "opsonized", "GAS", "was", "resistant", "to", "the", "phagocytosis", "by", "PMN", "[", "14", "]", ",", "we", "opsonized", "GAS", "with", "human", "plasma", "in", "advance", "to", "the", "assay", ".", "As", "shown", "in", "Figure", "1A", ",", "there", "was", "no", "significant", "difference", "between", "GAS", "that", "were", "isolated", "from", "non", "-", "invasive", "and", "severe", "invasive", "infections", "in", "phagocytosis", "by", "PMN", "(", "p=0.5556", ")", ".", "However", ",", "as", "shown", "in", "Figure", "1B", ",", "in", "vitro", "killing", "assay", "revealed", "that", "PMN", "killed", "non", "-", "invasive", "GAS", ",", "resulting", "in", "15", "-", "42", "%", "of", "initial", "number", "of", "bacteria", ",", "but", "not", "invasive", "GAS", "(", "p=0.019", ")", ".", "The", "similar", "results", "were", "obtained", "when", "opsonized", "with", "either", "FCS", "or", "human", "serum", "regardless", "of", "complements", "immobilization", "(", "data", "not", "shown", ")", ".", "These", "results", "were", "common", "among", "all", "PMN", "donors", ".", "These", "data", "indicated", "that", "clinically", "isolated", "severe", "invasive", "GAS", "were", "phagocytosed", ",", "but", "escaped", "from", "killing", "by", "human", "PMN", ".", "\n" ]	[ "Organism", "Protein" ]
Clinical investigation is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, patients is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, patients is an umlsterm, proven is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, tumor is an umlsterm, stage is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, Histograph is an umlsterm, tumor is an umlsterm, hemoglobin concentration is an umlsterm, cells is an umlsterm, tumors is an umlsterm, cells is an umlsterm, relative is an umlsterm, frequency is an umlsterm, values is an umlsterm, hemoglobin concentration is an umlsterm, tumor is an umlsterm, association is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, hypoxia is an umlsterm, malignancy is an umlsterm, tumor is an umlsterm, cells is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, tumors is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, selection is an umlsterm, tumor is an umlsterm, cells is an umlsterm, malignant is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, research is an umlsterm	Strahlentherapie+Onkologie.01760475.eng.abstr_task0	Sentence: Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship .	[ "Clinical", "investigation", "of", "a", "potential", "relationship", "between", "the", "polarographically", "measured", "tumor", "oxygenation", "and", "the", "p53", "status", "in", "patients", "with", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", ".", "In", "99", "patients", "with", "mostly", "advanced", ",", "histologically", "proven", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "were", "estimated", "the", "classical", "tumor", "parameters", "(", "TNM", "stage", ",", "histological", "grading", ")", "the", "immunohistochemical", "p53-overexpression", "(", "DO-7", ")", "and", "the", "tumor", "oxygenation", "status", "(", "Eppendorf", "pO2", "Histograph", ")", ".", "The", "tumor", "volume", "and", "the", "hemoglobin", "concentration", "were", "evaluated", "simultaneously", ".", "No", "statistically", "significant", "difference", "could", "be", "detected", "between", "immunohistological", "p53-positive", "(", "p53", ">", "=", "10", "%", "stained", "cells", ")", "and", "p53-negative", "tumors", "(", "p53", "10", "%", "stained", "cells", ")", "regarding", "both", "the", "median", "pO2", "and", "the", "relative", "frequency", "of", "values", "=", "5", "mm", "Hg", ".", "Moreover", ",", "no", "statistically", "relevant", "differences", "could", "be", "seen", "between", "both", "p53-groups", "considering", "the", "hemoglobin", "concentration", ",", "the", "TNM", "stag", ",", "the", "histological", "grading", "and", "the", "tumor", "volume", ".", "Our", "data", "imply", "that", "there", "is", "no", "association", "between", "p53-overexpression", "and", "tumor", "hypoxia", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "this", "is", "not", "necessarily", "in", "contradiction", "to", "experimental", "or", "clinical", "data", "that", "confirmed", "a", "relationship", "between", "hypoxia", "and", "p53-mediated", "increased", "malignancy", "of", "tumor", "cells", "in", "other", "tumor", "entities", ".", "The", "comparable", "oxygenation", "status", "of", "p53-positive", "and", "p53-negative", "tumors", "in", "our", "study", "is", "associated", "with", "an", "analogous", "clinical", "tumor", "aggressiveness", "of", "both", "groups", ".", "That", "could", "be", "caused", "by", "hypoxia", "related", "but", "p53-independent", "selection", "of", "tumor", "cells", "with", "a", "more", "malignant", "phenotype", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "further", "research", "is", "needed", "to", "prove", "this", "possible", "relationship", "." ]	[ "umlsterm" ]
Clinical investigation is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, patients is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, patients is an umlsterm, proven is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, tumor is an umlsterm, stage is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, Histograph is an umlsterm, tumor is an umlsterm, hemoglobin concentration is an umlsterm, cells is an umlsterm, tumors is an umlsterm, cells is an umlsterm, relative is an umlsterm, frequency is an umlsterm, values is an umlsterm, hemoglobin concentration is an umlsterm, tumor is an umlsterm, association is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, hypoxia is an umlsterm, malignancy is an umlsterm, tumor is an umlsterm, cells is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, tumors is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, selection is an umlsterm, tumor is an umlsterm, cells is an umlsterm, malignant is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, research is an umlsterm	Strahlentherapie+Onkologie.01760475.eng.abstr_task1	Sentence: Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship . Instructions: please typing these entity words according to sentence: Clinical investigation, tumor, oxygenation, patients, squamous cell carcinoma, head, neck, patients, proven, squamous cell carcinoma, head, neck, tumor, stage, tumor, oxygenation, Histograph, tumor, hemoglobin concentration, cells, tumors, cells, relative, frequency, values, hemoglobin concentration, tumor, association, tumor, hypoxia, head, neck, carcinomas, hypoxia, malignancy, tumor, cells, tumor, oxygenation, tumors, tumor, hypoxia, selection, tumor, cells, malignant, head, neck, carcinomas, research Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship .	[ "Clinical", "investigation", "of", "a", "potential", "relationship", "between", "the", "polarographically", "measured", "tumor", "oxygenation", "and", "the", "p53", "status", "in", "patients", "with", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", ".", "In", "99", "patients", "with", "mostly", "advanced", ",", "histologically", "proven", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "were", "estimated", "the", "classical", "tumor", "parameters", "(", "TNM", "stage", ",", "histological", "grading", ")", "the", "immunohistochemical", "p53-overexpression", "(", "DO-7", ")", "and", "the", "tumor", "oxygenation", "status", "(", "Eppendorf", "pO2", "Histograph", ")", ".", "The", "tumor", "volume", "and", "the", "hemoglobin", "concentration", "were", "evaluated", "simultaneously", ".", "No", "statistically", "significant", "difference", "could", "be", "detected", "between", "immunohistological", "p53-positive", "(", "p53", ">", "=", "10", "%", "stained", "cells", ")", "and", "p53-negative", "tumors", "(", "p53", "10", "%", "stained", "cells", ")", "regarding", "both", "the", "median", "pO2", "and", "the", "relative", "frequency", "of", "values", "=", "5", "mm", "Hg", ".", "Moreover", ",", "no", "statistically", "relevant", "differences", "could", "be", "seen", "between", "both", "p53-groups", "considering", "the", "hemoglobin", "concentration", ",", "the", "TNM", "stag", ",", "the", "histological", "grading", "and", "the", "tumor", "volume", ".", "Our", "data", "imply", "that", "there", "is", "no", "association", "between", "p53-overexpression", "and", "tumor", "hypoxia", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "this", "is", "not", "necessarily", "in", "contradiction", "to", "experimental", "or", "clinical", "data", "that", "confirmed", "a", "relationship", "between", "hypoxia", "and", "p53-mediated", "increased", "malignancy", "of", "tumor", "cells", "in", "other", "tumor", "entities", ".", "The", "comparable", "oxygenation", "status", "of", "p53-positive", "and", "p53-negative", "tumors", "in", "our", "study", "is", "associated", "with", "an", "analogous", "clinical", "tumor", "aggressiveness", "of", "both", "groups", ".", "That", "could", "be", "caused", "by", "hypoxia", "related", "but", "p53-independent", "selection", "of", "tumor", "cells", "with", "a", "more", "malignant", "phenotype", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "further", "research", "is", "needed", "to", "prove", "this", "possible", "relationship", "." ]	[ "umlsterm" ]
Clinical investigation, tumor, oxygenation, patients, squamous cell carcinoma, head, neck, patients, proven, squamous cell carcinoma, head, neck, tumor, stage, tumor, oxygenation, Histograph, tumor, hemoglobin concentration, cells, tumors, cells, relative, frequency, values, hemoglobin concentration, tumor, association, tumor, hypoxia, head, neck, carcinomas, hypoxia, malignancy, tumor, cells, tumor, oxygenation, tumors, tumor, hypoxia, selection, tumor, cells, malignant, head, neck, carcinomas, research	Strahlentherapie+Onkologie.01760475.eng.abstr_task2	Sentence: Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship .	[ "Clinical", "investigation", "of", "a", "potential", "relationship", "between", "the", "polarographically", "measured", "tumor", "oxygenation", "and", "the", "p53", "status", "in", "patients", "with", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", ".", "In", "99", "patients", "with", "mostly", "advanced", ",", "histologically", "proven", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "were", "estimated", "the", "classical", "tumor", "parameters", "(", "TNM", "stage", ",", "histological", "grading", ")", "the", "immunohistochemical", "p53-overexpression", "(", "DO-7", ")", "and", "the", "tumor", "oxygenation", "status", "(", "Eppendorf", "pO2", "Histograph", ")", ".", "The", "tumor", "volume", "and", "the", "hemoglobin", "concentration", "were", "evaluated", "simultaneously", ".", "No", "statistically", "significant", "difference", "could", "be", "detected", "between", "immunohistological", "p53-positive", "(", "p53", ">", "=", "10", "%", "stained", "cells", ")", "and", "p53-negative", "tumors", "(", "p53", "10", "%", "stained", "cells", ")", "regarding", "both", "the", "median", "pO2", "and", "the", "relative", "frequency", "of", "values", "=", "5", "mm", "Hg", ".", "Moreover", ",", "no", "statistically", "relevant", "differences", "could", "be", "seen", "between", "both", "p53-groups", "considering", "the", "hemoglobin", "concentration", ",", "the", "TNM", "stag", ",", "the", "histological", "grading", "and", "the", "tumor", "volume", ".", "Our", "data", "imply", "that", "there", "is", "no", "association", "between", "p53-overexpression", "and", "tumor", "hypoxia", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "this", "is", "not", "necessarily", "in", "contradiction", "to", "experimental", "or", "clinical", "data", "that", "confirmed", "a", "relationship", "between", "hypoxia", "and", "p53-mediated", "increased", "malignancy", "of", "tumor", "cells", "in", "other", "tumor", "entities", ".", "The", "comparable", "oxygenation", "status", "of", "p53-positive", "and", "p53-negative", "tumors", "in", "our", "study", "is", "associated", "with", "an", "analogous", "clinical", "tumor", "aggressiveness", "of", "both", "groups", ".", "That", "could", "be", "caused", "by", "hypoxia", "related", "but", "p53-independent", "selection", "of", "tumor", "cells", "with", "a", "more", "malignant", "phenotype", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "further", "research", "is", "needed", "to", "prove", "this", "possible", "relationship", "." ]	[ "umlsterm" ]
vitamin D3 supplementation is a Intervention_Pharmacological, children and young adults is a Participant_Age, HIV : is a Outcome_Physical, placebo - controlled trial is a Intervention_Control, HIV - infected is a Participant_Condition, safety and efficacy is a Outcome_Other, 7000 IU vitamin D3 is a Intervention_Pharmacological, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status is a Outcome_Physical, HIV - infected subjects is a Participant_Condition, perinatally acquired HIV ( PHIV ) -infected subjects is a Participant_Condition, behaviorally acquired HIV ( BHIV ) -infected subjects is a Participant_Condition, 5.0 - 24.9 years is a Participant_Age, Safety is a Outcome_Other, 25 ( OH ) D - related parameters is a Outcome_Other, Fifty - eight subjects enrolled is a Participant_Sample-size, 67 % male is a Participant_Sex, 85 % African American is a Participant_Sample-size, 64 % is a Participant_Sample-size, 50 completed with no safety concerns is a Participant_Sample-size, Percentage of naive T - helper cells ( Th naive % ) is a Outcome_Physical, T - helper cells ( CD4 % ) is a Outcome_Physical, RNA viral load is a Outcome_Physical, in 25 ( OH ) D predicted RNA viral load is a Outcome_Physical, and CD4 % is a Outcome_Physical, increasing 25 ( OH ) is a Outcome_Physical, some clinically important HIV immune markers is a Outcome_Physical	66554_task0	Sentence: High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation .	[ "High", "-", "dose", "vitamin", "D3", "supplementation", "in", "children", "and", "young", "adults", "with", "HIV", ":", "a", "randomized", ",", "placebo", "-", "controlled", "trial", ".", "BACKGROUND", "Suboptimal", "vitamin", "D", "status", "is", "prevalent", "in", "HIV", "-", "infected", "patients", "and", "associated", "with", "increased", "risk", "of", "disease", "severity", "and", "morbidity", ".", "We", "aimed", "to", "determine", "12-month", "safety", "and", "efficacy", "of", "daily", "7000", "IU", "vitamin", "D3", "(", "vitD3", ")", "versus", "placebo", "to", "sustain", "increased", "serum", "25-hydroxyvitamin", "D", "(", "25", "(", "OH", ")", "D", ")", "and", "improve", "immune", "status", "in", "HIV", "-", "infected", "subjects", ".", "METHODS", "This", "was", "a", "double", "-", "blind", "trial", "of", "perinatally", "acquired", "HIV", "(", "PHIV", ")", "-infected", "subjects", "or", "behaviorally", "acquired", "HIV", "(", "BHIV", ")", "-infected", "subjects", "(", "5.0", "-", "24.9", "years", ")", ".", "Safety", ",", "25", "(", "OH", ")", "D", "-", "related", "parameters", "and", "immune", "status", "were", "assessed", "at", "baseline", ",", "3", ",", "6", "and", "12", "months", ".", "RESULTS", "Fifty", "-", "eight", "subjects", "enrolled", "(", "67", "%", "male", ",", "85", "%", "African", "American", "and", "64", "%", "BHIV", ")", "and", "50", "completed", "with", "no", "safety", "concerns", ".", "In", "unadjusted", "analyses", ",", "there", "were", "no", "differences", "between", "randomization", "groups", "at", "baseline", ";", "at", "3", ",", "6", "and", "12", "months", ",", "25", "(", "OH", ")", "D", "was", "higher", "with", "supplementation", "than", "baseline", "and", "higher", "than", "with", "placebo", "(", "P", "<", "0.05", ")", ".", "In", "adjusted", "mixed", "models", ",", "in", "the", "supplementation", "group", ",", "the", "fixed", "effect", "of", "25", "(", "OH", ")", "D", "was", "higher", "(", "P", "<", "0.001", ")", ".", "Percentage", "of", "naive", "T", "-", "helper", "cells", "(", "Th", "naive", "%", ")", "were", "significantly", "(", "P", "<", "0.01", ")", "and", "T", "-", "helper", "cells", "(", "CD4", "%", ")", "marginally", "(", "P", "<", "0.10", ")", "increased", "with", "supplementation", "in", "those", "taking", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", ",", "and", "RNA", "viral", "load", "was", "reduced", "(", "P", "≤", "0.05", ")", ".", "In", "exploratory", "linear", "models", ",", "change", "in", "25", "(", "OH", ")", "D", "predicted", "RNA", "viral", "load", "at", "3", "and", "12", "months", "and", "CD4", "%", "at", "3", "months", "(", "P", "<", "0.05", ")", ".", "CONCLUSIONS", "Daily", "7000", "IU", "vitD3", "for", "12", "months", "was", "safe", "in", "HIV", "-", "infected", "subjects", "and", "effective", "in", "increasing", "25", "(", "OH", ")", "D.", "Supplementation", "improved", "some", "clinically", "important", "HIV", "immune", "markers", "in", "subjects", "on", "HAART", ".", "Adjunct", "therapy", "with", "high", "-", "dose", ",", "daily", "vitD3", "for", "HIV", "-", "infected", "subjects", "and", "for", "those", "on", "/", "off", "HAART", "requires", "further", "investigation", "." ]	[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Sex" ]
vitamin D3 supplementation is a Intervention_Pharmacological, children and young adults is a Participant_Age, HIV : is a Outcome_Physical, placebo - controlled trial is a Intervention_Control, HIV - infected is a Participant_Condition, safety and efficacy is a Outcome_Other, 7000 IU vitamin D3 is a Intervention_Pharmacological, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status is a Outcome_Physical, HIV - infected subjects is a Participant_Condition, perinatally acquired HIV ( PHIV ) -infected subjects is a Participant_Condition, behaviorally acquired HIV ( BHIV ) -infected subjects is a Participant_Condition, 5.0 - 24.9 years is a Participant_Age, Safety is a Outcome_Other, 25 ( OH ) D - related parameters is a Outcome_Other, Fifty - eight subjects enrolled is a Participant_Sample-size, 67 % male is a Participant_Sex, 85 % African American is a Participant_Sample-size, 64 % is a Participant_Sample-size, 50 completed with no safety concerns is a Participant_Sample-size, Percentage of naive T - helper cells ( Th naive % ) is a Outcome_Physical, T - helper cells ( CD4 % ) is a Outcome_Physical, RNA viral load is a Outcome_Physical, in 25 ( OH ) D predicted RNA viral load is a Outcome_Physical, and CD4 % is a Outcome_Physical, increasing 25 ( OH ) is a Outcome_Physical, some clinically important HIV immune markers is a Outcome_Physical	66554_task1	Sentence: High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation . Instructions: please typing these entity words according to sentence: vitamin D3 supplementation, children and young adults, HIV :, placebo - controlled trial, HIV - infected, safety and efficacy, 7000 IU vitamin D3, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status, HIV - infected subjects, perinatally acquired HIV ( PHIV ) -infected subjects, behaviorally acquired HIV ( BHIV ) -infected subjects, 5.0 - 24.9 years, Safety, 25 ( OH ) D - related parameters, Fifty - eight subjects enrolled, 67 % male, 85 % African American, 64 %, 50 completed with no safety concerns, Percentage of naive T - helper cells ( Th naive % ), T - helper cells ( CD4 % ), RNA viral load, in 25 ( OH ) D predicted RNA viral load, and CD4 %, increasing 25 ( OH ), some clinically important HIV immune markers Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation .	[ "High", "-", "dose", "vitamin", "D3", "supplementation", "in", "children", "and", "young", "adults", "with", "HIV", ":", "a", "randomized", ",", "placebo", "-", "controlled", "trial", ".", "BACKGROUND", "Suboptimal", "vitamin", "D", "status", "is", "prevalent", "in", "HIV", "-", "infected", "patients", "and", "associated", "with", "increased", "risk", "of", "disease", "severity", "and", "morbidity", ".", "We", "aimed", "to", "determine", "12-month", "safety", "and", "efficacy", "of", "daily", "7000", "IU", "vitamin", "D3", "(", "vitD3", ")", "versus", "placebo", "to", "sustain", "increased", "serum", "25-hydroxyvitamin", "D", "(", "25", "(", "OH", ")", "D", ")", "and", "improve", "immune", "status", "in", "HIV", "-", "infected", "subjects", ".", "METHODS", "This", "was", "a", "double", "-", "blind", "trial", "of", "perinatally", "acquired", "HIV", "(", "PHIV", ")", "-infected", "subjects", "or", "behaviorally", "acquired", "HIV", "(", "BHIV", ")", "-infected", "subjects", "(", "5.0", "-", "24.9", "years", ")", ".", "Safety", ",", "25", "(", "OH", ")", "D", "-", "related", "parameters", "and", "immune", "status", "were", "assessed", "at", "baseline", ",", "3", ",", "6", "and", "12", "months", ".", "RESULTS", "Fifty", "-", "eight", "subjects", "enrolled", "(", "67", "%", "male", ",", "85", "%", "African", "American", "and", "64", "%", "BHIV", ")", "and", "50", "completed", "with", "no", "safety", "concerns", ".", "In", "unadjusted", "analyses", ",", "there", "were", "no", "differences", "between", "randomization", "groups", "at", "baseline", ";", "at", "3", ",", "6", "and", "12", "months", ",", "25", "(", "OH", ")", "D", "was", "higher", "with", "supplementation", "than", "baseline", "and", "higher", "than", "with", "placebo", "(", "P", "<", "0.05", ")", ".", "In", "adjusted", "mixed", "models", ",", "in", "the", "supplementation", "group", ",", "the", "fixed", "effect", "of", "25", "(", "OH", ")", "D", "was", "higher", "(", "P", "<", "0.001", ")", ".", "Percentage", "of", "naive", "T", "-", "helper", "cells", "(", "Th", "naive", "%", ")", "were", "significantly", "(", "P", "<", "0.01", ")", "and", "T", "-", "helper", "cells", "(", "CD4", "%", ")", "marginally", "(", "P", "<", "0.10", ")", "increased", "with", "supplementation", "in", "those", "taking", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", ",", "and", "RNA", "viral", "load", "was", "reduced", "(", "P", "≤", "0.05", ")", ".", "In", "exploratory", "linear", "models", ",", "change", "in", "25", "(", "OH", ")", "D", "predicted", "RNA", "viral", "load", "at", "3", "and", "12", "months", "and", "CD4", "%", "at", "3", "months", "(", "P", "<", "0.05", ")", ".", "CONCLUSIONS", "Daily", "7000", "IU", "vitD3", "for", "12", "months", "was", "safe", "in", "HIV", "-", "infected", "subjects", "and", "effective", "in", "increasing", "25", "(", "OH", ")", "D.", "Supplementation", "improved", "some", "clinically", "important", "HIV", "immune", "markers", "in", "subjects", "on", "HAART", ".", "Adjunct", "therapy", "with", "high", "-", "dose", ",", "daily", "vitD3", "for", "HIV", "-", "infected", "subjects", "and", "for", "those", "on", "/", "off", "HAART", "requires", "further", "investigation", "." ]	[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Sex" ]
vitamin D3 supplementation, children and young adults, HIV :, placebo - controlled trial, HIV - infected, safety and efficacy, 7000 IU vitamin D3, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status, HIV - infected subjects, perinatally acquired HIV ( PHIV ) -infected subjects, behaviorally acquired HIV ( BHIV ) -infected subjects, 5.0 - 24.9 years, Safety, 25 ( OH ) D - related parameters, Fifty - eight subjects enrolled, 67 % male, 85 % African American, 64 %, 50 completed with no safety concerns, Percentage of naive T - helper cells ( Th naive % ), T - helper cells ( CD4 % ), RNA viral load, in 25 ( OH ) D predicted RNA viral load, and CD4 %, increasing 25 ( OH ), some clinically important HIV immune markers	66554_task2	Sentence: High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation .	[ "High", "-", "dose", "vitamin", "D3", "supplementation", "in", "children", "and", "young", "adults", "with", "HIV", ":", "a", "randomized", ",", "placebo", "-", "controlled", "trial", ".", "BACKGROUND", "Suboptimal", "vitamin", "D", "status", "is", "prevalent", "in", "HIV", "-", "infected", "patients", "and", "associated", "with", "increased", "risk", "of", "disease", "severity", "and", "morbidity", ".", "We", "aimed", "to", "determine", "12-month", "safety", "and", "efficacy", "of", "daily", "7000", "IU", "vitamin", "D3", "(", "vitD3", ")", "versus", "placebo", "to", "sustain", "increased", "serum", "25-hydroxyvitamin", "D", "(", "25", "(", "OH", ")", "D", ")", "and", "improve", "immune", "status", "in", "HIV", "-", "infected", "subjects", ".", "METHODS", "This", "was", "a", "double", "-", "blind", "trial", "of", "perinatally", "acquired", "HIV", "(", "PHIV", ")", "-infected", "subjects", "or", "behaviorally", "acquired", "HIV", "(", "BHIV", ")", "-infected", "subjects", "(", "5.0", "-", "24.9", "years", ")", ".", "Safety", ",", "25", "(", "OH", ")", "D", "-", "related", "parameters", "and", "immune", "status", "were", "assessed", "at", "baseline", ",", "3", ",", "6", "and", "12", "months", ".", "RESULTS", "Fifty", "-", "eight", "subjects", "enrolled", "(", "67", "%", "male", ",", "85", "%", "African", "American", "and", "64", "%", "BHIV", ")", "and", "50", "completed", "with", "no", "safety", "concerns", ".", "In", "unadjusted", "analyses", ",", "there", "were", "no", "differences", "between", "randomization", "groups", "at", "baseline", ";", "at", "3", ",", "6", "and", "12", "months", ",", "25", "(", "OH", ")", "D", "was", "higher", "with", "supplementation", "than", "baseline", "and", "higher", "than", "with", "placebo", "(", "P", "<", "0.05", ")", ".", "In", "adjusted", "mixed", "models", ",", "in", "the", "supplementation", "group", ",", "the", "fixed", "effect", "of", "25", "(", "OH", ")", "D", "was", "higher", "(", "P", "<", "0.001", ")", ".", "Percentage", "of", "naive", "T", "-", "helper", "cells", "(", "Th", "naive", "%", ")", "were", "significantly", "(", "P", "<", "0.01", ")", "and", "T", "-", "helper", "cells", "(", "CD4", "%", ")", "marginally", "(", "P", "<", "0.10", ")", "increased", "with", "supplementation", "in", "those", "taking", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", ",", "and", "RNA", "viral", "load", "was", "reduced", "(", "P", "≤", "0.05", ")", ".", "In", "exploratory", "linear", "models", ",", "change", "in", "25", "(", "OH", ")", "D", "predicted", "RNA", "viral", "load", "at", "3", "and", "12", "months", "and", "CD4", "%", "at", "3", "months", "(", "P", "<", "0.05", ")", ".", "CONCLUSIONS", "Daily", "7000", "IU", "vitD3", "for", "12", "months", "was", "safe", "in", "HIV", "-", "infected", "subjects", "and", "effective", "in", "increasing", "25", "(", "OH", ")", "D.", "Supplementation", "improved", "some", "clinically", "important", "HIV", "immune", "markers", "in", "subjects", "on", "HAART", ".", "Adjunct", "therapy", "with", "high", "-", "dose", ",", "daily", "vitD3", "for", "HIV", "-", "infected", "subjects", "and", "for", "those", "on", "/", "off", "HAART", "requires", "further", "investigation", "." ]	[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Sex" ]

Paxillin, GST, SH2, Grb2, SH2

1.0alpha7.train.59_task2

Sentence: Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules. Instructions: please extract entity words from the input sentence

[ "B-protein", "O", "O", "O", "B-experiment-tag", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O" ]

Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules.

[ "Paxillin", "failed", "to", "bind", "GST", "alone", "or", "the", "SH2", "domain", "of", "Grb2", "that", "belongs", "to", "the", "family", "of", "SH2", "/", "SH3-containing", "signaling", "molecules", "." ]

[ "protein", "protein-domain", "experiment-tag" ]

germline TaqI restriction fragment length polymorphism is a DNA_domain_or_region, progesterone receptor gene is a DNA_domain_or_region, ovarian carcinoma is an other_name

8248_task0

Sentence: A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name

[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "O", "O", "O", "O" ]

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments]

[ "A", "germline", "TaqI", "restriction", "fragment", "length", "polymorphism", "in", "the", "progesterone", "receptor", "gene", "in", "ovarian", "carcinoma", "[", "see", "comments", "]" ]

[ "DNA_domain_or_region", "DNA_molecule", "DNA_family_or_group", "other_name", "protein_family_or_group", "multi_cell", "DNA_N/A" ]

germline TaqI restriction fragment length polymorphism is a DNA_domain_or_region, progesterone receptor gene is a DNA_domain_or_region, ovarian carcinoma is an other_name

8248_task1

Sentence: A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments] Instructions: please typing these entity words according to sentence: germline TaqI restriction fragment length polymorphism, progesterone receptor gene, ovarian carcinoma Options: DNA_domain_or_region, other_name

[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "O", "O", "O", "O" ]

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments]

[ "A", "germline", "TaqI", "restriction", "fragment", "length", "polymorphism", "in", "the", "progesterone", "receptor", "gene", "in", "ovarian", "carcinoma", "[", "see", "comments", "]" ]

[ "DNA_domain_or_region", "DNA_molecule", "DNA_family_or_group", "other_name", "protein_family_or_group", "multi_cell", "DNA_N/A" ]

germline TaqI restriction fragment length polymorphism, progesterone receptor gene, ovarian carcinoma

8248_task2

Sentence: A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments] Instructions: please extract entity words from the input sentence

[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "O", "O", "O", "O" ]

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma [see comments]

[ "A", "germline", "TaqI", "restriction", "fragment", "length", "polymorphism", "in", "the", "progesterone", "receptor", "gene", "in", "ovarian", "carcinoma", "[", "see", "comments", "]" ]

[ "DNA_domain_or_region", "DNA_molecule", "DNA_family_or_group", "other_name", "protein_family_or_group", "multi_cell", "DNA_N/A" ]

imaging is an umlsterm, MRI is an umlsterm, role is an umlsterm, endoscopy is an umlsterm, laryngeal neoplasms is an umlsterm, knowledge is an umlsterm, familiarity is an umlsterm, diagnostic is an umlsterm, signs is an umlsterm, imaging is an umlsterm, treatment is an umlsterm, imaging is an umlsterm, cartilage is an umlsterm, value is an umlsterm, MRI is an umlsterm, cartilage is an umlsterm, specificity is an umlsterm, MRI is an umlsterm, methods is an umlsterm, tumor is an umlsterm, imaging is an umlsterm, methods is an umlsterm, tumors is an umlsterm, clinical examination is an umlsterm, biopsy is an umlsterm, MRI is an umlsterm, role is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, diagnosis is an umlsterm

DerRadiologe.80380093.eng.abstr_task0

Sentence: Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis .

[ "Cross", "-", "sectional", "imaging", "with", "CT", "and", "MRI", "plays", "an", "indispensable", "complementary", "role", "to", "endoscopy", "in", "the", "pretherapeutic", "workup", "and", "staging", "of", "laryngeal", "neoplasms", ".", "Adequate", "interpretation", "of", "the", "CT", "and", "MR", "images", "requires", "a", "thorough", "knowledge", "of", "the", "patterns", "of", "submucosal", "spread", "and", "familiarity", "with", "the", "diagnostic", "signs", "of", "neoplastic", "invasion", "as", "seen", "with", "each", "modality", ".", "In", "addition", ",", "the", "radiologist", "should", "be", "aware", "of", "the", "implications", "of", "imaging", "for", "staging", "and", "treatment", ".", "Both", "CT", "and", "MR", "imaging", "are", "highly", "sensitive", "for", "the", "detection", "of", "neoplastic", "invasion", "of", "the", "pre", "-", "epiglottic", "space", ",", "paraglottic", "space", ",", "subglottic", "region", "and", "cartilage", ".", "The", "high", "negative", "predictive", "value", "of", "both", "CT", "and", "MRI", "allows", "exclusion", "of", "neoplastic", "cartilage", "invasion", "quite", "reliably", ".", "The", "specificity", "of", "both", "CT", "and", "MRI", "is", ",", "however", ",", "limited", "and", "both", "methods", "may", "therefore", "overestimate", "the", "extent", "of", "tumor", "spread", ".", "Nevertheless", ",", "both", "cross", "-", "sectional", "imaging", "methods", "significantly", "improve", "the", "pretherapeutic", "staging", "accuracy", "of", "laryngeal", "tumors", "if", "used", "in", "addition", "to", "clinical", "examination", "and", "endoscopic", "biopsy", ".", "In", "the", "presence", "of", "a", "submucosal", "mass", ",", "CT", "and", "MRI", "play", "a", "key", "role", "for", "the", "diagnosis", ",", "as", "they", "may", "characterize", "the", "lesion", ",", "reliably", "depict", "its", "submucosal", "extent", ",", "and", "guide", "the", "endoscopist", "to", "perform", "deep", "biopsies", "that", "allow", "a", "definitive", "histological", "diagnosis", "." ]

[ "umlsterm" ]

imaging is an umlsterm, MRI is an umlsterm, role is an umlsterm, endoscopy is an umlsterm, laryngeal neoplasms is an umlsterm, knowledge is an umlsterm, familiarity is an umlsterm, diagnostic is an umlsterm, signs is an umlsterm, imaging is an umlsterm, treatment is an umlsterm, imaging is an umlsterm, cartilage is an umlsterm, value is an umlsterm, MRI is an umlsterm, cartilage is an umlsterm, specificity is an umlsterm, MRI is an umlsterm, methods is an umlsterm, tumor is an umlsterm, imaging is an umlsterm, methods is an umlsterm, tumors is an umlsterm, clinical examination is an umlsterm, biopsy is an umlsterm, MRI is an umlsterm, role is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, diagnosis is an umlsterm

DerRadiologe.80380093.eng.abstr_task1

Sentence: Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis . Instructions: please typing these entity words according to sentence: imaging, MRI, role, endoscopy, laryngeal neoplasms, knowledge, familiarity, diagnostic, signs, imaging, treatment, imaging, cartilage, value, MRI, cartilage, specificity, MRI, methods, tumor, imaging, methods, tumors, clinical examination, biopsy, MRI, role, diagnosis, biopsies, diagnosis Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis .

[ "Cross", "-", "sectional", "imaging", "with", "CT", "and", "MRI", "plays", "an", "indispensable", "complementary", "role", "to", "endoscopy", "in", "the", "pretherapeutic", "workup", "and", "staging", "of", "laryngeal", "neoplasms", ".", "Adequate", "interpretation", "of", "the", "CT", "and", "MR", "images", "requires", "a", "thorough", "knowledge", "of", "the", "patterns", "of", "submucosal", "spread", "and", "familiarity", "with", "the", "diagnostic", "signs", "of", "neoplastic", "invasion", "as", "seen", "with", "each", "modality", ".", "In", "addition", ",", "the", "radiologist", "should", "be", "aware", "of", "the", "implications", "of", "imaging", "for", "staging", "and", "treatment", ".", "Both", "CT", "and", "MR", "imaging", "are", "highly", "sensitive", "for", "the", "detection", "of", "neoplastic", "invasion", "of", "the", "pre", "-", "epiglottic", "space", ",", "paraglottic", "space", ",", "subglottic", "region", "and", "cartilage", ".", "The", "high", "negative", "predictive", "value", "of", "both", "CT", "and", "MRI", "allows", "exclusion", "of", "neoplastic", "cartilage", "invasion", "quite", "reliably", ".", "The", "specificity", "of", "both", "CT", "and", "MRI", "is", ",", "however", ",", "limited", "and", "both", "methods", "may", "therefore", "overestimate", "the", "extent", "of", "tumor", "spread", ".", "Nevertheless", ",", "both", "cross", "-", "sectional", "imaging", "methods", "significantly", "improve", "the", "pretherapeutic", "staging", "accuracy", "of", "laryngeal", "tumors", "if", "used", "in", "addition", "to", "clinical", "examination", "and", "endoscopic", "biopsy", ".", "In", "the", "presence", "of", "a", "submucosal", "mass", ",", "CT", "and", "MRI", "play", "a", "key", "role", "for", "the", "diagnosis", ",", "as", "they", "may", "characterize", "the", "lesion", ",", "reliably", "depict", "its", "submucosal", "extent", ",", "and", "guide", "the", "endoscopist", "to", "perform", "deep", "biopsies", "that", "allow", "a", "definitive", "histological", "diagnosis", "." ]

[ "umlsterm" ]

imaging, MRI, role, endoscopy, laryngeal neoplasms, knowledge, familiarity, diagnostic, signs, imaging, treatment, imaging, cartilage, value, MRI, cartilage, specificity, MRI, methods, tumor, imaging, methods, tumors, clinical examination, biopsy, MRI, role, diagnosis, biopsies, diagnosis

DerRadiologe.80380093.eng.abstr_task2

Sentence: Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Cross-sectional imaging with CT and MRI plays an indispensable complementary role to endoscopy in the pretherapeutic workup and staging of laryngeal neoplasms . Adequate interpretation of the CT and MR images requires a thorough knowledge of the patterns of submucosal spread and familiarity with the diagnostic signs of neoplastic invasion as seen with each modality . In addition , the radiologist should be aware of the implications of imaging for staging and treatment . Both CT and MR imaging are highly sensitive for the detection of neoplastic invasion of the pre-epiglottic space , paraglottic space , subglottic region and cartilage . The high negative predictive value of both CT and MRI allows exclusion of neoplastic cartilage invasion quite reliably . The specificity of both CT and MRI is , however , limited and both methods may therefore overestimate the extent of tumor spread . Nevertheless , both cross-sectional imaging methods significantly improve the pretherapeutic staging accuracy of laryngeal tumors if used in addition to clinical examination and endoscopic biopsy . In the presence of a submucosal mass , CT and MRI play a key role for the diagnosis , as they may characterize the lesion , reliably depict its submucosal extent , and guide the endoscopist to perform deep biopsies that allow a definitive histological diagnosis .

[ "Cross", "-", "sectional", "imaging", "with", "CT", "and", "MRI", "plays", "an", "indispensable", "complementary", "role", "to", "endoscopy", "in", "the", "pretherapeutic", "workup", "and", "staging", "of", "laryngeal", "neoplasms", ".", "Adequate", "interpretation", "of", "the", "CT", "and", "MR", "images", "requires", "a", "thorough", "knowledge", "of", "the", "patterns", "of", "submucosal", "spread", "and", "familiarity", "with", "the", "diagnostic", "signs", "of", "neoplastic", "invasion", "as", "seen", "with", "each", "modality", ".", "In", "addition", ",", "the", "radiologist", "should", "be", "aware", "of", "the", "implications", "of", "imaging", "for", "staging", "and", "treatment", ".", "Both", "CT", "and", "MR", "imaging", "are", "highly", "sensitive", "for", "the", "detection", "of", "neoplastic", "invasion", "of", "the", "pre", "-", "epiglottic", "space", ",", "paraglottic", "space", ",", "subglottic", "region", "and", "cartilage", ".", "The", "high", "negative", "predictive", "value", "of", "both", "CT", "and", "MRI", "allows", "exclusion", "of", "neoplastic", "cartilage", "invasion", "quite", "reliably", ".", "The", "specificity", "of", "both", "CT", "and", "MRI", "is", ",", "however", ",", "limited", "and", "both", "methods", "may", "therefore", "overestimate", "the", "extent", "of", "tumor", "spread", ".", "Nevertheless", ",", "both", "cross", "-", "sectional", "imaging", "methods", "significantly", "improve", "the", "pretherapeutic", "staging", "accuracy", "of", "laryngeal", "tumors", "if", "used", "in", "addition", "to", "clinical", "examination", "and", "endoscopic", "biopsy", ".", "In", "the", "presence", "of", "a", "submucosal", "mass", ",", "CT", "and", "MRI", "play", "a", "key", "role", "for", "the", "diagnosis", ",", "as", "they", "may", "characterize", "the", "lesion", ",", "reliably", "depict", "its", "submucosal", "extent", ",", "and", "guide", "the", "endoscopist", "to", "perform", "deep", "biopsies", "that", "allow", "a", "definitive", "histological", "diagnosis", "." ]

[ "umlsterm" ]

PTCA is an umlsterm, patients is an umlsterm, staff 's is an umlsterm, hospital costs is an umlsterm, length of stay is an umlsterm, safety is an umlsterm, hemostatic is an umlsterm, collagen is an umlsterm, device is an umlsterm, complications is an umlsterm, device is an umlsterm, old is an umlsterm, female is an umlsterm, patient is an umlsterm, weight is an umlsterm, PTCA is an umlsterm, anterior is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm, device is an umlsterm, standard is an umlsterm, technique is an umlsterm, device is an umlsterm, device is an umlsterm, hemostasis is an umlsterm, heparin is an umlsterm, protamine is an umlsterm, complications is an umlsterm, hemostasis is an umlsterm, patient is an umlsterm, symptoms is an umlsterm, right is an umlsterm, femoral artery is an umlsterm, patient is an umlsterm, vascular surgery is an umlsterm, collagen is an umlsterm, surgery is an umlsterm

ZfuerKardiologie.80870051.eng.abstr_task0

Sentence: Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery .

[ "Removal", "of", "the", "arterial", "sheath", "immediately", "after", "PTCA", "is", "desirable", "for", "patients", ",", "reduces", "the", "medical", "staff", "'s", "workload", ",", "and", "may", "decrease", "hospital", "costs", "due", "to", "a", "shortened", "length", "of", "stay", ".", "Although", "the", "safety", "and", "efficacy", "of", "the", "hemostatic", "systems", "used", "especially", "for", "the", "above", "purpose", "have", "been", "sufficiently", "documented", ",", "inadvertent", "intraluminal", "vascular", "occlusion", "is", "theoretically", "possible", ".", "While", "partial", "or", "complete", "arterial", "occlusion", "in", "conjunction", "with", "the", "VasoSeal", "collagen", "prototype", "device", "has", "been", "previously", "reported", ",", "similar", "complications", "occurring", "with", "the", "Angio", "-", "SealTM", "device", "were", "not", "published", ".", "In", "this", "report", ",", "we", "describe", "a", "54-year", "old", "female", "patient", "(", "height", ":", "150", "cm", ",", "weight", ":", "42.5", "kg", ")", "who", "was", "transferred", "for", "PTCA", "following", "an", "acute", "anterior", "wall", "myocardial", "infarction", ".", "Immediately", "after", "PTCA", ",", "the", "Angio", "-", "SealTM", "device", "was", "deployed", "utilizing", "standard", "technique", ".", "No", "difficulties", "were", "encountered", "during", "device", "deployment", ",", "however", ",", "immediately", "following", "device", "placement", "active", "arterial", "bleeding", "occurred", ".", "Due", "to", "the", "inadequacy", "of", "hemostasis", ",", "heparin", "was", "reversed", "with", "protamine", "to", "avoid", "further", "hemorrhagic", "complications", ".", "Following", "this", ",", "the", "desired", "hemostasis", "quickly", "occurred", ",", "but", "the", "patient", "soon", "complained", "about", "symptoms", "suggestive", "of", "an", "acute", "occlusion", "of", "the", "right", "femoral", "artery", ".", "Unsatisfactory", "attempts", "as", "lysis", "resulted", "in", "the", "patient", "being", "transferred", "to", "vascular", "surgery", ".", "The", "complete", "Angio", "-", "SealTM", "system", "(", "anchor", "including", "collagen", ")", "was", "located", "intravasculary", ",", "and", "removed", "during", "surgery", "." ]

[ "umlsterm" ]

PTCA is an umlsterm, patients is an umlsterm, staff 's is an umlsterm, hospital costs is an umlsterm, length of stay is an umlsterm, safety is an umlsterm, hemostatic is an umlsterm, collagen is an umlsterm, device is an umlsterm, complications is an umlsterm, device is an umlsterm, old is an umlsterm, female is an umlsterm, patient is an umlsterm, weight is an umlsterm, PTCA is an umlsterm, anterior is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm, device is an umlsterm, standard is an umlsterm, technique is an umlsterm, device is an umlsterm, device is an umlsterm, hemostasis is an umlsterm, heparin is an umlsterm, protamine is an umlsterm, complications is an umlsterm, hemostasis is an umlsterm, patient is an umlsterm, symptoms is an umlsterm, right is an umlsterm, femoral artery is an umlsterm, patient is an umlsterm, vascular surgery is an umlsterm, collagen is an umlsterm, surgery is an umlsterm

ZfuerKardiologie.80870051.eng.abstr_task1

Sentence: Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery . Instructions: please typing these entity words according to sentence: PTCA, patients, staff 's, hospital costs, length of stay, safety, hemostatic, collagen, device, complications, device, old, female, patient, weight, PTCA, anterior, myocardial infarction, PTCA, device, standard, technique, device, device, hemostasis, heparin, protamine, complications, hemostasis, patient, symptoms, right, femoral artery, patient, vascular surgery, collagen, surgery Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery .

[ "Removal", "of", "the", "arterial", "sheath", "immediately", "after", "PTCA", "is", "desirable", "for", "patients", ",", "reduces", "the", "medical", "staff", "'s", "workload", ",", "and", "may", "decrease", "hospital", "costs", "due", "to", "a", "shortened", "length", "of", "stay", ".", "Although", "the", "safety", "and", "efficacy", "of", "the", "hemostatic", "systems", "used", "especially", "for", "the", "above", "purpose", "have", "been", "sufficiently", "documented", ",", "inadvertent", "intraluminal", "vascular", "occlusion", "is", "theoretically", "possible", ".", "While", "partial", "or", "complete", "arterial", "occlusion", "in", "conjunction", "with", "the", "VasoSeal", "collagen", "prototype", "device", "has", "been", "previously", "reported", ",", "similar", "complications", "occurring", "with", "the", "Angio", "-", "SealTM", "device", "were", "not", "published", ".", "In", "this", "report", ",", "we", "describe", "a", "54-year", "old", "female", "patient", "(", "height", ":", "150", "cm", ",", "weight", ":", "42.5", "kg", ")", "who", "was", "transferred", "for", "PTCA", "following", "an", "acute", "anterior", "wall", "myocardial", "infarction", ".", "Immediately", "after", "PTCA", ",", "the", "Angio", "-", "SealTM", "device", "was", "deployed", "utilizing", "standard", "technique", ".", "No", "difficulties", "were", "encountered", "during", "device", "deployment", ",", "however", ",", "immediately", "following", "device", "placement", "active", "arterial", "bleeding", "occurred", ".", "Due", "to", "the", "inadequacy", "of", "hemostasis", ",", "heparin", "was", "reversed", "with", "protamine", "to", "avoid", "further", "hemorrhagic", "complications", ".", "Following", "this", ",", "the", "desired", "hemostasis", "quickly", "occurred", ",", "but", "the", "patient", "soon", "complained", "about", "symptoms", "suggestive", "of", "an", "acute", "occlusion", "of", "the", "right", "femoral", "artery", ".", "Unsatisfactory", "attempts", "as", "lysis", "resulted", "in", "the", "patient", "being", "transferred", "to", "vascular", "surgery", ".", "The", "complete", "Angio", "-", "SealTM", "system", "(", "anchor", "including", "collagen", ")", "was", "located", "intravasculary", ",", "and", "removed", "during", "surgery", "." ]

[ "umlsterm" ]

PTCA, patients, staff 's, hospital costs, length of stay, safety, hemostatic, collagen, device, complications, device, old, female, patient, weight, PTCA, anterior, myocardial infarction, PTCA, device, standard, technique, device, device, hemostasis, heparin, protamine, complications, hemostasis, patient, symptoms, right, femoral artery, patient, vascular surgery, collagen, surgery

ZfuerKardiologie.80870051.eng.abstr_task2

Sentence: Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Removal of the arterial sheath immediately after PTCA is desirable for patients , reduces the medical staff's workload , and may decrease hospital costs due to a shortened length of stay . Although the safety and efficacy of the hemostatic systems used especially for the above purpose have been sufficiently documented , inadvertent intraluminal vascular occlusion is theoretically possible . While partial or complete arterial occlusion in conjunction with the VasoSeal collagen prototype device has been previously reported , similar complications occurring with the Angio-SealTM device were not published . In this report , we describe a 54-year old female patient ( height : 150 cm , weight : 42.5 kg ) who was transferred for PTCA following an acute anterior wall myocardial infarction . Immediately after PTCA , the Angio-SealTM device was deployed utilizing standard technique . No difficulties were encountered during device deployment , however , immediately following device placement active arterial bleeding occurred . Due to the inadequacy of hemostasis , heparin was reversed with protamine to avoid further hemorrhagic complications . Following this , the desired hemostasis quickly occurred , but the patient soon complained about symptoms suggestive of an acute occlusion of the right femoral artery . Unsatisfactory attempts as lysis resulted in the patient being transferred to vascular surgery . The complete Angio-SealTM system ( anchor including collagen ) was located intravasculary , and removed during surgery .

[ "Removal", "of", "the", "arterial", "sheath", "immediately", "after", "PTCA", "is", "desirable", "for", "patients", ",", "reduces", "the", "medical", "staff", "'s", "workload", ",", "and", "may", "decrease", "hospital", "costs", "due", "to", "a", "shortened", "length", "of", "stay", ".", "Although", "the", "safety", "and", "efficacy", "of", "the", "hemostatic", "systems", "used", "especially", "for", "the", "above", "purpose", "have", "been", "sufficiently", "documented", ",", "inadvertent", "intraluminal", "vascular", "occlusion", "is", "theoretically", "possible", ".", "While", "partial", "or", "complete", "arterial", "occlusion", "in", "conjunction", "with", "the", "VasoSeal", "collagen", "prototype", "device", "has", "been", "previously", "reported", ",", "similar", "complications", "occurring", "with", "the", "Angio", "-", "SealTM", "device", "were", "not", "published", ".", "In", "this", "report", ",", "we", "describe", "a", "54-year", "old", "female", "patient", "(", "height", ":", "150", "cm", ",", "weight", ":", "42.5", "kg", ")", "who", "was", "transferred", "for", "PTCA", "following", "an", "acute", "anterior", "wall", "myocardial", "infarction", ".", "Immediately", "after", "PTCA", ",", "the", "Angio", "-", "SealTM", "device", "was", "deployed", "utilizing", "standard", "technique", ".", "No", "difficulties", "were", "encountered", "during", "device", "deployment", ",", "however", ",", "immediately", "following", "device", "placement", "active", "arterial", "bleeding", "occurred", ".", "Due", "to", "the", "inadequacy", "of", "hemostasis", ",", "heparin", "was", "reversed", "with", "protamine", "to", "avoid", "further", "hemorrhagic", "complications", ".", "Following", "this", ",", "the", "desired", "hemostasis", "quickly", "occurred", ",", "but", "the", "patient", "soon", "complained", "about", "symptoms", "suggestive", "of", "an", "acute", "occlusion", "of", "the", "right", "femoral", "artery", ".", "Unsatisfactory", "attempts", "as", "lysis", "resulted", "in", "the", "patient", "being", "transferred", "to", "vascular", "surgery", ".", "The", "complete", "Angio", "-", "SealTM", "system", "(", "anchor", "including", "collagen", ")", "was", "located", "intravasculary", ",", "and", "removed", "during", "surgery", "." ]

[ "umlsterm" ]

active is a Qualifier, respiratory , cardiovascular or other disease is a Scope, requiring is a Mood, treatment is a Procedure, relevant is a Mood, tolerance is a Condition, hypoxia or altitude exposure is a Scope, heavy smoking is a Condition, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years is a Scope, regular use of alcohol is a Condition, Allergy is a Condition, acetazolamide and other sulfonamides is a Scope

NCT03537924_exc_task0

Sentence: Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Procedure, Scope, Mood

[ "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Mood", "O", "B-Procedure", "O", "O", "O", "B-Mood", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides.

[ "Any", "active", "respiratory", ",", "cardiovascular", "or", "other", "disease", "requiring", "regular", "treatment", "or", "being", "otherwise", "relevant", "for", "tolerance", "of", "hypoxia", "or", "altitude", "exposure", ".", "\n", "Any", "condition", "that", "may", "interfere", "with", "protocol", "compliance", "including", "current", "heavy", "smoking", "(", ">", "20", "cigarettes", "per", "day", "or", ">", "20", "pack", "-", "years", "with", "active", "smoking", "during", "the", "last", "10", "years", ")", ",", "regular", "use", "of", "alcohol", ".", "\n", "Allergy", "to", "acetazolamide", "and", "other", "sulfonamides", ".", "\n" ]

[ "Scope", "Temporal", "Condition", "Measurement", "Drug", "Mood", "Procedure", "Qualifier", "Value" ]

active is a Qualifier, respiratory , cardiovascular or other disease is a Scope, requiring is a Mood, treatment is a Procedure, relevant is a Mood, tolerance is a Condition, hypoxia or altitude exposure is a Scope, heavy smoking is a Condition, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years is a Scope, regular use of alcohol is a Condition, Allergy is a Condition, acetazolamide and other sulfonamides is a Scope

NCT03537924_exc_task1

Sentence: Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides. Instructions: please typing these entity words according to sentence: active, respiratory , cardiovascular or other disease, requiring, treatment, relevant, tolerance, hypoxia or altitude exposure, heavy smoking, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years, regular use of alcohol, Allergy, acetazolamide and other sulfonamides Options: Condition, Qualifier, Procedure, Scope, Mood

[ "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Mood", "O", "B-Procedure", "O", "O", "O", "B-Mood", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides.

[ "Any", "active", "respiratory", ",", "cardiovascular", "or", "other", "disease", "requiring", "regular", "treatment", "or", "being", "otherwise", "relevant", "for", "tolerance", "of", "hypoxia", "or", "altitude", "exposure", ".", "\n", "Any", "condition", "that", "may", "interfere", "with", "protocol", "compliance", "including", "current", "heavy", "smoking", "(", ">", "20", "cigarettes", "per", "day", "or", ">", "20", "pack", "-", "years", "with", "active", "smoking", "during", "the", "last", "10", "years", ")", ",", "regular", "use", "of", "alcohol", ".", "\n", "Allergy", "to", "acetazolamide", "and", "other", "sulfonamides", ".", "\n" ]

[ "Scope", "Temporal", "Condition", "Measurement", "Drug", "Mood", "Procedure", "Qualifier", "Value" ]

active, respiratory , cardiovascular or other disease, requiring, treatment, relevant, tolerance, hypoxia or altitude exposure, heavy smoking, > 20 cigarettes per day or > 20 pack - years with active smoking during the last 10 years, regular use of alcohol, Allergy, acetazolamide and other sulfonamides

NCT03537924_exc_task2

Sentence: Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides. Instructions: please extract entity words from the input sentence

[ "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Mood", "O", "B-Procedure", "O", "O", "O", "B-Mood", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. Allergy to acetazolamide and other sulfonamides.

[ "Any", "active", "respiratory", ",", "cardiovascular", "or", "other", "disease", "requiring", "regular", "treatment", "or", "being", "otherwise", "relevant", "for", "tolerance", "of", "hypoxia", "or", "altitude", "exposure", ".", "\n", "Any", "condition", "that", "may", "interfere", "with", "protocol", "compliance", "including", "current", "heavy", "smoking", "(", ">", "20", "cigarettes", "per", "day", "or", ">", "20", "pack", "-", "years", "with", "active", "smoking", "during", "the", "last", "10", "years", ")", ",", "regular", "use", "of", "alcohol", ".", "\n", "Allergy", "to", "acetazolamide", "and", "other", "sulfonamides", ".", "\n" ]

[ "Scope", "Temporal", "Condition", "Measurement", "Drug", "Mood", "Procedure", "Qualifier", "Value" ]

development is an umlsterm, Australia is an umlsterm, Oregon is an umlsterm, assisted suicide is an umlsterm, Netherlands is an umlsterm, suicide is an umlsterm, psychiatrist is an umlsterm

DerNervenarzt.70680878.eng.abstr_task0

Sentence: The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view .

[ "The", "international", "discussion", "on", "physician", "-", "assisted", "dying", "as", "well", "as", "the", "recent", "development", "in", "North", "Australia", "and", "Oregon", "point", "to", "a", "growing", "tendency", "to", "favour", "assisted", "suicide", "as", "against", "killing", "on", "request", "-", "last", "not", "least", "for", "reasons", "of", "public", "acceptance", ".", "The", "decision", "of", "the", "Supreme", "Court", "of", "the", "Netherlands", "in", "a", "case", "of", "suicide", "assisted", "by", "a", "psychiatrist", "gives", "the", "opportunity", "to", "discuss", "the", "problem", "from", "the", "psychiatric", "point", "of", "view", "." ]

[ "umlsterm" ]

development is an umlsterm, Australia is an umlsterm, Oregon is an umlsterm, assisted suicide is an umlsterm, Netherlands is an umlsterm, suicide is an umlsterm, psychiatrist is an umlsterm

DerNervenarzt.70680878.eng.abstr_task1

Sentence: The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view . Instructions: please typing these entity words according to sentence: development, Australia, Oregon, assisted suicide, Netherlands, suicide, psychiatrist Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view .

[ "The", "international", "discussion", "on", "physician", "-", "assisted", "dying", "as", "well", "as", "the", "recent", "development", "in", "North", "Australia", "and", "Oregon", "point", "to", "a", "growing", "tendency", "to", "favour", "assisted", "suicide", "as", "against", "killing", "on", "request", "-", "last", "not", "least", "for", "reasons", "of", "public", "acceptance", ".", "The", "decision", "of", "the", "Supreme", "Court", "of", "the", "Netherlands", "in", "a", "case", "of", "suicide", "assisted", "by", "a", "psychiatrist", "gives", "the", "opportunity", "to", "discuss", "the", "problem", "from", "the", "psychiatric", "point", "of", "view", "." ]

[ "umlsterm" ]

development, Australia, Oregon, assisted suicide, Netherlands, suicide, psychiatrist

DerNervenarzt.70680878.eng.abstr_task2

Sentence: The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The international discussion on physician-assisted dying as well as the recent development in North Australia and Oregon point to a growing tendency to favour assisted suicide as against killing on request - last not least for reasons of public acceptance . The decision of the Supreme Court of the Netherlands in a case of suicide assisted by a psychiatrist gives the opportunity to discuss the problem from the psychiatric point of view .

[ "The", "international", "discussion", "on", "physician", "-", "assisted", "dying", "as", "well", "as", "the", "recent", "development", "in", "North", "Australia", "and", "Oregon", "point", "to", "a", "growing", "tendency", "to", "favour", "assisted", "suicide", "as", "against", "killing", "on", "request", "-", "last", "not", "least", "for", "reasons", "of", "public", "acceptance", ".", "The", "decision", "of", "the", "Supreme", "Court", "of", "the", "Netherlands", "in", "a", "case", "of", "suicide", "assisted", "by", "a", "psychiatrist", "gives", "the", "opportunity", "to", "discuss", "the", "problem", "from", "the", "psychiatric", "point", "of", "view", "." ]

[ "umlsterm" ]

Pollex is an umlsterm, Bewegungseinschraenkung is an umlsterm, Diagnostik is an umlsterm, Tendovaginitis is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Daumens is an umlsterm, passive Gelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Ringbandspaltung is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Operationstechnik is an umlsterm, Hand is an umlsterm, Tendovaginitis is an umlsterm, Kind is an umlsterm

DerChirurg.70681190.ger.abstr_task0

Sentence: Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten .

[ "Zusammenfassung", ".", "Die", "eigene", "Behandlungsmethode", "bei", "Pollex", "flexus", "congenitus", "wird", "vorgestellt", ".", "Leitsymptome", "sind", "die", "fixierte", "Beugefehlstellung", ",", "eine", "schmerzhafte", ")", "Bewegungseinschraenkung", "(", "(", "mit", "Klick", "-", "Phaenomen", ")", "oder", "eine", "persistierende", "Streckfehlstellung", ".", "Obwohl", "es", "sich", "um", "ein", "einfaches", "Krankheitsbild", "handelt", ",", "ist", "eine", "sorgfaeltige", "Diagnostik", "mit", "Ausschluss", "seltener", "Ursachen", ",", "welche", "eine", "Tendovaginitis", "stenosans", "imitieren", "koennen", ",", "notwendig", ",", "da", "gerade", "diese", "Faelle", "zu", "schwerwiegenden", "Komplikationen", "fuehren", "koennen", ".", "26", "Patienten", "mit", "persistierenden", "Beschwerden", "wurde", "operativ", "das", "A1-Ringband", "des", "Daumens", "gespalten", ".", "Eine", "freie", "aktive", "und", "passive", "Gelenkbeweglichkeit", "im", "Seitenvergleich", "trat", "bei", "92,7", "%", "der", "Patienten", "auf", ",", "wobei", "aufgrund", "einer", "inkompletten", "Ringbandspaltung", "bei", "2", "Patienten", "eine", "erneute", "Operation", "durchgefuehrt", "wurde", ".", "Bei", "adaequater", "Diagnostik", ",", "fruehzeitiger", "Indikationsstellung", "und", "exakter", "Operationstechnik", "sollten", "heutzutage", "aesthetische", "und", "funktionelle", "Beeintraechtigungen", "der", "Hand", "aufgrund", "einer", "Tendovaginitis", "stenosans", "beim", "Kind", "nicht", "mehr", "auftreten", "." ]

[ "umlsterm" ]

Pollex is an umlsterm, Bewegungseinschraenkung is an umlsterm, Diagnostik is an umlsterm, Tendovaginitis is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Daumens is an umlsterm, passive Gelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Ringbandspaltung is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Operationstechnik is an umlsterm, Hand is an umlsterm, Tendovaginitis is an umlsterm, Kind is an umlsterm

DerChirurg.70681190.ger.abstr_task1

Sentence: Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten . Instructions: please typing these entity words according to sentence: Pollex, Bewegungseinschraenkung, Diagnostik, Tendovaginitis, Komplikationen, Patienten, Daumens, passive Gelenkbeweglichkeit, Patienten, Ringbandspaltung, Patienten, Diagnostik, Operationstechnik, Hand, Tendovaginitis, Kind Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten .

[ "Zusammenfassung", ".", "Die", "eigene", "Behandlungsmethode", "bei", "Pollex", "flexus", "congenitus", "wird", "vorgestellt", ".", "Leitsymptome", "sind", "die", "fixierte", "Beugefehlstellung", ",", "eine", "schmerzhafte", ")", "Bewegungseinschraenkung", "(", "(", "mit", "Klick", "-", "Phaenomen", ")", "oder", "eine", "persistierende", "Streckfehlstellung", ".", "Obwohl", "es", "sich", "um", "ein", "einfaches", "Krankheitsbild", "handelt", ",", "ist", "eine", "sorgfaeltige", "Diagnostik", "mit", "Ausschluss", "seltener", "Ursachen", ",", "welche", "eine", "Tendovaginitis", "stenosans", "imitieren", "koennen", ",", "notwendig", ",", "da", "gerade", "diese", "Faelle", "zu", "schwerwiegenden", "Komplikationen", "fuehren", "koennen", ".", "26", "Patienten", "mit", "persistierenden", "Beschwerden", "wurde", "operativ", "das", "A1-Ringband", "des", "Daumens", "gespalten", ".", "Eine", "freie", "aktive", "und", "passive", "Gelenkbeweglichkeit", "im", "Seitenvergleich", "trat", "bei", "92,7", "%", "der", "Patienten", "auf", ",", "wobei", "aufgrund", "einer", "inkompletten", "Ringbandspaltung", "bei", "2", "Patienten", "eine", "erneute", "Operation", "durchgefuehrt", "wurde", ".", "Bei", "adaequater", "Diagnostik", ",", "fruehzeitiger", "Indikationsstellung", "und", "exakter", "Operationstechnik", "sollten", "heutzutage", "aesthetische", "und", "funktionelle", "Beeintraechtigungen", "der", "Hand", "aufgrund", "einer", "Tendovaginitis", "stenosans", "beim", "Kind", "nicht", "mehr", "auftreten", "." ]

[ "umlsterm" ]

Pollex, Bewegungseinschraenkung, Diagnostik, Tendovaginitis, Komplikationen, Patienten, Daumens, passive Gelenkbeweglichkeit, Patienten, Ringbandspaltung, Patienten, Diagnostik, Operationstechnik, Hand, Tendovaginitis, Kind

DerChirurg.70681190.ger.abstr_task2

Sentence: Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die eigene Behandlungsmethode bei Pollex flexus congenitus wird vorgestellt . Leitsymptome sind die fixierte Beugefehlstellung , eine schmerzhafte ) Bewegungseinschraenkung ( ( mit Klick-Phaenomen ) oder eine persistierende Streckfehlstellung . Obwohl es sich um ein einfaches Krankheitsbild handelt , ist eine sorgfaeltige Diagnostik mit Ausschluss seltener Ursachen , welche eine Tendovaginitis stenosans imitieren koennen , notwendig , da gerade diese Faelle zu schwerwiegenden Komplikationen fuehren koennen . 26 Patienten mit persistierenden Beschwerden wurde operativ das A1-Ringband des Daumens gespalten . Eine freie aktive und passive Gelenkbeweglichkeit im Seitenvergleich trat bei 92,7 % der Patienten auf , wobei aufgrund einer inkompletten Ringbandspaltung bei 2 Patienten eine erneute Operation durchgefuehrt wurde . Bei adaequater Diagnostik , fruehzeitiger Indikationsstellung und exakter Operationstechnik sollten heutzutage aesthetische und funktionelle Beeintraechtigungen der Hand aufgrund einer Tendovaginitis stenosans beim Kind nicht mehr auftreten .

[ "Zusammenfassung", ".", "Die", "eigene", "Behandlungsmethode", "bei", "Pollex", "flexus", "congenitus", "wird", "vorgestellt", ".", "Leitsymptome", "sind", "die", "fixierte", "Beugefehlstellung", ",", "eine", "schmerzhafte", ")", "Bewegungseinschraenkung", "(", "(", "mit", "Klick", "-", "Phaenomen", ")", "oder", "eine", "persistierende", "Streckfehlstellung", ".", "Obwohl", "es", "sich", "um", "ein", "einfaches", "Krankheitsbild", "handelt", ",", "ist", "eine", "sorgfaeltige", "Diagnostik", "mit", "Ausschluss", "seltener", "Ursachen", ",", "welche", "eine", "Tendovaginitis", "stenosans", "imitieren", "koennen", ",", "notwendig", ",", "da", "gerade", "diese", "Faelle", "zu", "schwerwiegenden", "Komplikationen", "fuehren", "koennen", ".", "26", "Patienten", "mit", "persistierenden", "Beschwerden", "wurde", "operativ", "das", "A1-Ringband", "des", "Daumens", "gespalten", ".", "Eine", "freie", "aktive", "und", "passive", "Gelenkbeweglichkeit", "im", "Seitenvergleich", "trat", "bei", "92,7", "%", "der", "Patienten", "auf", ",", "wobei", "aufgrund", "einer", "inkompletten", "Ringbandspaltung", "bei", "2", "Patienten", "eine", "erneute", "Operation", "durchgefuehrt", "wurde", ".", "Bei", "adaequater", "Diagnostik", ",", "fruehzeitiger", "Indikationsstellung", "und", "exakter", "Operationstechnik", "sollten", "heutzutage", "aesthetische", "und", "funktionelle", "Beeintraechtigungen", "der", "Hand", "aufgrund", "einer", "Tendovaginitis", "stenosans", "beim", "Kind", "nicht", "mehr", "auftreten", "." ]

[ "umlsterm" ]

Fas ligand is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bax is a Protein, Bad is a Protein, microtubule is a Entity, Fas is a Protein, Fas ligand is a Protein, FasL is a Protein, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, microtubule is a Entity, FasL is a Protein, microtubule is a Entity, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, calcineurin is a Protein, FasL is a Protein, Bcl-2 is a Protein

687_task0

Sentence: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.

[ "Bcl-2-mediated", "drug", "resistance", ":", "inhibition", "of", "apoptosis", "by", "blocking", "nuclear", "factor", "of", "activated", "T", "lymphocytes", "(", "NFAT)-induced", "Fas", "ligand", "transcription", ".", "\n", "Bcl-2", "inhibits", "apoptosis", "induced", "by", "a", "variety", "of", "stimuli", ",", "including", "chemotherapy", "drugs", "and", "glucocorticoids", ".", "It", "is", "generally", "accepted", "that", "Bcl-2", "exerts", "its", "antiapoptotic", "effects", "mainly", "by", "dimerizing", "with", "proapoptotic", "members", "of", "the", "Bcl-2", "family", "such", "as", "Bax", "and", "Bad", ".", "However", ",", "the", "mechanism", "of", "the", "antiapoptotic", "effects", "is", "unclear", ".", "Paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "dynamics", "kill", "cells", "in", "a", "Fas", "/", "Fas", "ligand", "(", "FasL)-dependent", "manner", ";", "antibody", "to", "FasL", "inhibits", "paclitaxel", "-", "induced", "apoptosis", ".", "We", "have", "found", "that", "Bcl-2", "overexpression", "leads", "to", "the", "prevention", "of", "chemotherapy", "(", "paclitaxel)-induced", "expression", "of", "FasL", "and", "blocks", "paclitaxel", "-", "induced", "apoptosis", ".", "The", "mechanism", "of", "this", "effect", "is", "that", "Bcl-2", "prevents", "the", "nuclear", "translocation", "of", "NFAT", "(", "nuclear", "factor", "of", "activated", "T", "lymphocytes", ",", "a", "transcription", "factor", "activated", "by", "microtubule", "damage", ")", "by", "binding", "and", "sequestering", "calcineurin", ",", "a", "calcium", "-", "dependent", "phosphatase", "that", "must", "dephosphorylate", "NFAT", "to", "move", "to", "the", "nucleus", ".", "Without", "NFAT", "nuclear", "translocation", ",", "the", "FasL", "gene", "is", "not", "transcribed", ".", "Thus", ",", "it", "appears", "that", "paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "function", "kill", "cells", "at", "least", "in", "part", "through", "the", "induction", "of", "FasL.", "Furthermore", ",", "Bcl-2", "antagonizes", "drug", "-", "induced", "apoptosis", "by", "inhibiting", "calcineurin", "activation", ",", "blocking", "NFAT", "nuclear", "translocation", ",", "and", "preventing", "FasL", "expression", ".", "The", "effects", "of", "Bcl-2", "can", "be", "overcome", ",", "at", "least", "partially", ",", "through", "phosphorylation", "of", "Bcl-2", ".", "Phosphorylated", "Bcl-2", "cannot", "bind", "calcineurin", ",", "and", "NFAT", "activation", ",", "FasL", "expression", ",", "and", "apoptosis", "can", "occur", "after", "Bcl-2", "phosphorylation", ".", "\n" ]

[ "Protein", "Entity" ]

Fas ligand is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bax is a Protein, Bad is a Protein, microtubule is a Entity, Fas is a Protein, Fas ligand is a Protein, FasL is a Protein, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, microtubule is a Entity, FasL is a Protein, microtubule is a Entity, Bcl-2 is a Protein, FasL is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, Bcl-2 is a Protein, calcineurin is a Protein, FasL is a Protein, Bcl-2 is a Protein

687_task1

Sentence: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation. Instructions: please typing these entity words according to sentence: Fas ligand, Bcl-2, Bcl-2, Bax, Bad, microtubule, Fas, Fas ligand, FasL, Bcl-2, FasL, Bcl-2, microtubule, FasL, microtubule, Bcl-2, FasL, Bcl-2, Bcl-2, Bcl-2, calcineurin, FasL, Bcl-2 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.

[ "Bcl-2-mediated", "drug", "resistance", ":", "inhibition", "of", "apoptosis", "by", "blocking", "nuclear", "factor", "of", "activated", "T", "lymphocytes", "(", "NFAT)-induced", "Fas", "ligand", "transcription", ".", "\n", "Bcl-2", "inhibits", "apoptosis", "induced", "by", "a", "variety", "of", "stimuli", ",", "including", "chemotherapy", "drugs", "and", "glucocorticoids", ".", "It", "is", "generally", "accepted", "that", "Bcl-2", "exerts", "its", "antiapoptotic", "effects", "mainly", "by", "dimerizing", "with", "proapoptotic", "members", "of", "the", "Bcl-2", "family", "such", "as", "Bax", "and", "Bad", ".", "However", ",", "the", "mechanism", "of", "the", "antiapoptotic", "effects", "is", "unclear", ".", "Paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "dynamics", "kill", "cells", "in", "a", "Fas", "/", "Fas", "ligand", "(", "FasL)-dependent", "manner", ";", "antibody", "to", "FasL", "inhibits", "paclitaxel", "-", "induced", "apoptosis", ".", "We", "have", "found", "that", "Bcl-2", "overexpression", "leads", "to", "the", "prevention", "of", "chemotherapy", "(", "paclitaxel)-induced", "expression", "of", "FasL", "and", "blocks", "paclitaxel", "-", "induced", "apoptosis", ".", "The", "mechanism", "of", "this", "effect", "is", "that", "Bcl-2", "prevents", "the", "nuclear", "translocation", "of", "NFAT", "(", "nuclear", "factor", "of", "activated", "T", "lymphocytes", ",", "a", "transcription", "factor", "activated", "by", "microtubule", "damage", ")", "by", "binding", "and", "sequestering", "calcineurin", ",", "a", "calcium", "-", "dependent", "phosphatase", "that", "must", "dephosphorylate", "NFAT", "to", "move", "to", "the", "nucleus", ".", "Without", "NFAT", "nuclear", "translocation", ",", "the", "FasL", "gene", "is", "not", "transcribed", ".", "Thus", ",", "it", "appears", "that", "paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "function", "kill", "cells", "at", "least", "in", "part", "through", "the", "induction", "of", "FasL.", "Furthermore", ",", "Bcl-2", "antagonizes", "drug", "-", "induced", "apoptosis", "by", "inhibiting", "calcineurin", "activation", ",", "blocking", "NFAT", "nuclear", "translocation", ",", "and", "preventing", "FasL", "expression", ".", "The", "effects", "of", "Bcl-2", "can", "be", "overcome", ",", "at", "least", "partially", ",", "through", "phosphorylation", "of", "Bcl-2", ".", "Phosphorylated", "Bcl-2", "cannot", "bind", "calcineurin", ",", "and", "NFAT", "activation", ",", "FasL", "expression", ",", "and", "apoptosis", "can", "occur", "after", "Bcl-2", "phosphorylation", ".", "\n" ]

[ "Protein", "Entity" ]

Fas ligand, Bcl-2, Bcl-2, Bax, Bad, microtubule, Fas, Fas ligand, FasL, Bcl-2, FasL, Bcl-2, microtubule, FasL, microtubule, Bcl-2, FasL, Bcl-2, Bcl-2, Bcl-2, calcineurin, FasL, Bcl-2

687_task2

Sentence: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.

[ "Bcl-2-mediated", "drug", "resistance", ":", "inhibition", "of", "apoptosis", "by", "blocking", "nuclear", "factor", "of", "activated", "T", "lymphocytes", "(", "NFAT)-induced", "Fas", "ligand", "transcription", ".", "\n", "Bcl-2", "inhibits", "apoptosis", "induced", "by", "a", "variety", "of", "stimuli", ",", "including", "chemotherapy", "drugs", "and", "glucocorticoids", ".", "It", "is", "generally", "accepted", "that", "Bcl-2", "exerts", "its", "antiapoptotic", "effects", "mainly", "by", "dimerizing", "with", "proapoptotic", "members", "of", "the", "Bcl-2", "family", "such", "as", "Bax", "and", "Bad", ".", "However", ",", "the", "mechanism", "of", "the", "antiapoptotic", "effects", "is", "unclear", ".", "Paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "dynamics", "kill", "cells", "in", "a", "Fas", "/", "Fas", "ligand", "(", "FasL)-dependent", "manner", ";", "antibody", "to", "FasL", "inhibits", "paclitaxel", "-", "induced", "apoptosis", ".", "We", "have", "found", "that", "Bcl-2", "overexpression", "leads", "to", "the", "prevention", "of", "chemotherapy", "(", "paclitaxel)-induced", "expression", "of", "FasL", "and", "blocks", "paclitaxel", "-", "induced", "apoptosis", ".", "The", "mechanism", "of", "this", "effect", "is", "that", "Bcl-2", "prevents", "the", "nuclear", "translocation", "of", "NFAT", "(", "nuclear", "factor", "of", "activated", "T", "lymphocytes", ",", "a", "transcription", "factor", "activated", "by", "microtubule", "damage", ")", "by", "binding", "and", "sequestering", "calcineurin", ",", "a", "calcium", "-", "dependent", "phosphatase", "that", "must", "dephosphorylate", "NFAT", "to", "move", "to", "the", "nucleus", ".", "Without", "NFAT", "nuclear", "translocation", ",", "the", "FasL", "gene", "is", "not", "transcribed", ".", "Thus", ",", "it", "appears", "that", "paclitaxel", "and", "other", "drugs", "that", "disturb", "microtubule", "function", "kill", "cells", "at", "least", "in", "part", "through", "the", "induction", "of", "FasL.", "Furthermore", ",", "Bcl-2", "antagonizes", "drug", "-", "induced", "apoptosis", "by", "inhibiting", "calcineurin", "activation", ",", "blocking", "NFAT", "nuclear", "translocation", ",", "and", "preventing", "FasL", "expression", ".", "The", "effects", "of", "Bcl-2", "can", "be", "overcome", ",", "at", "least", "partially", ",", "through", "phosphorylation", "of", "Bcl-2", ".", "Phosphorylated", "Bcl-2", "cannot", "bind", "calcineurin", ",", "and", "NFAT", "activation", ",", "FasL", "expression", ",", "and", "apoptosis", "can", "occur", "after", "Bcl-2", "phosphorylation", ".", "\n" ]

[ "Protein", "Entity" ]

placenta pathology is a Condition, praevia , acreta , pre - eclampsia is a Scope, bleeding disorders is a Condition, intolerance is a Condition, one of the two is a Multiplier, drugs is a Drug, prolonged QT - time is a Condition, other is a Qualifier, serious cardiac diseases is a Condition, kidney failure is a Condition, Epilepsy is a Condition

NCT02528136_exc_task0

Sentence: Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Multiplier, Scope, Drug

[ "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate

[ "Patients", "with", "placenta", "pathology", "such", "as", "praevia", ",", "acreta", ",", "pre", "-", "eclampsia", "\n", "Patients", "with", "bleeding", "disorders", "including", "vonWillebrand", "disease", "type", "I.", "\n", "Known", "intolerance", "to", "one", "of", "the", "two", "drugs", ".", "\n", "Patients", "with", "prolonged", "QT", "-", "time", "or", "other", "serious", "cardiac", "diseases", ".", "\n", "Liver", "or", "kidney", "failure", ".", "\n", "Epilepsy", ".", "\n", "Any", "medical", "reason", "why", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "the", "patient", "should", "not", "participate", "\n" ]

[ "Scope", "Condition", "Multiplier", "Drug", "Qualifier" ]

placenta pathology is a Condition, praevia , acreta , pre - eclampsia is a Scope, bleeding disorders is a Condition, intolerance is a Condition, one of the two is a Multiplier, drugs is a Drug, prolonged QT - time is a Condition, other is a Qualifier, serious cardiac diseases is a Condition, kidney failure is a Condition, Epilepsy is a Condition

NCT02528136_exc_task1

Sentence: Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate Instructions: please typing these entity words according to sentence: placenta pathology, praevia , acreta , pre - eclampsia, bleeding disorders, intolerance, one of the two, drugs, prolonged QT - time, other, serious cardiac diseases, kidney failure, Epilepsy Options: Condition, Qualifier, Multiplier, Scope, Drug

[ "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate

[ "Patients", "with", "placenta", "pathology", "such", "as", "praevia", ",", "acreta", ",", "pre", "-", "eclampsia", "\n", "Patients", "with", "bleeding", "disorders", "including", "vonWillebrand", "disease", "type", "I.", "\n", "Known", "intolerance", "to", "one", "of", "the", "two", "drugs", ".", "\n", "Patients", "with", "prolonged", "QT", "-", "time", "or", "other", "serious", "cardiac", "diseases", ".", "\n", "Liver", "or", "kidney", "failure", ".", "\n", "Epilepsy", ".", "\n", "Any", "medical", "reason", "why", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "the", "patient", "should", "not", "participate", "\n" ]

[ "Scope", "Condition", "Multiplier", "Drug", "Qualifier" ]

placenta pathology, praevia , acreta , pre - eclampsia, bleeding disorders, intolerance, one of the two, drugs, prolonged QT - time, other, serious cardiac diseases, kidney failure, Epilepsy

NCT02528136_exc_task2

Sentence: Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Patients with placenta pathology such as praevia, acreta, pre-eclampsia Patients with bleeding disorders including vonWillebrand disease type I. Known intolerance to one of the two drugs. Patients with prolonged QT-time or other serious cardiac diseases. Liver or kidney failure. Epilepsy. Any medical reason why, in the opinion of the investigator, the patient should not participate

[ "Patients", "with", "placenta", "pathology", "such", "as", "praevia", ",", "acreta", ",", "pre", "-", "eclampsia", "\n", "Patients", "with", "bleeding", "disorders", "including", "vonWillebrand", "disease", "type", "I.", "\n", "Known", "intolerance", "to", "one", "of", "the", "two", "drugs", ".", "\n", "Patients", "with", "prolonged", "QT", "-", "time", "or", "other", "serious", "cardiac", "diseases", ".", "\n", "Liver", "or", "kidney", "failure", ".", "\n", "Epilepsy", ".", "\n", "Any", "medical", "reason", "why", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "the", "patient", "should", "not", "participate", "\n" ]

[ "Scope", "Condition", "Multiplier", "Drug", "Qualifier" ]

Minor is an umlsterm, fistula is an umlsterm, syndrome is an umlsterm, syndrome is an umlsterm, vertigo is an umlsterm, noises is an umlsterm, middle ear is an umlsterm, pressure is an umlsterm, bone is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm, oval windows is an umlsterm, pressure is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm

DerNervenarzt.00710138.eng.abstr_task0

Sentence: In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O" ]

In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal .

[ "In", "1998", "Minor", "et", "al", ".", "described", "a", "new", "variant", "of", "perilymphatic", "fistula", ":", "the", "\"", "superior", "canal", "dehiscence", "syndrome", "\"", ".", "This", "syndrome", "is", "clinically", "characterized", "by", "recurrent", "attacks", "of", "vertigo", "and", "oscillopsia", "induced", "by", "loud", "noises", "or", "stimuli", "that", "result", "in", "changes", "in", "intracranial", "or", "middle", "ear", "pressure", ".", "It", "is", "caused", "by", "a", "dehiscence", "of", "bone", "overlying", "the", "superior", "(", "anterior", ")", "semicircular", "canal", ".", "Due", "to", "this", "dehiscence", ",", "a", "third", ",", "mobile", "window", "(", "in", "addition", "to", "the", "round", "and", "oval", "windows", ")", "is", "formed", ",", "and", "changes", "in", "pressure", "are", "pathologically", "transduced", "to", "the", "anterior", "semicircular", "canal", "." ]

[ "umlsterm" ]

Minor is an umlsterm, fistula is an umlsterm, syndrome is an umlsterm, syndrome is an umlsterm, vertigo is an umlsterm, noises is an umlsterm, middle ear is an umlsterm, pressure is an umlsterm, bone is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm, oval windows is an umlsterm, pressure is an umlsterm, anterior is an umlsterm, semicircular canal is an umlsterm

DerNervenarzt.00710138.eng.abstr_task1

Sentence: In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal . Instructions: please typing these entity words according to sentence: Minor, fistula, syndrome, syndrome, vertigo, noises, middle ear, pressure, bone, anterior, semicircular canal, oval windows, pressure, anterior, semicircular canal Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O" ]

In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal .

[ "In", "1998", "Minor", "et", "al", ".", "described", "a", "new", "variant", "of", "perilymphatic", "fistula", ":", "the", "\"", "superior", "canal", "dehiscence", "syndrome", "\"", ".", "This", "syndrome", "is", "clinically", "characterized", "by", "recurrent", "attacks", "of", "vertigo", "and", "oscillopsia", "induced", "by", "loud", "noises", "or", "stimuli", "that", "result", "in", "changes", "in", "intracranial", "or", "middle", "ear", "pressure", ".", "It", "is", "caused", "by", "a", "dehiscence", "of", "bone", "overlying", "the", "superior", "(", "anterior", ")", "semicircular", "canal", ".", "Due", "to", "this", "dehiscence", ",", "a", "third", ",", "mobile", "window", "(", "in", "addition", "to", "the", "round", "and", "oval", "windows", ")", "is", "formed", ",", "and", "changes", "in", "pressure", "are", "pathologically", "transduced", "to", "the", "anterior", "semicircular", "canal", "." ]

[ "umlsterm" ]

Minor, fistula, syndrome, syndrome, vertigo, noises, middle ear, pressure, bone, anterior, semicircular canal, oval windows, pressure, anterior, semicircular canal

DerNervenarzt.00710138.eng.abstr_task2

Sentence: In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O" ]

In 1998 Minor et al. described a new variant of perilymphatic fistula : the " superior canal dehiscence syndrome " . This syndrome is clinically characterized by recurrent attacks of vertigo and oscillopsia induced by loud noises or stimuli that result in changes in intracranial or middle ear pressure . It is caused by a dehiscence of bone overlying the superior ( anterior ) semicircular canal . Due to this dehiscence , a third , mobile window ( in addition to the round and oval windows ) is formed , and changes in pressure are pathologically transduced to the anterior semicircular canal .

[ "In", "1998", "Minor", "et", "al", ".", "described", "a", "new", "variant", "of", "perilymphatic", "fistula", ":", "the", "\"", "superior", "canal", "dehiscence", "syndrome", "\"", ".", "This", "syndrome", "is", "clinically", "characterized", "by", "recurrent", "attacks", "of", "vertigo", "and", "oscillopsia", "induced", "by", "loud", "noises", "or", "stimuli", "that", "result", "in", "changes", "in", "intracranial", "or", "middle", "ear", "pressure", ".", "It", "is", "caused", "by", "a", "dehiscence", "of", "bone", "overlying", "the", "superior", "(", "anterior", ")", "semicircular", "canal", ".", "Due", "to", "this", "dehiscence", ",", "a", "third", ",", "mobile", "window", "(", "in", "addition", "to", "the", "round", "and", "oval", "windows", ")", "is", "formed", ",", "and", "changes", "in", "pressure", "are", "pathologically", "transduced", "to", "the", "anterior", "semicircular", "canal", "." ]

[ "umlsterm" ]

generic warfarin is a Intervention_Pharmacological, Warfarin is a Intervention_Pharmacological, safety is a Outcome_Other, efficacy is a Outcome_Other, Coumadin is a Intervention_Pharmacological, ( N = 7 ) is a Participant_Sample-size, generic warfarin formulation ( Apo - warfarin ) is a Intervention_Pharmacological, Coumadin over 30 weeks is a Intervention_Pharmacological, Study patients took each drug for five 3-week periods is a Participant_Condition, with international normalized ratio ( INR ) measurements taken twice per period is a Participant_Condition, INR results is a Outcome_Other, safely and effectively switch is a Outcome_Other

21881_task0

Sentence: Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Participant_Sample-size

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O" ]

Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin .

[ "Are", "brand", "-", "name", "and", "generic", "warfarin", "interchangeable", "?", "Multiple", "n", "-", "of-1", "randomized", ",", "crossover", "trials", ".", "BACKGROUND", "Warfarin", "is", "a", "commonly", "used", "anticoagulant", "in", "North", "America", ".", "Several", "generic", "formulations", "have", "been", "approved", ",", "raising", "concern", "over", "the", "safety", "and", "efficacy", "of", "these", "products", "compared", "with", "brand", "-", "name", "Coumadin", ".", "OBJECTIVE", "To", "ensure", "that", "generic", "warfarin", "products", "can", "be", "safely", "interchanged", "with", "Coumadin", ".", "METHODS", "Multiple", "n", "-", "of-1", "randomized", ",", "double", "-", "blind", ",", "crossover", "trials", "switched", "outpatients", "(", "N", "=", "7", ")", "between", "a", "generic", "warfarin", "formulation", "(", "Apo", "-", "warfarin", ")", "and", "Coumadin", "over", "30", "weeks", ".", "Study", "patients", "took", "each", "drug", "for", "five", "3-week", "periods", ",", "with", "international", "normalized", "ratio", "(", "INR", ")", "measurements", "taken", "twice", "per", "period", ".", "Inter-", "and", "intrapatient", "differences", "between", "generic", "warfarin", "and", "Coumadin", "were", "compared", ",", "and", "overall", "study", "patient", "results", "were", "compared", "with", "those", "of", "a", "Coumadin", "control", "group", ".", "RESULTS", "There", "were", "no", "differences", "between", "warfarin", "products", "in", "terms", "of", "mean", "INR", "results", "or", "number", "of", "dosage", "adjustments", "required", ".", "There", "also", "was", "no", "difference", "in", "INR", "variation", "based", "on", "warfarin", "formulation", "(", "p", ">", "0.69", ")", ",", "nor", "was", "a", "patient", "and", "warfarin", "interaction", "found", "(", "p", ">", "0.81", ")", ".", "The", "INR", "results", "were", "not", "influenced", "by", "whether", "patients", "were", "maintained", "on", "Coumadin", "only", "(", "control", "group", ")", "or", "interchanged", "between", "Coumadin", "and", "generic", "warfarin", "(", "p", "=", "0.98", ")", ".", "CONCLUSIONS", "It", "appears", "that", "patients", "can", "safely", "and", "effectively", "switch", "between", "generic", "warfarin", "and", "Coumadin", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]

generic warfarin is a Intervention_Pharmacological, Warfarin is a Intervention_Pharmacological, safety is a Outcome_Other, efficacy is a Outcome_Other, Coumadin is a Intervention_Pharmacological, ( N = 7 ) is a Participant_Sample-size, generic warfarin formulation ( Apo - warfarin ) is a Intervention_Pharmacological, Coumadin over 30 weeks is a Intervention_Pharmacological, Study patients took each drug for five 3-week periods is a Participant_Condition, with international normalized ratio ( INR ) measurements taken twice per period is a Participant_Condition, INR results is a Outcome_Other, safely and effectively switch is a Outcome_Other

21881_task1

Sentence: Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin . Instructions: please typing these entity words according to sentence: generic warfarin, Warfarin, safety, efficacy, Coumadin, ( N = 7 ), generic warfarin formulation ( Apo - warfarin ), Coumadin over 30 weeks, Study patients took each drug for five 3-week periods, with international normalized ratio ( INR ) measurements taken twice per period, INR results, safely and effectively switch Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Participant_Sample-size

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O" ]

Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin .

[ "Are", "brand", "-", "name", "and", "generic", "warfarin", "interchangeable", "?", "Multiple", "n", "-", "of-1", "randomized", ",", "crossover", "trials", ".", "BACKGROUND", "Warfarin", "is", "a", "commonly", "used", "anticoagulant", "in", "North", "America", ".", "Several", "generic", "formulations", "have", "been", "approved", ",", "raising", "concern", "over", "the", "safety", "and", "efficacy", "of", "these", "products", "compared", "with", "brand", "-", "name", "Coumadin", ".", "OBJECTIVE", "To", "ensure", "that", "generic", "warfarin", "products", "can", "be", "safely", "interchanged", "with", "Coumadin", ".", "METHODS", "Multiple", "n", "-", "of-1", "randomized", ",", "double", "-", "blind", ",", "crossover", "trials", "switched", "outpatients", "(", "N", "=", "7", ")", "between", "a", "generic", "warfarin", "formulation", "(", "Apo", "-", "warfarin", ")", "and", "Coumadin", "over", "30", "weeks", ".", "Study", "patients", "took", "each", "drug", "for", "five", "3-week", "periods", ",", "with", "international", "normalized", "ratio", "(", "INR", ")", "measurements", "taken", "twice", "per", "period", ".", "Inter-", "and", "intrapatient", "differences", "between", "generic", "warfarin", "and", "Coumadin", "were", "compared", ",", "and", "overall", "study", "patient", "results", "were", "compared", "with", "those", "of", "a", "Coumadin", "control", "group", ".", "RESULTS", "There", "were", "no", "differences", "between", "warfarin", "products", "in", "terms", "of", "mean", "INR", "results", "or", "number", "of", "dosage", "adjustments", "required", ".", "There", "also", "was", "no", "difference", "in", "INR", "variation", "based", "on", "warfarin", "formulation", "(", "p", ">", "0.69", ")", ",", "nor", "was", "a", "patient", "and", "warfarin", "interaction", "found", "(", "p", ">", "0.81", ")", ".", "The", "INR", "results", "were", "not", "influenced", "by", "whether", "patients", "were", "maintained", "on", "Coumadin", "only", "(", "control", "group", ")", "or", "interchanged", "between", "Coumadin", "and", "generic", "warfarin", "(", "p", "=", "0.98", ")", ".", "CONCLUSIONS", "It", "appears", "that", "patients", "can", "safely", "and", "effectively", "switch", "between", "generic", "warfarin", "and", "Coumadin", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]

generic warfarin, Warfarin, safety, efficacy, Coumadin, ( N = 7 ), generic warfarin formulation ( Apo - warfarin ), Coumadin over 30 weeks, Study patients took each drug for five 3-week periods, with international normalized ratio ( INR ) measurements taken twice per period, INR results, safely and effectively switch

21881_task2

Sentence: Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O" ]

Are brand-name and generic warfarin interchangeable ? Multiple n-of-1 randomized , crossover trials . BACKGROUND Warfarin is a commonly used anticoagulant in North America . Several generic formulations have been approved , raising concern over the safety and efficacy of these products compared with brand-name Coumadin . OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin . METHODS Multiple n-of-1 randomized , double-blind , crossover trials switched outpatients ( N = 7 ) between a generic warfarin formulation ( Apo-warfarin ) and Coumadin over 30 weeks . Study patients took each drug for five 3-week periods , with international normalized ratio ( INR ) measurements taken twice per period . Inter- and intrapatient differences between generic warfarin and Coumadin were compared , and overall study patient results were compared with those of a Coumadin control group . RESULTS There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required . There also was no difference in INR variation based on warfarin formulation ( p > 0.69 ) , nor was a patient and warfarin interaction found ( p > 0.81 ) . The INR results were not influenced by whether patients were maintained on Coumadin only ( control group ) or interchanged between Coumadin and generic warfarin ( p = 0.98 ) . CONCLUSIONS It appears that patients can safely and effectively switch between generic warfarin and Coumadin .

[ "Are", "brand", "-", "name", "and", "generic", "warfarin", "interchangeable", "?", "Multiple", "n", "-", "of-1", "randomized", ",", "crossover", "trials", ".", "BACKGROUND", "Warfarin", "is", "a", "commonly", "used", "anticoagulant", "in", "North", "America", ".", "Several", "generic", "formulations", "have", "been", "approved", ",", "raising", "concern", "over", "the", "safety", "and", "efficacy", "of", "these", "products", "compared", "with", "brand", "-", "name", "Coumadin", ".", "OBJECTIVE", "To", "ensure", "that", "generic", "warfarin", "products", "can", "be", "safely", "interchanged", "with", "Coumadin", ".", "METHODS", "Multiple", "n", "-", "of-1", "randomized", ",", "double", "-", "blind", ",", "crossover", "trials", "switched", "outpatients", "(", "N", "=", "7", ")", "between", "a", "generic", "warfarin", "formulation", "(", "Apo", "-", "warfarin", ")", "and", "Coumadin", "over", "30", "weeks", ".", "Study", "patients", "took", "each", "drug", "for", "five", "3-week", "periods", ",", "with", "international", "normalized", "ratio", "(", "INR", ")", "measurements", "taken", "twice", "per", "period", ".", "Inter-", "and", "intrapatient", "differences", "between", "generic", "warfarin", "and", "Coumadin", "were", "compared", ",", "and", "overall", "study", "patient", "results", "were", "compared", "with", "those", "of", "a", "Coumadin", "control", "group", ".", "RESULTS", "There", "were", "no", "differences", "between", "warfarin", "products", "in", "terms", "of", "mean", "INR", "results", "or", "number", "of", "dosage", "adjustments", "required", ".", "There", "also", "was", "no", "difference", "in", "INR", "variation", "based", "on", "warfarin", "formulation", "(", "p", ">", "0.69", ")", ",", "nor", "was", "a", "patient", "and", "warfarin", "interaction", "found", "(", "p", ">", "0.81", ")", ".", "The", "INR", "results", "were", "not", "influenced", "by", "whether", "patients", "were", "maintained", "on", "Coumadin", "only", "(", "control", "group", ")", "or", "interchanged", "between", "Coumadin", "and", "generic", "warfarin", "(", "p", "=", "0.98", ")", ".", "CONCLUSIONS", "It", "appears", "that", "patients", "can", "safely", "and", "effectively", "switch", "between", "generic", "warfarin", "and", "Coumadin", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]

glucocorticoid receptor is a GENE-Y, ERK is a GENE-N, ginsenoside Rg1 is a CHEMICAL, β - amyloid peptide is a GENE-Y, β - amyloid is a GENE-Y, Aβ is a GENE-Y, Ginsenoside Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, Aβ is a GENE-Y, Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, HIF-1α is a GENE-Y, nitrogen is a CHEMICAL, glucocorticoid receptor is a GENE-Y, GR is a GENE-Y, RU486 is a CHEMICAL, p - ERK is a GENE-N, U0126 is a CHEMICAL, estrogen receptor α is a GENE-Y, ICI 82,780 is a CHEMICAL, Rg1 is a CHEMICAL, GR is a GENE-Y, ERK is a GENE-N, HIF-1α is a GENE-Y, GR is a GENE-Y, ERK is a GENE-N

14269_task0

Sentence: Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N

[ "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.

[ "Activating", "glucocorticoid", "receptor", "-", "ERK", "signaling", "pathway", "contributes", "to", "ginsenoside", "Rg1", "protection", "against", "β", "-", "amyloid", "peptide", "-", "induced", "human", "endothelial", "cells", "apoptosis", ".", "\n", "The", "deposition", "of", "β", "-", "amyloid", "(", "Aβ", ")", "in", "neurons", "and", "vascular", "cells", "of", "the", "brain", "has", "been", "characterized", "in", "Alzheimer", "'s", "disease", ".", "Ginsenoside", "Rg1", "(", "Rg1", ")", "is", "an", "active", "components", "in", "Panax", "ginseng", ",", "a", "famous", "traditional", "Chinese", "medicines", "recorded", "in", "Compendium", "of", "Materia", "Medica", ".", "Present", "study", "attempted", "to", "evaluate", "the", "potential", "mechanisms", "of", "Aβ", "-", "mediated", "insult", "and", "the", "protective", "effects", "of", "Rg1", "on", "human", "endothelial", "cells", ".", "Rg1", "attenuated", "the", "Aβ25", "-", "35-associated", "mitochondrial", "apoptotic", "events", ",", "accompanied", "by", "inhibiting", "HIF-1α", "expression", "followed", "by", "intracellular", "reactive", "nitrogen", "species", "generation", ",", "and", "protein", "nitrotyrosination", ".", "These", "protective", "effects", "were", "abolished", "by", "glucocorticoid", "receptor", "(", "GR", ")", "antagonist", "RU486", "or", "p", "-", "ERK", "inhibitor", "U0126", "rather", "than", "estrogen", "receptor", "α", "antagonist", "ICI", "82,780", ".", "Taken", "together", ",", "our", "results", "suggested", "that", "Rg1", "protected", "against", "Aβ25", "-", "35-induced", "apoptosis", "at", "least", "in", "part", "by", "two", "complementary", "GR", "-", "dependent", "ERK", "phosphorylation", "pathways", ":", "(", "1", ")", "down", "-", "regulating", "HIF-1α", "initiated", "protein", "nitrotyrosination", ",", "and", "(", "2", ")", "inhibiting", "mitochondrial", "apoptotic", "cascades", ".", "These", "data", "provided", "a", "novel", "insight", "to", "the", "mechanisms", "of", "Rg1protective", "effects", "on", "Aβ25", "-", "35-induced", "endothelial", "cells", "apoptosis", ",", "suggesting", "that", "GR", "-", "ERK", "signaling", "pathway", "might", "play", "an", "important", "role", "in", "it", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

glucocorticoid receptor is a GENE-Y, ERK is a GENE-N, ginsenoside Rg1 is a CHEMICAL, β - amyloid peptide is a GENE-Y, β - amyloid is a GENE-Y, Aβ is a GENE-Y, Ginsenoside Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, Aβ is a GENE-Y, Rg1 is a CHEMICAL, Rg1 is a CHEMICAL, HIF-1α is a GENE-Y, nitrogen is a CHEMICAL, glucocorticoid receptor is a GENE-Y, GR is a GENE-Y, RU486 is a CHEMICAL, p - ERK is a GENE-N, U0126 is a CHEMICAL, estrogen receptor α is a GENE-Y, ICI 82,780 is a CHEMICAL, Rg1 is a CHEMICAL, GR is a GENE-Y, ERK is a GENE-N, HIF-1α is a GENE-Y, GR is a GENE-Y, ERK is a GENE-N

14269_task1

Sentence: Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it. Instructions: please typing these entity words according to sentence: glucocorticoid receptor, ERK, ginsenoside Rg1, β - amyloid peptide, β - amyloid, Aβ, Ginsenoside Rg1, Rg1, Aβ, Rg1, Rg1, HIF-1α, nitrogen, glucocorticoid receptor, GR, RU486, p - ERK, U0126, estrogen receptor α, ICI 82,780, Rg1, GR, ERK, HIF-1α, GR, ERK Options: CHEMICAL, GENE-Y, GENE-N

[ "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.

[ "Activating", "glucocorticoid", "receptor", "-", "ERK", "signaling", "pathway", "contributes", "to", "ginsenoside", "Rg1", "protection", "against", "β", "-", "amyloid", "peptide", "-", "induced", "human", "endothelial", "cells", "apoptosis", ".", "\n", "The", "deposition", "of", "β", "-", "amyloid", "(", "Aβ", ")", "in", "neurons", "and", "vascular", "cells", "of", "the", "brain", "has", "been", "characterized", "in", "Alzheimer", "'s", "disease", ".", "Ginsenoside", "Rg1", "(", "Rg1", ")", "is", "an", "active", "components", "in", "Panax", "ginseng", ",", "a", "famous", "traditional", "Chinese", "medicines", "recorded", "in", "Compendium", "of", "Materia", "Medica", ".", "Present", "study", "attempted", "to", "evaluate", "the", "potential", "mechanisms", "of", "Aβ", "-", "mediated", "insult", "and", "the", "protective", "effects", "of", "Rg1", "on", "human", "endothelial", "cells", ".", "Rg1", "attenuated", "the", "Aβ25", "-", "35-associated", "mitochondrial", "apoptotic", "events", ",", "accompanied", "by", "inhibiting", "HIF-1α", "expression", "followed", "by", "intracellular", "reactive", "nitrogen", "species", "generation", ",", "and", "protein", "nitrotyrosination", ".", "These", "protective", "effects", "were", "abolished", "by", "glucocorticoid", "receptor", "(", "GR", ")", "antagonist", "RU486", "or", "p", "-", "ERK", "inhibitor", "U0126", "rather", "than", "estrogen", "receptor", "α", "antagonist", "ICI", "82,780", ".", "Taken", "together", ",", "our", "results", "suggested", "that", "Rg1", "protected", "against", "Aβ25", "-", "35-induced", "apoptosis", "at", "least", "in", "part", "by", "two", "complementary", "GR", "-", "dependent", "ERK", "phosphorylation", "pathways", ":", "(", "1", ")", "down", "-", "regulating", "HIF-1α", "initiated", "protein", "nitrotyrosination", ",", "and", "(", "2", ")", "inhibiting", "mitochondrial", "apoptotic", "cascades", ".", "These", "data", "provided", "a", "novel", "insight", "to", "the", "mechanisms", "of", "Rg1protective", "effects", "on", "Aβ25", "-", "35-induced", "endothelial", "cells", "apoptosis", ",", "suggesting", "that", "GR", "-", "ERK", "signaling", "pathway", "might", "play", "an", "important", "role", "in", "it", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

glucocorticoid receptor, ERK, ginsenoside Rg1, β - amyloid peptide, β - amyloid, Aβ, Ginsenoside Rg1, Rg1, Aβ, Rg1, Rg1, HIF-1α, nitrogen, glucocorticoid receptor, GR, RU486, p - ERK, U0126, estrogen receptor α, ICI 82,780, Rg1, GR, ERK, HIF-1α, GR, ERK

14269_task2

Sentence: Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it. Instructions: please extract entity words from the input sentence

[ "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis. The deposition of β-amyloid (Aβ) in neurons and vascular cells of the brain has been characterized in Alzheimer's disease. Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica. Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of Rg1 on human endothelial cells. Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination. These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780. Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades. These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.

[ "Activating", "glucocorticoid", "receptor", "-", "ERK", "signaling", "pathway", "contributes", "to", "ginsenoside", "Rg1", "protection", "against", "β", "-", "amyloid", "peptide", "-", "induced", "human", "endothelial", "cells", "apoptosis", ".", "\n", "The", "deposition", "of", "β", "-", "amyloid", "(", "Aβ", ")", "in", "neurons", "and", "vascular", "cells", "of", "the", "brain", "has", "been", "characterized", "in", "Alzheimer", "'s", "disease", ".", "Ginsenoside", "Rg1", "(", "Rg1", ")", "is", "an", "active", "components", "in", "Panax", "ginseng", ",", "a", "famous", "traditional", "Chinese", "medicines", "recorded", "in", "Compendium", "of", "Materia", "Medica", ".", "Present", "study", "attempted", "to", "evaluate", "the", "potential", "mechanisms", "of", "Aβ", "-", "mediated", "insult", "and", "the", "protective", "effects", "of", "Rg1", "on", "human", "endothelial", "cells", ".", "Rg1", "attenuated", "the", "Aβ25", "-", "35-associated", "mitochondrial", "apoptotic", "events", ",", "accompanied", "by", "inhibiting", "HIF-1α", "expression", "followed", "by", "intracellular", "reactive", "nitrogen", "species", "generation", ",", "and", "protein", "nitrotyrosination", ".", "These", "protective", "effects", "were", "abolished", "by", "glucocorticoid", "receptor", "(", "GR", ")", "antagonist", "RU486", "or", "p", "-", "ERK", "inhibitor", "U0126", "rather", "than", "estrogen", "receptor", "α", "antagonist", "ICI", "82,780", ".", "Taken", "together", ",", "our", "results", "suggested", "that", "Rg1", "protected", "against", "Aβ25", "-", "35-induced", "apoptosis", "at", "least", "in", "part", "by", "two", "complementary", "GR", "-", "dependent", "ERK", "phosphorylation", "pathways", ":", "(", "1", ")", "down", "-", "regulating", "HIF-1α", "initiated", "protein", "nitrotyrosination", ",", "and", "(", "2", ")", "inhibiting", "mitochondrial", "apoptotic", "cascades", ".", "These", "data", "provided", "a", "novel", "insight", "to", "the", "mechanisms", "of", "Rg1protective", "effects", "on", "Aβ25", "-", "35-induced", "endothelial", "cells", "apoptosis", ",", "suggesting", "that", "GR", "-", "ERK", "signaling", "pathway", "might", "play", "an", "important", "role", "in", "it", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, Neg-1 is a Protein, Neg-2 is a Protein, IL-4 is a Protein, promoter is a Entity, IL-4 is a Protein

1541828_task0

Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]

T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells.

[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", ".", "\n", "IL-4", "secreted", "by", "activated", "T", "cells", "is", "a", "pleiotropic", "cytokine", "affecting", "growth", "and", "differentiation", "of", "diverse", "cell", "types", "such", "as", "T", "cells", ",", "B", "cells", ",", "and", "mast", "cells", ".", "We", "investigated", "the", "upstream", "regulatory", "elements", "of", "the", "human", "IL-4", "promoter", ".", "A", "novel", "T", "cell", "-", "specific", "negative", "regulatory", "element", "(", "NRE", ")", "composed", "of", "two", "protein", "-", "binding", "sites", "were", "mapped", "in", "the", "5", "'", "flanking", "region", "of", "the", "IL-4", "gene", ":", "-311CTCCCTTCT-303", "(", "NRE", "-", "I", ")", "and", "-288CTTTTTGCTT", "-", "TGC-300", "(", "NRE", "-", "II", ")", ".", "A", "T", "cell", "-", "specific", "protein", "Neg-1", "and", "a", "ubiquitous", "protein", "Neg-2", "binding", "to", "NRE", "-", "I", "and", "NRE", "-", "II", ",", "respectively", ",", "were", "identified", ".", "Furthermore", ",", "a", "positive", "regulatory", "element", "was", "found", "45", "bp", "downstream", "of", "the", "NRE", ".", "The", "enhancer", "activity", "of", "the", "PRE", "was", "completely", "suppressed", "when", "the", "NRE", "was", "present", ".", "These", "data", "suggest", "that", "IL-4", "promoter", "activity", "is", "normally", "down", "-", "regulated", "by", "an", "NRE", "via", "repression", "of", "the", "enhancer", "positive", "regulatory", "element", ".", "These", "data", "may", "have", "implications", "for", "the", "stringent", "control", "of", "IL-4", "expression", "in", "T", "cells", "." ]

[ "Entity", "Protein" ]

IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, IL-4 is a Protein, Neg-1 is a Protein, Neg-2 is a Protein, IL-4 is a Protein, promoter is a Entity, IL-4 is a Protein

1541828_task1

Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells. Instructions: please typing these entity words according to sentence: IL-4, IL-4, IL-4, IL-4, Neg-1, Neg-2, IL-4, promoter, IL-4 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]

T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells.

[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", ".", "\n", "IL-4", "secreted", "by", "activated", "T", "cells", "is", "a", "pleiotropic", "cytokine", "affecting", "growth", "and", "differentiation", "of", "diverse", "cell", "types", "such", "as", "T", "cells", ",", "B", "cells", ",", "and", "mast", "cells", ".", "We", "investigated", "the", "upstream", "regulatory", "elements", "of", "the", "human", "IL-4", "promoter", ".", "A", "novel", "T", "cell", "-", "specific", "negative", "regulatory", "element", "(", "NRE", ")", "composed", "of", "two", "protein", "-", "binding", "sites", "were", "mapped", "in", "the", "5", "'", "flanking", "region", "of", "the", "IL-4", "gene", ":", "-311CTCCCTTCT-303", "(", "NRE", "-", "I", ")", "and", "-288CTTTTTGCTT", "-", "TGC-300", "(", "NRE", "-", "II", ")", ".", "A", "T", "cell", "-", "specific", "protein", "Neg-1", "and", "a", "ubiquitous", "protein", "Neg-2", "binding", "to", "NRE", "-", "I", "and", "NRE", "-", "II", ",", "respectively", ",", "were", "identified", ".", "Furthermore", ",", "a", "positive", "regulatory", "element", "was", "found", "45", "bp", "downstream", "of", "the", "NRE", ".", "The", "enhancer", "activity", "of", "the", "PRE", "was", "completely", "suppressed", "when", "the", "NRE", "was", "present", ".", "These", "data", "suggest", "that", "IL-4", "promoter", "activity", "is", "normally", "down", "-", "regulated", "by", "an", "NRE", "via", "repression", "of", "the", "enhancer", "positive", "regulatory", "element", ".", "These", "data", "may", "have", "implications", "for", "the", "stringent", "control", "of", "IL-4", "expression", "in", "T", "cells", "." ]

[ "Entity", "Protein" ]

IL-4, IL-4, IL-4, IL-4, Neg-1, Neg-2, IL-4, promoter, IL-4

1541828_task2

Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]

T cell-specific negative regulation of transcription of the human cytokine IL-4. IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells. We investigated the upstream regulatory elements of the human IL-4 promoter. A novel T cell-specific negative regulatory element (NRE) composed of two protein-binding sites were mapped in the 5' flanking region of the IL-4 gene: -311CTCCCTTCT-303 (NRE-I) and -288CTTTTTGCTT-TGC-300 (NRE-II). A T cell-specific protein Neg-1 and a ubiquitous protein Neg-2 binding to NRE-I and NRE-II, respectively, were identified. Furthermore, a positive regulatory element was found 45 bp downstream of the NRE. The enhancer activity of the PRE was completely suppressed when the NRE was present. These data suggest that IL-4 promoter activity is normally down-regulated by an NRE via repression of the enhancer positive regulatory element. These data may have implications for the stringent control of IL-4 expression in T cells.

[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", ".", "\n", "IL-4", "secreted", "by", "activated", "T", "cells", "is", "a", "pleiotropic", "cytokine", "affecting", "growth", "and", "differentiation", "of", "diverse", "cell", "types", "such", "as", "T", "cells", ",", "B", "cells", ",", "and", "mast", "cells", ".", "We", "investigated", "the", "upstream", "regulatory", "elements", "of", "the", "human", "IL-4", "promoter", ".", "A", "novel", "T", "cell", "-", "specific", "negative", "regulatory", "element", "(", "NRE", ")", "composed", "of", "two", "protein", "-", "binding", "sites", "were", "mapped", "in", "the", "5", "'", "flanking", "region", "of", "the", "IL-4", "gene", ":", "-311CTCCCTTCT-303", "(", "NRE", "-", "I", ")", "and", "-288CTTTTTGCTT", "-", "TGC-300", "(", "NRE", "-", "II", ")", ".", "A", "T", "cell", "-", "specific", "protein", "Neg-1", "and", "a", "ubiquitous", "protein", "Neg-2", "binding", "to", "NRE", "-", "I", "and", "NRE", "-", "II", ",", "respectively", ",", "were", "identified", ".", "Furthermore", ",", "a", "positive", "regulatory", "element", "was", "found", "45", "bp", "downstream", "of", "the", "NRE", ".", "The", "enhancer", "activity", "of", "the", "PRE", "was", "completely", "suppressed", "when", "the", "NRE", "was", "present", ".", "These", "data", "suggest", "that", "IL-4", "promoter", "activity", "is", "normally", "down", "-", "regulated", "by", "an", "NRE", "via", "repression", "of", "the", "enhancer", "positive", "regulatory", "element", ".", "These", "data", "may", "have", "implications", "for", "the", "stringent", "control", "of", "IL-4", "expression", "in", "T", "cells", "." ]

[ "Entity", "Protein" ]

SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, mac is a Protein, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, mouse is a Organism, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, horses is a Organism, mice is a Organism, S. equi is a Organism, SeMac is a Protein, SeMac is a Protein

103_task0

Sentence: Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Protein

[ "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Organism", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection.

[ "Recombinant", "SeMac", "and", "In", "Vitro", "and", "In", "Vivo", "Expression", "of", "SeMac", "\n", "To", "characterize", "SeMac", ",", "the", "fragment", "of", "S.", "equi", "mac", "gene", "encoding", "mature", "SeMac", "was", "cloned", ",", "and", "recombinant", "SeMac", "was", "purified", "to", ">", "95", "%", "purity", "as", "assessed", "by", "SDS", "-", "PAGE", "(", "Fig", ".", "3A", ")", ".", "To", "assess", "the", "in", "vitro", "production", "of", "SeMac", ",", "culture", "supernatant", "of", "the", "10", "S.", "equi", "strains", "was", "prepared", "by", "the", "method", "of", "Lei", "et", "al", ".", "[", "16", "]", ",", "resolved", "by", "SDS", "-", "PAGE", ",", "and", "probed", "by", "Western", "immunoblot", "with", "anti", "-", "SeMac", "mouse", "antisera", ".", "No", "SeMac", "was", "detected", "in", "all", "the", "samples", "(", "data", "not", "shown", ")", ",", "suggesting", "that", "SeMac", "is", "not", "produced", "in", "vitro", ".", "To", "test", "whether", "SeMac", "is", "produced", "in", "vivo", "during", "S.", "equi", "infection", ",", "the", "presence", "of", "SeMac", "-", "specific", "antibody", "was", "assessed", "by", "Western", "immunoblot", "analysis", "with", "convalescent", "sera", "from", "3", "horses", "suffered", "from", "strangles", "and", "mice", "with", "experimental", "S.", "equi", "infection", ".", "All", "the", "convalescent", "sera", "tested", "had", "SeMac", "-", "specific", "antibody", "(", "Fig", ".", "3B", ")", ",", "indicating", "that", "SeMac", "is", "produced", "in", "vivo", "during", "infection", ".", "\n" ]

[ "Organism", "Protein" ]

SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, mac is a Protein, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, mouse is a Organism, SeMac is a Protein, SeMac is a Protein, SeMac is a Protein, S. equi is a Organism, SeMac is a Protein, horses is a Organism, mice is a Organism, S. equi is a Organism, SeMac is a Protein, SeMac is a Protein

103_task1

Sentence: Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection. Instructions: please typing these entity words according to sentence: SeMac, SeMac, SeMac, S. equi, mac, SeMac, SeMac, SeMac, S. equi, SeMac, mouse, SeMac, SeMac, SeMac, S. equi, SeMac, horses, mice, S. equi, SeMac, SeMac Options: Organism, Protein

[ "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Organism", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection.

[ "Recombinant", "SeMac", "and", "In", "Vitro", "and", "In", "Vivo", "Expression", "of", "SeMac", "\n", "To", "characterize", "SeMac", ",", "the", "fragment", "of", "S.", "equi", "mac", "gene", "encoding", "mature", "SeMac", "was", "cloned", ",", "and", "recombinant", "SeMac", "was", "purified", "to", ">", "95", "%", "purity", "as", "assessed", "by", "SDS", "-", "PAGE", "(", "Fig", ".", "3A", ")", ".", "To", "assess", "the", "in", "vitro", "production", "of", "SeMac", ",", "culture", "supernatant", "of", "the", "10", "S.", "equi", "strains", "was", "prepared", "by", "the", "method", "of", "Lei", "et", "al", ".", "[", "16", "]", ",", "resolved", "by", "SDS", "-", "PAGE", ",", "and", "probed", "by", "Western", "immunoblot", "with", "anti", "-", "SeMac", "mouse", "antisera", ".", "No", "SeMac", "was", "detected", "in", "all", "the", "samples", "(", "data", "not", "shown", ")", ",", "suggesting", "that", "SeMac", "is", "not", "produced", "in", "vitro", ".", "To", "test", "whether", "SeMac", "is", "produced", "in", "vivo", "during", "S.", "equi", "infection", ",", "the", "presence", "of", "SeMac", "-", "specific", "antibody", "was", "assessed", "by", "Western", "immunoblot", "analysis", "with", "convalescent", "sera", "from", "3", "horses", "suffered", "from", "strangles", "and", "mice", "with", "experimental", "S.", "equi", "infection", ".", "All", "the", "convalescent", "sera", "tested", "had", "SeMac", "-", "specific", "antibody", "(", "Fig", ".", "3B", ")", ",", "indicating", "that", "SeMac", "is", "produced", "in", "vivo", "during", "infection", ".", "\n" ]

[ "Organism", "Protein" ]

SeMac, SeMac, SeMac, S. equi, mac, SeMac, SeMac, SeMac, S. equi, SeMac, mouse, SeMac, SeMac, SeMac, S. equi, SeMac, horses, mice, S. equi, SeMac, SeMac

103_task2

Sentence: Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection. Instructions: please extract entity words from the input sentence

[ "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Organism", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Recombinant SeMac and In Vitro and In Vivo Expression of SeMac To characterize SeMac, the fragment of S. equi mac gene encoding mature SeMac was cloned, and recombinant SeMac was purified to >95% purity as assessed by SDS-PAGE (Fig. 3A). To assess the in vitro production of SeMac, culture supernatant of the 10 S. equi strains was prepared by the method of Lei et al. [16], resolved by SDS-PAGE, and probed by Western immunoblot with anti-SeMac mouse antisera. No SeMac was detected in all the samples (data not shown), suggesting that SeMac is not produced in vitro. To test whether SeMac is produced in vivo during S. equi infection, the presence of SeMac-specific antibody was assessed by Western immunoblot analysis with convalescent sera from 3 horses suffered from strangles and mice with experimental S. equi infection. All the convalescent sera tested had SeMac-specific antibody (Fig. 3B), indicating that SeMac is produced in vivo during infection.

[ "Recombinant", "SeMac", "and", "In", "Vitro", "and", "In", "Vivo", "Expression", "of", "SeMac", "\n", "To", "characterize", "SeMac", ",", "the", "fragment", "of", "S.", "equi", "mac", "gene", "encoding", "mature", "SeMac", "was", "cloned", ",", "and", "recombinant", "SeMac", "was", "purified", "to", ">", "95", "%", "purity", "as", "assessed", "by", "SDS", "-", "PAGE", "(", "Fig", ".", "3A", ")", ".", "To", "assess", "the", "in", "vitro", "production", "of", "SeMac", ",", "culture", "supernatant", "of", "the", "10", "S.", "equi", "strains", "was", "prepared", "by", "the", "method", "of", "Lei", "et", "al", ".", "[", "16", "]", ",", "resolved", "by", "SDS", "-", "PAGE", ",", "and", "probed", "by", "Western", "immunoblot", "with", "anti", "-", "SeMac", "mouse", "antisera", ".", "No", "SeMac", "was", "detected", "in", "all", "the", "samples", "(", "data", "not", "shown", ")", ",", "suggesting", "that", "SeMac", "is", "not", "produced", "in", "vitro", ".", "To", "test", "whether", "SeMac", "is", "produced", "in", "vivo", "during", "S.", "equi", "infection", ",", "the", "presence", "of", "SeMac", "-", "specific", "antibody", "was", "assessed", "by", "Western", "immunoblot", "analysis", "with", "convalescent", "sera", "from", "3", "horses", "suffered", "from", "strangles", "and", "mice", "with", "experimental", "S.", "equi", "infection", ".", "All", "the", "convalescent", "sera", "tested", "had", "SeMac", "-", "specific", "antibody", "(", "Fig", ".", "3B", ")", ",", "indicating", "that", "SeMac", "is", "produced", "in", "vivo", "during", "infection", ".", "\n" ]

[ "Organism", "Protein" ]

Hydralazine is a compound, APC is a protein

DS.d281_task0

Sentence: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.

[ "Hydralazine", "inhibits", "human", "cervical", "cancer", "cell", "growth", "in", "vitro", "in", "association", "with", "APC", "demethylation", "and", "re", "-", "expression", "." ]

[ "compound", "protein" ]

Hydralazine is a compound, APC is a protein

DS.d281_task1

Sentence: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Instructions: please typing these entity words according to sentence: Hydralazine, APC Options: compound, protein

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.

[ "Hydralazine", "inhibits", "human", "cervical", "cancer", "cell", "growth", "in", "vitro", "in", "association", "with", "APC", "demethylation", "and", "re", "-", "expression", "." ]

[ "compound", "protein" ]

Hydralazine, APC

DS.d281_task2

Sentence: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Instructions: please extract entity words from the input sentence

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.

[ "Hydralazine", "inhibits", "human", "cervical", "cancer", "cell", "growth", "in", "vitro", "in", "association", "with", "APC", "demethylation", "and", "re", "-", "expression", "." ]

[ "compound", "protein" ]

Effectiveness is an outcome, hygienic - dietary recommendations is an intervention, patients with depression is a participant

105_task0

Sentence: Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome, participant

[ "B-outcome", "O", "B-intervention", "I-intervention", "I-intervention", "I-intervention", "O", "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .

[ "Effectiveness", "of", "hygienic", "-", "dietary", "recommendations", "as", "enhancers", "of", "antidepressant", "treatment", "in", "patients", "with", "depression", ":", "study", "protocol", "of", "a", "randomized", "controlled", "trial", "." ]

[ "intervention", "participant", "outcome" ]

Effectiveness is an outcome, hygienic - dietary recommendations is an intervention, patients with depression is a participant

105_task1

Sentence: Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial . Instructions: please typing these entity words according to sentence: Effectiveness, hygienic - dietary recommendations, patients with depression Options: intervention, outcome, participant

[ "B-outcome", "O", "B-intervention", "I-intervention", "I-intervention", "I-intervention", "O", "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .

[ "Effectiveness", "of", "hygienic", "-", "dietary", "recommendations", "as", "enhancers", "of", "antidepressant", "treatment", "in", "patients", "with", "depression", ":", "study", "protocol", "of", "a", "randomized", "controlled", "trial", "." ]

[ "intervention", "participant", "outcome" ]

Effectiveness, hygienic - dietary recommendations, patients with depression

105_task2

Sentence: Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial . Instructions: please extract entity words from the input sentence

[ "B-outcome", "O", "B-intervention", "I-intervention", "I-intervention", "I-intervention", "O", "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .

[ "Effectiveness", "of", "hygienic", "-", "dietary", "recommendations", "as", "enhancers", "of", "antidepressant", "treatment", "in", "patients", "with", "depression", ":", "study", "protocol", "of", "a", "randomized", "controlled", "trial", "." ]

[ "intervention", "participant", "outcome" ]

Human Cytochromes P450 2A13 , 2A6 , and 1B1 is a GENE-N

23432429_task0

Sentence: Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N

[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]

Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.

[ "Binding", "of", "Diverse", "Environmental", "Chemicals", "with", "Human", "Cytochromes", "P450", "2A13", ",", "2A6", ",", "and", "1B1", "and", "Enzyme", "Inhibition", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Human Cytochromes P450 2A13 , 2A6 , and 1B1 is a GENE-N

23432429_task1

Sentence: Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Instructions: please typing these entity words according to sentence: Human Cytochromes P450 2A13 , 2A6 , and 1B1 Options: GENE-N

[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]

Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.

[ "Binding", "of", "Diverse", "Environmental", "Chemicals", "with", "Human", "Cytochromes", "P450", "2A13", ",", "2A6", ",", "and", "1B1", "and", "Enzyme", "Inhibition", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Human Cytochromes P450 2A13 , 2A6 , and 1B1

23432429_task2

Sentence: Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]

Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.

[ "Binding", "of", "Diverse", "Environmental", "Chemicals", "with", "Human", "Cytochromes", "P450", "2A13", ",", "2A6", ",", "and", "1B1", "and", "Enzyme", "Inhibition", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

woman is an umlsterm, syndrome is an umlsterm, blood pressure is an umlsterm, relaxation is an umlsterm, baclofen is an umlsterm, regulation is an umlsterm, cardiovascular system is an umlsterm

DerNervenarzt.60671027.eng.abstr_task0

Sentence: A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system .

[ "A", "woman", "with", "severe", "stiff", "-", "man", "syndrome", "showed", "periodic", "cardiovascular", "dysregulation", ".", "The", "blood", "pressure", "changed", "spontaneously", "every", "5", "-", "10", "min", ".", "This", "rhythm", "was", "also", "maintained", "after", "relaxation", ".", "However", ",", "the", "vegetative", "and", "motoric", "disturbances", "disappeared", "after", "intrathecal", "application", "of", "baclofen", ".", "It", "is", "speculated", "that", "spinal", "GABAergic", "mechanisms", "are", "responsible", "for", "the", "tonic", "regulation", "of", "the", "cardiovascular", "system", "." ]

[ "umlsterm" ]

woman is an umlsterm, syndrome is an umlsterm, blood pressure is an umlsterm, relaxation is an umlsterm, baclofen is an umlsterm, regulation is an umlsterm, cardiovascular system is an umlsterm

DerNervenarzt.60671027.eng.abstr_task1

Sentence: A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system . Instructions: please typing these entity words according to sentence: woman, syndrome, blood pressure, relaxation, baclofen, regulation, cardiovascular system Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system .

[ "A", "woman", "with", "severe", "stiff", "-", "man", "syndrome", "showed", "periodic", "cardiovascular", "dysregulation", ".", "The", "blood", "pressure", "changed", "spontaneously", "every", "5", "-", "10", "min", ".", "This", "rhythm", "was", "also", "maintained", "after", "relaxation", ".", "However", ",", "the", "vegetative", "and", "motoric", "disturbances", "disappeared", "after", "intrathecal", "application", "of", "baclofen", ".", "It", "is", "speculated", "that", "spinal", "GABAergic", "mechanisms", "are", "responsible", "for", "the", "tonic", "regulation", "of", "the", "cardiovascular", "system", "." ]

[ "umlsterm" ]

woman, syndrome, blood pressure, relaxation, baclofen, regulation, cardiovascular system

DerNervenarzt.60671027.eng.abstr_task2

Sentence: A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

A woman with severe stiff-man syndrome showed periodic cardiovascular dysregulation . The blood pressure changed spontaneously every 5-10 min . This rhythm was also maintained after relaxation . However , the vegetative and motoric disturbances disappeared after intrathecal application of baclofen . It is speculated that spinal GABAergic mechanisms are responsible for the tonic regulation of the cardiovascular system .

[ "A", "woman", "with", "severe", "stiff", "-", "man", "syndrome", "showed", "periodic", "cardiovascular", "dysregulation", ".", "The", "blood", "pressure", "changed", "spontaneously", "every", "5", "-", "10", "min", ".", "This", "rhythm", "was", "also", "maintained", "after", "relaxation", ".", "However", ",", "the", "vegetative", "and", "motoric", "disturbances", "disappeared", "after", "intrathecal", "application", "of", "baclofen", ".", "It", "is", "speculated", "that", "spinal", "GABAergic", "mechanisms", "are", "responsible", "for", "the", "tonic", "regulation", "of", "the", "cardiovascular", "system", "." ]

[ "umlsterm" ]

myocardial infarction is an umlsterm, PTCA is an umlsterm, occurrence is an umlsterm, function is an umlsterm, function is an umlsterm, patients is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm

ZfuerKardiologie.00890330.eng.abstr_task0

Sentence: In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) .

[ "In", "acute", "myocardial", "infarction", "intracoronary", "stenting", "is", "superior", "to", "PTCA", "regarding", "interventional", "success", "and", "occurrence", "of", "cardiac", "events", ".", "It", "is", ",", "however", ",", "uncertain", "whether", "myocardial", "function", "also", "improves", "with", "stenting", ".", "We", ",", "therefore", ",", "assessed", "angiographic", "parameters", "of", "myocardial", "function", "in", "patients", "with", "acute", "myocardial", "infarction", "who", "were", "treated", "with", "primary", "PTCA", "and", "received", "additional", "stenting", "in", "case", "of", "an", "unsatisfactory", "angiographic", "result", "(", "provisional", "stenting", ")", "." ]

[ "umlsterm" ]

myocardial infarction is an umlsterm, PTCA is an umlsterm, occurrence is an umlsterm, function is an umlsterm, function is an umlsterm, patients is an umlsterm, myocardial infarction is an umlsterm, PTCA is an umlsterm

ZfuerKardiologie.00890330.eng.abstr_task1

Sentence: In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) . Instructions: please typing these entity words according to sentence: myocardial infarction, PTCA, occurrence, function, function, patients, myocardial infarction, PTCA Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) .

[ "In", "acute", "myocardial", "infarction", "intracoronary", "stenting", "is", "superior", "to", "PTCA", "regarding", "interventional", "success", "and", "occurrence", "of", "cardiac", "events", ".", "It", "is", ",", "however", ",", "uncertain", "whether", "myocardial", "function", "also", "improves", "with", "stenting", ".", "We", ",", "therefore", ",", "assessed", "angiographic", "parameters", "of", "myocardial", "function", "in", "patients", "with", "acute", "myocardial", "infarction", "who", "were", "treated", "with", "primary", "PTCA", "and", "received", "additional", "stenting", "in", "case", "of", "an", "unsatisfactory", "angiographic", "result", "(", "provisional", "stenting", ")", "." ]

[ "umlsterm" ]

myocardial infarction, PTCA, occurrence, function, function, patients, myocardial infarction, PTCA

ZfuerKardiologie.00890330.eng.abstr_task2

Sentence: In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In acute myocardial infarction intracoronary stenting is superior to PTCA regarding interventional success and occurrence of cardiac events . It is , however , uncertain whether myocardial function also improves with stenting . We , therefore , assessed angiographic parameters of myocardial function in patients with acute myocardial infarction who were treated with primary PTCA and received additional stenting in case of an unsatisfactory angiographic result ( provisional stenting ) .

[ "In", "acute", "myocardial", "infarction", "intracoronary", "stenting", "is", "superior", "to", "PTCA", "regarding", "interventional", "success", "and", "occurrence", "of", "cardiac", "events", ".", "It", "is", ",", "however", ",", "uncertain", "whether", "myocardial", "function", "also", "improves", "with", "stenting", ".", "We", ",", "therefore", ",", "assessed", "angiographic", "parameters", "of", "myocardial", "function", "in", "patients", "with", "acute", "myocardial", "infarction", "who", "were", "treated", "with", "primary", "PTCA", "and", "received", "additional", "stenting", "in", "case", "of", "an", "unsatisfactory", "angiographic", "result", "(", "provisional", "stenting", ")", "." ]

[ "umlsterm" ]

Movements is an umlsterm, vibrations is an umlsterm, vitrectomy is an umlsterm, motion is an umlsterm, artifacts is an umlsterm, erbium is an umlsterm, laser is an umlsterm, vitrectomy is an umlsterm

DerOpthalmologe.00970615.eng.abstr_task0

Sentence: Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy .

[ "Background", ".", "Movements", "and", "vibrations", "of", "intraocular", "structures", "can", "be", "observed", "during", "vitrectomy", "with", "mechanical", "cutting", "systems", ".", "We", "experimentally", "compared", "these", "intraocular", "motion", "artifacts", "between", "mechanical", "and", "erbium", ":", "YAG", "laser", "vitrectomy", "." ]

[ "umlsterm" ]

Movements is an umlsterm, vibrations is an umlsterm, vitrectomy is an umlsterm, motion is an umlsterm, artifacts is an umlsterm, erbium is an umlsterm, laser is an umlsterm, vitrectomy is an umlsterm

DerOpthalmologe.00970615.eng.abstr_task1

Sentence: Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy . Instructions: please typing these entity words according to sentence: Movements, vibrations, vitrectomy, motion, artifacts, erbium, laser, vitrectomy Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy .

[ "Background", ".", "Movements", "and", "vibrations", "of", "intraocular", "structures", "can", "be", "observed", "during", "vitrectomy", "with", "mechanical", "cutting", "systems", ".", "We", "experimentally", "compared", "these", "intraocular", "motion", "artifacts", "between", "mechanical", "and", "erbium", ":", "YAG", "laser", "vitrectomy", "." ]

[ "umlsterm" ]

Movements, vibrations, vitrectomy, motion, artifacts, erbium, laser, vitrectomy

DerOpthalmologe.00970615.eng.abstr_task2

Sentence: Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Background . Movements and vibrations of intraocular structures can be observed during vitrectomy with mechanical cutting systems . We experimentally compared these intraocular motion artifacts between mechanical and erbium : YAG laser vitrectomy .

[ "Background", ".", "Movements", "and", "vibrations", "of", "intraocular", "structures", "can", "be", "observed", "during", "vitrectomy", "with", "mechanical", "cutting", "systems", ".", "We", "experimentally", "compared", "these", "intraocular", "motion", "artifacts", "between", "mechanical", "and", "erbium", ":", "YAG", "laser", "vitrectomy", "." ]

[ "umlsterm" ]

p300deltaSRC is a protein, p300 is a protein, SRC/ p160 is a protein-family

1.0alpha7.train.1037_task0

Sentence: In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O" ]

In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins.

[ "In", " ", "p300deltaSRC", ",", "there", "is", "a", "deletion", "of", "the", "C", "-", "terminal", "segment", "of", " ", "p300", "that", "binds", "to", "the", " ", "SRC/", "p160", "family", "of", "coactivator", "proteins", "." ]

[ "protein", "protein-family" ]

p300deltaSRC is a protein, p300 is a protein, SRC/ p160 is a protein-family

1.0alpha7.train.1037_task1

Sentence: In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins. Instructions: please typing these entity words according to sentence: p300deltaSRC, p300, SRC/ p160 Options: protein-family, protein

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O" ]

In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins.

[ "In", " ", "p300deltaSRC", ",", "there", "is", "a", "deletion", "of", "the", "C", "-", "terminal", "segment", "of", " ", "p300", "that", "binds", "to", "the", " ", "SRC/", "p160", "family", "of", "coactivator", "proteins", "." ]

[ "protein", "protein-family" ]

p300deltaSRC, p300, SRC/ p160

1.0alpha7.train.1037_task2

Sentence: In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O" ]

In p300deltaSRC, there is a deletion of the C-terminal segment of p300 that binds to the SRC/ p160 family of coactivator proteins.

[ "In", " ", "p300deltaSRC", ",", "there", "is", "a", "deletion", "of", "the", "C", "-", "terminal", "segment", "of", " ", "p300", "that", "binds", "to", "the", " ", "SRC/", "p160", "family", "of", "coactivator", "proteins", "." ]

[ "protein", "protein-family" ]

DNA is a Entity, Epstein - Barr virus nuclear antigen 2 is a Protein, EBNA-2 is a Protein, Epstein - Barr virus ( EBV ) nuclear antigen 2 is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, genes is a Entity, CD23 is a Protein, c - fgr is a Protein, latent membrane protein 1 is a Protein, LMP1 is a Protein, terminal protein 1 is a Protein, TP1 is a Protein, TP1 is a Protein, promoter is a Entity, BamHI C is a Protein, promoter is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2 is a Protein, LMP is a Protein, cis - acting elements is a Entity, LMP is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, promoter is a Entity, LMP is a Protein, protein - binding region is a Entity, LMP is a Protein, promoter is a Entity, 42 bp fragment is a Entity, nucleotides -135 to -176 is a Entity, LMP transcriptional start site is a Entity, DNA fragments is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2A is a Protein, TP1 is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity, specific complexes is a Entity, LMP is a Protein, promoter is a Entity

467_task0

Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.

[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", ".", "\n" ]

[ "Protein", "Entity" ]

DNA is a Entity, Epstein - Barr virus nuclear antigen 2 is a Protein, EBNA-2 is a Protein, Epstein - Barr virus ( EBV ) nuclear antigen 2 is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, genes is a Entity, CD23 is a Protein, c - fgr is a Protein, latent membrane protein 1 is a Protein, LMP1 is a Protein, terminal protein 1 is a Protein, TP1 is a Protein, TP1 is a Protein, promoter is a Entity, BamHI C is a Protein, promoter is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2 is a Protein, LMP is a Protein, cis - acting elements is a Entity, LMP is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, promoter is a Entity, LMP is a Protein, protein - binding region is a Entity, LMP is a Protein, promoter is a Entity, 42 bp fragment is a Entity, nucleotides -135 to -176 is a Entity, LMP transcriptional start site is a Entity, DNA fragments is a Entity, EBNA-2 is a Protein, DNA is a Entity, EBNA-2A is a Protein, TP1 is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity, specific complexes is a Entity, LMP is a Protein, promoter is a Entity

467_task1

Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please typing these entity words according to sentence: DNA, Epstein - Barr virus nuclear antigen 2, EBNA-2, Epstein - Barr virus ( EBV ) nuclear antigen 2, EBNA-2, EBNA-2, genes, CD23, c - fgr, latent membrane protein 1, LMP1, terminal protein 1, TP1, TP1, promoter, BamHI C, promoter, EBNA-2, DNA, EBNA-2, LMP, cis - acting elements, LMP, promoter, EBNA-2, EBNA-2, LMP, promoter, LMP, protein - binding region, LMP, promoter, 42 bp fragment, nucleotides -135 to -176, LMP transcriptional start site, DNA fragments, EBNA-2, DNA, EBNA-2A, TP1, promoter, LMP, promoter, specific complexes, LMP, promoter Options: Entity, Protein

[ "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.

[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", ".", "\n" ]

[ "Protein", "Entity" ]

DNA, Epstein - Barr virus nuclear antigen 2, EBNA-2, Epstein - Barr virus ( EBV ) nuclear antigen 2, EBNA-2, EBNA-2, genes, CD23, c - fgr, latent membrane protein 1, LMP1, terminal protein 1, TP1, TP1, promoter, BamHI C, promoter, EBNA-2, DNA, EBNA-2, LMP, cis - acting elements, LMP, promoter, EBNA-2, EBNA-2, LMP, promoter, LMP, protein - binding region, LMP, promoter, 42 bp fragment, nucleotides -135 to -176, LMP transcriptional start site, DNA fragments, EBNA-2, DNA, EBNA-2A, TP1, promoter, LMP, promoter, specific complexes, LMP, promoter

467_task2

Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please extract entity words from the input sentence

[ "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.

[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", ".", "\n" ]

[ "Protein", "Entity" ]

patient is an umlsterm, measurements is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, radiation is an umlsterm, patient is an umlsterm, measurements is an umlsterm, patient is an umlsterm, use is an umlsterm, art is an umlsterm

DerRadiologe.80380993.eng.abstr_task0

Sentence: To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution .

[ "To", "compare", "patient", "dose", "and", "image", "quality", "of", "electron", "-", "beam", "-", "CT", "vs", ".", "spiral", "-", "CT", "by", "means", "of", "phantom", "measurements", ".", "An", "EBCT", "scanner", "(", "C-150", "XP", ")", "and", "a", "spiral", "-", "CT", "scanner", "(", "GE", "HiSpeed", "Advantage", ")", "were", "used", "to", "scan", "three", "different", "phantoms", ".", "Administered", "dose", ",", "high", "contrast", "(", "HC", ")", "resolution", ",", "low", "contrast", "(", "LC", ")", "lesion", "detectability", "and", "the", "width", "of", "the", "radiation", "beams", "were", "measured", ".", "EBCT", "showed", "25", "-", "35", "%", "lower", "HC", "resolution", "in", "comparison", "to", "spiral", "-", "CT", ".", "LC", "lesion", "detectability", "showed", "equivalent", "results", "for", "S", "/", "N", "vs", ".", "patient", "dose", "using", "3", "mm", "collimation", "with", "EBCT", "and", "spiral", "-", "CT", ",", "whereas", "spiral", "-", "CT", "was", "superior", "for", "1,5", "and", "6", "mm", "collimation", ".", "Dose", "measurements", "revealed", "a", "2", "fold", "higher", "patient", "dose", "using", "EBCT", "with", "1,5", "mm", "or", "6", "mm", "collimation", "compared", "to", "spiral", "-", "CT", "using", "equivalent", "scan", "parameters", ".", "No", "differences", "were", "seen", "using", "3", "mm", "collimation", ".", "Differences", "were", "due", "to", "insufficient", "beamside", "collimation", "of", "the", "EBCT", ".", "The", "use", "of", "EBCT", "with", "6", "mm", "collimation", "should", "be", "avoided", ",", "because", "of", "impaired", "performance", ".", "Using", "3", "mm", "collimation", ",", "EBCT", "showed", "comparable", "performance", "like", "state", "of", "the", "art", "spiral", "-", "CT", "despite", "lower", "HC", "resolution", "." ]

[ "umlsterm" ]

patient is an umlsterm, measurements is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, radiation is an umlsterm, patient is an umlsterm, measurements is an umlsterm, patient is an umlsterm, use is an umlsterm, art is an umlsterm

DerRadiologe.80380993.eng.abstr_task1

Sentence: To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution . Instructions: please typing these entity words according to sentence: patient, measurements, contrast, contrast, radiation, patient, measurements, patient, use, art Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution .

[ "To", "compare", "patient", "dose", "and", "image", "quality", "of", "electron", "-", "beam", "-", "CT", "vs", ".", "spiral", "-", "CT", "by", "means", "of", "phantom", "measurements", ".", "An", "EBCT", "scanner", "(", "C-150", "XP", ")", "and", "a", "spiral", "-", "CT", "scanner", "(", "GE", "HiSpeed", "Advantage", ")", "were", "used", "to", "scan", "three", "different", "phantoms", ".", "Administered", "dose", ",", "high", "contrast", "(", "HC", ")", "resolution", ",", "low", "contrast", "(", "LC", ")", "lesion", "detectability", "and", "the", "width", "of", "the", "radiation", "beams", "were", "measured", ".", "EBCT", "showed", "25", "-", "35", "%", "lower", "HC", "resolution", "in", "comparison", "to", "spiral", "-", "CT", ".", "LC", "lesion", "detectability", "showed", "equivalent", "results", "for", "S", "/", "N", "vs", ".", "patient", "dose", "using", "3", "mm", "collimation", "with", "EBCT", "and", "spiral", "-", "CT", ",", "whereas", "spiral", "-", "CT", "was", "superior", "for", "1,5", "and", "6", "mm", "collimation", ".", "Dose", "measurements", "revealed", "a", "2", "fold", "higher", "patient", "dose", "using", "EBCT", "with", "1,5", "mm", "or", "6", "mm", "collimation", "compared", "to", "spiral", "-", "CT", "using", "equivalent", "scan", "parameters", ".", "No", "differences", "were", "seen", "using", "3", "mm", "collimation", ".", "Differences", "were", "due", "to", "insufficient", "beamside", "collimation", "of", "the", "EBCT", ".", "The", "use", "of", "EBCT", "with", "6", "mm", "collimation", "should", "be", "avoided", ",", "because", "of", "impaired", "performance", ".", "Using", "3", "mm", "collimation", ",", "EBCT", "showed", "comparable", "performance", "like", "state", "of", "the", "art", "spiral", "-", "CT", "despite", "lower", "HC", "resolution", "." ]

[ "umlsterm" ]

patient, measurements, contrast, contrast, radiation, patient, measurements, patient, use, art

DerRadiologe.80380993.eng.abstr_task2

Sentence: To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

To compare patient dose and image quality of electron-beam-CT vs. spiral-CT by means of phantom measurements . An EBCT scanner ( C-150 XP ) and a spiral-CT scanner ( GE HiSpeed Advantage ) were used to scan three different phantoms . Administered dose , high contrast ( HC ) resolution , low contrast ( LC ) lesion detectability and the width of the radiation beams were measured . EBCT showed 25-35% lower HC resolution in comparison to spiral-CT . LC lesion detectability showed equivalent results for S/N vs. patient dose using 3 mm collimation with EBCT and spiral-CT , whereas spiral-CT was superior for 1,5 and 6 mm collimation . Dose measurements revealed a 2 fold higher patient dose using EBCT with 1,5 mm or 6 mm collimation compared to spiral-CT using equivalent scan parameters . No differences were seen using 3 mm collimation . Differences were due to insufficient beamside collimation of the EBCT . The use of EBCT with 6 mm collimation should be avoided , because of impaired performance . Using 3 mm collimation , EBCT showed comparable performance like state of the art spiral-CT despite lower HC resolution .

[ "To", "compare", "patient", "dose", "and", "image", "quality", "of", "electron", "-", "beam", "-", "CT", "vs", ".", "spiral", "-", "CT", "by", "means", "of", "phantom", "measurements", ".", "An", "EBCT", "scanner", "(", "C-150", "XP", ")", "and", "a", "spiral", "-", "CT", "scanner", "(", "GE", "HiSpeed", "Advantage", ")", "were", "used", "to", "scan", "three", "different", "phantoms", ".", "Administered", "dose", ",", "high", "contrast", "(", "HC", ")", "resolution", ",", "low", "contrast", "(", "LC", ")", "lesion", "detectability", "and", "the", "width", "of", "the", "radiation", "beams", "were", "measured", ".", "EBCT", "showed", "25", "-", "35", "%", "lower", "HC", "resolution", "in", "comparison", "to", "spiral", "-", "CT", ".", "LC", "lesion", "detectability", "showed", "equivalent", "results", "for", "S", "/", "N", "vs", ".", "patient", "dose", "using", "3", "mm", "collimation", "with", "EBCT", "and", "spiral", "-", "CT", ",", "whereas", "spiral", "-", "CT", "was", "superior", "for", "1,5", "and", "6", "mm", "collimation", ".", "Dose", "measurements", "revealed", "a", "2", "fold", "higher", "patient", "dose", "using", "EBCT", "with", "1,5", "mm", "or", "6", "mm", "collimation", "compared", "to", "spiral", "-", "CT", "using", "equivalent", "scan", "parameters", ".", "No", "differences", "were", "seen", "using", "3", "mm", "collimation", ".", "Differences", "were", "due", "to", "insufficient", "beamside", "collimation", "of", "the", "EBCT", ".", "The", "use", "of", "EBCT", "with", "6", "mm", "collimation", "should", "be", "avoided", ",", "because", "of", "impaired", "performance", ".", "Using", "3", "mm", "collimation", ",", "EBCT", "showed", "comparable", "performance", "like", "state", "of", "the", "art", "spiral", "-", "CT", "despite", "lower", "HC", "resolution", "." ]

[ "umlsterm" ]

polytetrafluorethylene is an umlsterm, aim is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, elements is an umlsterm, incorporation is an umlsterm, prostheses is an umlsterm, high density polyethylene is an umlsterm, neck muscle is an umlsterm, pigs is an umlsterm, prostheses is an umlsterm, cell is an umlsterm, technique is an umlsterm, defect is an umlsterm, endoscopy is an umlsterm, light is an umlsterm, scanning electron microscopy is an umlsterm, prostheses is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, ability is an umlsterm, prosthesis is an umlsterm, cell differentiation is an umlsterm, prostheses is an umlsterm, epitheliums is an umlsterm, solution is an umlsterm, defects is an umlsterm

HNO.70450453.eng.abstr_task0

Sentence: Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects .

[ "Replacement", "of", "the", "tracheal", "conduit", "remains", "an", "unresolved", "problem", ".", "The", "microporous", "material", "expanded", "polytetrafluorethylene", "(", "ePTFE", ")", "is", "suitable", "for", "tracheal", "reconstruction", ".", "The", "aim", "of", "our", "study", "was", "to", "improve", "the", "limited", "mechanical", "properties", "of", "this", "material", "by", "incorporating", "reinforcement", "elements", "and", "to", "examine", "the", "influence", "of", "these", "elements", "on", "host", "incorporation", "and", "epithelialization", ".", "In", "so", "dours", "ePTFE", "prostheses", "were", "reinforced", "with", "Ionomer", "cement", "and", "porous", "high", "density", "polyethylene", "(", "pHDPE", ")", "rings", "and", "implanted", "into", "the", "neck", "muscle", "of", "miniature", "pigs", ".", "One", "of", "these", "prostheses", "was", "epithelialized", "by", "a", "cell", "seeding", "technique", "and", "was", "thus", "placed", "into", "a", "tracheal", "defect", ".", "Results", "were", "examined", "grossly", "by", "endoscopy", "and", "than", "by", "light", "and", "scanning", "electron", "microscopy", ".", "The", "shapes", "of", "both", "types", "of", "prostheses", "showed", "a", "high", "stability", ".", "The", "reinforcement", "elements", "did", "not", "impair", "bioincorporation", "or", "the", "ability", "to", "epithelialize", ".", "In", "vivo", "interposition", "of", "an", "incorporated", "and", "epithelialized", "prosthesis", "to", "a", "host", "led", "to", "cell", "differentiation", ".", "The", "improved", "biomechanical", "properties", "of", "the", "prostheses", "waid", "and", "the", "reproducible", "formation", "of", "epitheliums", "are", "important", "advances", "in", "the", "solution", "of", "effectively", "correcting", "tracheal", "defects", "." ]

[ "umlsterm" ]

polytetrafluorethylene is an umlsterm, aim is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, elements is an umlsterm, incorporation is an umlsterm, prostheses is an umlsterm, high density polyethylene is an umlsterm, neck muscle is an umlsterm, pigs is an umlsterm, prostheses is an umlsterm, cell is an umlsterm, technique is an umlsterm, defect is an umlsterm, endoscopy is an umlsterm, light is an umlsterm, scanning electron microscopy is an umlsterm, prostheses is an umlsterm, reinforcement is an umlsterm, elements is an umlsterm, ability is an umlsterm, prosthesis is an umlsterm, cell differentiation is an umlsterm, prostheses is an umlsterm, epitheliums is an umlsterm, solution is an umlsterm, defects is an umlsterm

HNO.70450453.eng.abstr_task1

Sentence: Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects . Instructions: please typing these entity words according to sentence: polytetrafluorethylene, aim, reinforcement, elements, elements, incorporation, prostheses, high density polyethylene, neck muscle, pigs, prostheses, cell, technique, defect, endoscopy, light, scanning electron microscopy, prostheses, reinforcement, elements, ability, prosthesis, cell differentiation, prostheses, epitheliums, solution, defects Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects .

[ "Replacement", "of", "the", "tracheal", "conduit", "remains", "an", "unresolved", "problem", ".", "The", "microporous", "material", "expanded", "polytetrafluorethylene", "(", "ePTFE", ")", "is", "suitable", "for", "tracheal", "reconstruction", ".", "The", "aim", "of", "our", "study", "was", "to", "improve", "the", "limited", "mechanical", "properties", "of", "this", "material", "by", "incorporating", "reinforcement", "elements", "and", "to", "examine", "the", "influence", "of", "these", "elements", "on", "host", "incorporation", "and", "epithelialization", ".", "In", "so", "dours", "ePTFE", "prostheses", "were", "reinforced", "with", "Ionomer", "cement", "and", "porous", "high", "density", "polyethylene", "(", "pHDPE", ")", "rings", "and", "implanted", "into", "the", "neck", "muscle", "of", "miniature", "pigs", ".", "One", "of", "these", "prostheses", "was", "epithelialized", "by", "a", "cell", "seeding", "technique", "and", "was", "thus", "placed", "into", "a", "tracheal", "defect", ".", "Results", "were", "examined", "grossly", "by", "endoscopy", "and", "than", "by", "light", "and", "scanning", "electron", "microscopy", ".", "The", "shapes", "of", "both", "types", "of", "prostheses", "showed", "a", "high", "stability", ".", "The", "reinforcement", "elements", "did", "not", "impair", "bioincorporation", "or", "the", "ability", "to", "epithelialize", ".", "In", "vivo", "interposition", "of", "an", "incorporated", "and", "epithelialized", "prosthesis", "to", "a", "host", "led", "to", "cell", "differentiation", ".", "The", "improved", "biomechanical", "properties", "of", "the", "prostheses", "waid", "and", "the", "reproducible", "formation", "of", "epitheliums", "are", "important", "advances", "in", "the", "solution", "of", "effectively", "correcting", "tracheal", "defects", "." ]

[ "umlsterm" ]

polytetrafluorethylene, aim, reinforcement, elements, elements, incorporation, prostheses, high density polyethylene, neck muscle, pigs, prostheses, cell, technique, defect, endoscopy, light, scanning electron microscopy, prostheses, reinforcement, elements, ability, prosthesis, cell differentiation, prostheses, epitheliums, solution, defects

HNO.70450453.eng.abstr_task2

Sentence: Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Replacement of the tracheal conduit remains an unresolved problem . The microporous material expanded polytetrafluorethylene ( ePTFE ) is suitable for tracheal reconstruction . The aim of our study was to improve the limited mechanical properties of this material by incorporating reinforcement elements and to examine the influence of these elements on host incorporation and epithelialization . In so dours ePTFE prostheses were reinforced with Ionomer cement and porous high density polyethylene ( pHDPE ) rings and implanted into the neck muscle of miniature pigs . One of these prostheses was epithelialized by a cell seeding technique and was thus placed into a tracheal defect . Results were examined grossly by endoscopy and than by light and scanning electron microscopy . The shapes of both types of prostheses showed a high stability . The reinforcement elements did not impair bioincorporation or the ability to epithelialize . In vivo interposition of an incorporated and epithelialized prosthesis to a host led to cell differentiation . The improved biomechanical properties of the prostheses waid and the reproducible formation of epitheliums are important advances in the solution of effectively correcting tracheal defects .

[ "Replacement", "of", "the", "tracheal", "conduit", "remains", "an", "unresolved", "problem", ".", "The", "microporous", "material", "expanded", "polytetrafluorethylene", "(", "ePTFE", ")", "is", "suitable", "for", "tracheal", "reconstruction", ".", "The", "aim", "of", "our", "study", "was", "to", "improve", "the", "limited", "mechanical", "properties", "of", "this", "material", "by", "incorporating", "reinforcement", "elements", "and", "to", "examine", "the", "influence", "of", "these", "elements", "on", "host", "incorporation", "and", "epithelialization", ".", "In", "so", "dours", "ePTFE", "prostheses", "were", "reinforced", "with", "Ionomer", "cement", "and", "porous", "high", "density", "polyethylene", "(", "pHDPE", ")", "rings", "and", "implanted", "into", "the", "neck", "muscle", "of", "miniature", "pigs", ".", "One", "of", "these", "prostheses", "was", "epithelialized", "by", "a", "cell", "seeding", "technique", "and", "was", "thus", "placed", "into", "a", "tracheal", "defect", ".", "Results", "were", "examined", "grossly", "by", "endoscopy", "and", "than", "by", "light", "and", "scanning", "electron", "microscopy", ".", "The", "shapes", "of", "both", "types", "of", "prostheses", "showed", "a", "high", "stability", ".", "The", "reinforcement", "elements", "did", "not", "impair", "bioincorporation", "or", "the", "ability", "to", "epithelialize", ".", "In", "vivo", "interposition", "of", "an", "incorporated", "and", "epithelialized", "prosthesis", "to", "a", "host", "led", "to", "cell", "differentiation", ".", "The", "improved", "biomechanical", "properties", "of", "the", "prostheses", "waid", "and", "the", "reproducible", "formation", "of", "epitheliums", "are", "important", "advances", "in", "the", "solution", "of", "effectively", "correcting", "tracheal", "defects", "." ]

[ "umlsterm" ]

2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a CHEMICAL, PhIP is a CHEMICAL, creatinine is a CHEMICAL, phenylalanine is a CHEMICAL, creatinine is a CHEMICAL

23265474_task0

Sentence: Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]

Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures.

[ "Comparative", "formation", "of", "2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine", "(", "PhIP", ")", "in", "creatinine", "/", "phenylalanine", "and", "creatinine", "/", "phenylalanine/4-oxo-2-nonenal", "reaction", "mixtures", "." ]

[ "CHEMICAL" ]

2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a CHEMICAL, PhIP is a CHEMICAL, creatinine is a CHEMICAL, phenylalanine is a CHEMICAL, creatinine is a CHEMICAL

23265474_task1

Sentence: Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures. Instructions: please typing these entity words according to sentence: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, PhIP, creatinine, phenylalanine, creatinine Options: CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]

Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures.

[ "Comparative", "formation", "of", "2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine", "(", "PhIP", ")", "in", "creatinine", "/", "phenylalanine", "and", "creatinine", "/", "phenylalanine/4-oxo-2-nonenal", "reaction", "mixtures", "." ]

[ "CHEMICAL" ]

2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, PhIP, creatinine, phenylalanine, creatinine

23265474_task2

Sentence: Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]

Comparative formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in creatinine/phenylalanine and creatinine/phenylalanine/4-oxo-2-nonenal reaction mixtures.

[ "Comparative", "formation", "of", "2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine", "(", "PhIP", ")", "in", "creatinine", "/", "phenylalanine", "and", "creatinine", "/", "phenylalanine/4-oxo-2-nonenal", "reaction", "mixtures", "." ]

[ "CHEMICAL" ]

p50 is a Protein, p50 is a Protein, p65 is a Protein, Ets-1 is a Protein

690_task0

Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.

[ "Physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "play", "an", "important", "role", "in", "their", "cooperative", "activation", "of", "the", "human", "immunodeficiency", "virus", "enhancer", "in", "T", "cells", ".", "\n", "The", "transcriptional", "regulatory", "elements", "of", "many", "inducible", "T", "-", "cell", "genes", "contain", "adjacent", "or", "overlapping", "binding", "sites", "for", "the", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "families", "of", "transcription", "factors", ".", "Similar", "arrays", "of", "functionally", "important", "NF", "-", "kappaB", "/", "NFAT", "and", "Ets", "binding", "sites", "are", "present", "in", "the", "transcriptional", "enhancers", "of", "human", "immunodeficiency", "viruses", "types", "1", "and", "2", "(", "HIV-1", "and", "HIV-2", ")", ",", "suggesting", "that", "this", "pattern", "of", "nuclear", "protein", "binding", "sites", "reflects", "an", "evolutionarily", "conserved", "mechanism", "for", "regulating", "inducible", "T", "-", "cell", "gene", "expression", "that", "has", "been", "co", "-", "opted", "during", "HIV", "evolution", ".", "Despite", "these", "findings", ",", "the", "molecular", "mechanisms", "by", "which", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "cooperatively", "regulate", "inducible", "T", "-", "cell", "gene", "expression", "remained", "unknown", ".", "In", "the", "studies", "described", "in", "this", "report", ",", "we", "demonstrated", "a", "physical", "interaction", "between", "multiple", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "both", "in", "vitro", "and", "in", "activated", "normal", "human", "T", "cells", ".", "This", "interaction", "is", "mediated", "by", "the", "Ets", "domain", "of", "Ets", "proteins", "and", "the", "C", "-", "terminal", "region", "of", "the", "Rel", "homology", "domains", "of", "NF", "-", "kappaB", "/", "NFAT", "proteins", ".", "In", "addition", ",", "the", "Ets", "-", "NF", "-", "kappaB", "/", "NFAT", "interaction", "requires", "the", "presence", "of", "DNA", "binding", "sites", "for", "both", "proteins", ",", "as", "it", "is", "abolished", "by", "the", "DNA", "intercalating", "agents", "propidium", "iodide", "and", "ethidium", "bromide", "and", "enhanced", "by", "the", "presence", "of", "synthetic", "oligonucleotides", "containing", "binding", "sites", "for", "Ets", "and", "NF", "-", "kappaB", "proteins", ".", "A", "dominant", "-", "negative", "mutant", "of", "NF", "-", "kappaB", "p50", "that", "binds", "DNA", "but", "fails", "to", "interact", "with", "Ets", "proteins", "inhibits", "the", "synergistic", "activation", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", "by", "NF", "-", "kappaB", "(", "p50", "+", "p65", ")", "and", "Ets-1", ",", "suggesting", "that", "physical", "interaction", "between", "Ets", "and", "NF", "-", "kappaB", "proteins", "is", "required", "for", "the", "transcriptional", "activity", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", ".", "Taken", "together", ",", "these", "findings", "suggest", "that", "evolutionarily", "conserved", "physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "are", "important", "in", "regulating", "the", "inducible", "expression", "of", "T", "-", "cell", "genes", "and", "viruses", ".", "These", "interactions", "represent", "a", "potential", "target", "for", "the", "development", "of", "novel", "immunosuppressive", "and", "antiviral", "therapies", "." ]

[ "Protein" ]

p50 is a Protein, p50 is a Protein, p65 is a Protein, Ets-1 is a Protein

690_task1

Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies. Instructions: please typing these entity words according to sentence: p50, p50, p65, Ets-1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.

[ "Physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "play", "an", "important", "role", "in", "their", "cooperative", "activation", "of", "the", "human", "immunodeficiency", "virus", "enhancer", "in", "T", "cells", ".", "\n", "The", "transcriptional", "regulatory", "elements", "of", "many", "inducible", "T", "-", "cell", "genes", "contain", "adjacent", "or", "overlapping", "binding", "sites", "for", "the", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "families", "of", "transcription", "factors", ".", "Similar", "arrays", "of", "functionally", "important", "NF", "-", "kappaB", "/", "NFAT", "and", "Ets", "binding", "sites", "are", "present", "in", "the", "transcriptional", "enhancers", "of", "human", "immunodeficiency", "viruses", "types", "1", "and", "2", "(", "HIV-1", "and", "HIV-2", ")", ",", "suggesting", "that", "this", "pattern", "of", "nuclear", "protein", "binding", "sites", "reflects", "an", "evolutionarily", "conserved", "mechanism", "for", "regulating", "inducible", "T", "-", "cell", "gene", "expression", "that", "has", "been", "co", "-", "opted", "during", "HIV", "evolution", ".", "Despite", "these", "findings", ",", "the", "molecular", "mechanisms", "by", "which", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "cooperatively", "regulate", "inducible", "T", "-", "cell", "gene", "expression", "remained", "unknown", ".", "In", "the", "studies", "described", "in", "this", "report", ",", "we", "demonstrated", "a", "physical", "interaction", "between", "multiple", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "both", "in", "vitro", "and", "in", "activated", "normal", "human", "T", "cells", ".", "This", "interaction", "is", "mediated", "by", "the", "Ets", "domain", "of", "Ets", "proteins", "and", "the", "C", "-", "terminal", "region", "of", "the", "Rel", "homology", "domains", "of", "NF", "-", "kappaB", "/", "NFAT", "proteins", ".", "In", "addition", ",", "the", "Ets", "-", "NF", "-", "kappaB", "/", "NFAT", "interaction", "requires", "the", "presence", "of", "DNA", "binding", "sites", "for", "both", "proteins", ",", "as", "it", "is", "abolished", "by", "the", "DNA", "intercalating", "agents", "propidium", "iodide", "and", "ethidium", "bromide", "and", "enhanced", "by", "the", "presence", "of", "synthetic", "oligonucleotides", "containing", "binding", "sites", "for", "Ets", "and", "NF", "-", "kappaB", "proteins", ".", "A", "dominant", "-", "negative", "mutant", "of", "NF", "-", "kappaB", "p50", "that", "binds", "DNA", "but", "fails", "to", "interact", "with", "Ets", "proteins", "inhibits", "the", "synergistic", "activation", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", "by", "NF", "-", "kappaB", "(", "p50", "+", "p65", ")", "and", "Ets-1", ",", "suggesting", "that", "physical", "interaction", "between", "Ets", "and", "NF", "-", "kappaB", "proteins", "is", "required", "for", "the", "transcriptional", "activity", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", ".", "Taken", "together", ",", "these", "findings", "suggest", "that", "evolutionarily", "conserved", "physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "are", "important", "in", "regulating", "the", "inducible", "expression", "of", "T", "-", "cell", "genes", "and", "viruses", ".", "These", "interactions", "represent", "a", "potential", "target", "for", "the", "development", "of", "novel", "immunosuppressive", "and", "antiviral", "therapies", "." ]

[ "Protein" ]

p50, p50, p65, Ets-1

690_task2

Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.

[ "Physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "play", "an", "important", "role", "in", "their", "cooperative", "activation", "of", "the", "human", "immunodeficiency", "virus", "enhancer", "in", "T", "cells", ".", "\n", "The", "transcriptional", "regulatory", "elements", "of", "many", "inducible", "T", "-", "cell", "genes", "contain", "adjacent", "or", "overlapping", "binding", "sites", "for", "the", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "families", "of", "transcription", "factors", ".", "Similar", "arrays", "of", "functionally", "important", "NF", "-", "kappaB", "/", "NFAT", "and", "Ets", "binding", "sites", "are", "present", "in", "the", "transcriptional", "enhancers", "of", "human", "immunodeficiency", "viruses", "types", "1", "and", "2", "(", "HIV-1", "and", "HIV-2", ")", ",", "suggesting", "that", "this", "pattern", "of", "nuclear", "protein", "binding", "sites", "reflects", "an", "evolutionarily", "conserved", "mechanism", "for", "regulating", "inducible", "T", "-", "cell", "gene", "expression", "that", "has", "been", "co", "-", "opted", "during", "HIV", "evolution", ".", "Despite", "these", "findings", ",", "the", "molecular", "mechanisms", "by", "which", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "cooperatively", "regulate", "inducible", "T", "-", "cell", "gene", "expression", "remained", "unknown", ".", "In", "the", "studies", "described", "in", "this", "report", ",", "we", "demonstrated", "a", "physical", "interaction", "between", "multiple", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "both", "in", "vitro", "and", "in", "activated", "normal", "human", "T", "cells", ".", "This", "interaction", "is", "mediated", "by", "the", "Ets", "domain", "of", "Ets", "proteins", "and", "the", "C", "-", "terminal", "region", "of", "the", "Rel", "homology", "domains", "of", "NF", "-", "kappaB", "/", "NFAT", "proteins", ".", "In", "addition", ",", "the", "Ets", "-", "NF", "-", "kappaB", "/", "NFAT", "interaction", "requires", "the", "presence", "of", "DNA", "binding", "sites", "for", "both", "proteins", ",", "as", "it", "is", "abolished", "by", "the", "DNA", "intercalating", "agents", "propidium", "iodide", "and", "ethidium", "bromide", "and", "enhanced", "by", "the", "presence", "of", "synthetic", "oligonucleotides", "containing", "binding", "sites", "for", "Ets", "and", "NF", "-", "kappaB", "proteins", ".", "A", "dominant", "-", "negative", "mutant", "of", "NF", "-", "kappaB", "p50", "that", "binds", "DNA", "but", "fails", "to", "interact", "with", "Ets", "proteins", "inhibits", "the", "synergistic", "activation", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", "by", "NF", "-", "kappaB", "(", "p50", "+", "p65", ")", "and", "Ets-1", ",", "suggesting", "that", "physical", "interaction", "between", "Ets", "and", "NF", "-", "kappaB", "proteins", "is", "required", "for", "the", "transcriptional", "activity", "of", "the", "HIV-1", "and", "HIV-2", "enhancers", ".", "Taken", "together", ",", "these", "findings", "suggest", "that", "evolutionarily", "conserved", "physical", "interactions", "between", "Ets", "and", "NF", "-", "kappaB", "/", "NFAT", "proteins", "are", "important", "in", "regulating", "the", "inducible", "expression", "of", "T", "-", "cell", "genes", "and", "viruses", ".", "These", "interactions", "represent", "a", "potential", "target", "for", "the", "development", "of", "novel", "immunosuppressive", "and", "antiviral", "therapies", "." ]

[ "Protein" ]

Retinal is a Multi-tissue_structure, patient is a Organism, vessels is a Multi-tissue_structure, retinal periphery is a Tissue, capillary is a Tissue, macula is a Tissue, eye is a Organ, vessels is a Multi-tissue_structure, vessels is a Multi-tissue_structure, retina is a Multi-tissue_structure, vessels is a Multi-tissue_structure

10_task0

Sentence: Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Tissue, Multi-tissue_structure, Organ

[ "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O" ]

Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels.

[ "Retinal", "revascularisation", "in", "diabetic", "retinopathy", ".", "\n\n", "The", "case", "history", "of", "a", "33-year", "-", "old", "diabetic", "patient", "who", "has", "had", "diabetes", "for", "24", "years", "is", "presented", ".", "When", "first", "seen", "in", "1975", "he", "had", "bilateral", "proliferative", "retinopathy", "with", "new", "vessels", "in", "the", "retinal", "periphery", ".", "He", "had", "large", "areas", "of", "capillary", "non", "-", "perfusion", "lateral", "to", "the", "macula", "in", "the", "right", "eye", "associated", "with", "the", "new", "vessels", ".", "Nine", "years", "later", ",", "after", "extensive", "repeated", "photocoagulation", ",", "revascularisation", "of", "large", "areas", "previously", "not", "perfused", "were", "seen", ".", "The", "vessels", "are", "in", "the", "plane", "of", "the", "retina", "and", "do", "not", "have", "the", "appearance", "of", "new", "vessels", ".", "\n" ]

[ "Tissue", "Multi-tissue_structure", "Organism", "Organ" ]

Retinal is a Multi-tissue_structure, patient is a Organism, vessels is a Multi-tissue_structure, retinal periphery is a Tissue, capillary is a Tissue, macula is a Tissue, eye is a Organ, vessels is a Multi-tissue_structure, vessels is a Multi-tissue_structure, retina is a Multi-tissue_structure, vessels is a Multi-tissue_structure

10_task1

Sentence: Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels. Instructions: please typing these entity words according to sentence: Retinal, patient, vessels, retinal periphery, capillary, macula, eye, vessels, vessels, retina, vessels Options: Organism, Tissue, Multi-tissue_structure, Organ

[ "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O" ]

Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels.

[ "Retinal", "revascularisation", "in", "diabetic", "retinopathy", ".", "\n\n", "The", "case", "history", "of", "a", "33-year", "-", "old", "diabetic", "patient", "who", "has", "had", "diabetes", "for", "24", "years", "is", "presented", ".", "When", "first", "seen", "in", "1975", "he", "had", "bilateral", "proliferative", "retinopathy", "with", "new", "vessels", "in", "the", "retinal", "periphery", ".", "He", "had", "large", "areas", "of", "capillary", "non", "-", "perfusion", "lateral", "to", "the", "macula", "in", "the", "right", "eye", "associated", "with", "the", "new", "vessels", ".", "Nine", "years", "later", ",", "after", "extensive", "repeated", "photocoagulation", ",", "revascularisation", "of", "large", "areas", "previously", "not", "perfused", "were", "seen", ".", "The", "vessels", "are", "in", "the", "plane", "of", "the", "retina", "and", "do", "not", "have", "the", "appearance", "of", "new", "vessels", ".", "\n" ]

[ "Tissue", "Multi-tissue_structure", "Organism", "Organ" ]

Retinal, patient, vessels, retinal periphery, capillary, macula, eye, vessels, vessels, retina, vessels

10_task2

Sentence: Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels. Instructions: please extract entity words from the input sentence

[ "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O" ]

Retinal revascularisation in diabetic retinopathy. The case history of a 33-year-old diabetic patient who has had diabetes for 24 years is presented. When first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery. He had large areas of capillary non-perfusion lateral to the macula in the right eye associated with the new vessels. Nine years later, after extensive repeated photocoagulation, revascularisation of large areas previously not perfused were seen. The vessels are in the plane of the retina and do not have the appearance of new vessels.

[ "Retinal", "revascularisation", "in", "diabetic", "retinopathy", ".", "\n\n", "The", "case", "history", "of", "a", "33-year", "-", "old", "diabetic", "patient", "who", "has", "had", "diabetes", "for", "24", "years", "is", "presented", ".", "When", "first", "seen", "in", "1975", "he", "had", "bilateral", "proliferative", "retinopathy", "with", "new", "vessels", "in", "the", "retinal", "periphery", ".", "He", "had", "large", "areas", "of", "capillary", "non", "-", "perfusion", "lateral", "to", "the", "macula", "in", "the", "right", "eye", "associated", "with", "the", "new", "vessels", ".", "Nine", "years", "later", ",", "after", "extensive", "repeated", "photocoagulation", ",", "revascularisation", "of", "large", "areas", "previously", "not", "perfused", "were", "seen", ".", "The", "vessels", "are", "in", "the", "plane", "of", "the", "retina", "and", "do", "not", "have", "the", "appearance", "of", "new", "vessels", ".", "\n" ]

[ "Tissue", "Multi-tissue_structure", "Organism", "Organ" ]

narcotics control is an umlsterm, therapeutic is an umlsterm, physician is an umlsterm, time is an umlsterm, use is an umlsterm, narcotics is an umlsterm, control is an umlsterm, use is an umlsterm, narcotics is an umlsterm, conflicts is an umlsterm, physicians is an umlsterm, use is an umlsterm, opioids is an umlsterm, pain therapy is an umlsterm, opioids is an umlsterm, Narcotics is an umlsterm, Drug is an umlsterm

DerSchmerz.60100302.eng.abstr_task0

Sentence: Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O" ]

Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act .

[ "Rules", "still", "valid", "today", "continue", "the", "tradition", "of", "state", "narcotics", "control", ",", "conceding", "therapeutic", "decisions", "to", "the", "physician", ",", "but", "at", "the", "same", "time", "allowing", "only", "restrictive", "use", "of", "narcotics", ".", "Legal", "control", "of", "medically", "indicated", "use", "of", "narcotics", "is", "burdened", "with", "conflicts", ".", "Recently", ",", "physicians", "have", "been", "given", "more", "scope", "in", "the", "use", "of", "strong", "opioids", "for", "pain", "therapy", ".", "Existing", "limits", "for", "a", "dose", "of", "opioids", "may", "be", "exceeded", "when", "necessary", ".", "However", ",", "there", "are", "still", "formal", "rules", "in", "the", "German", "Narcotics", "Drug", "Act", "." ]

[ "umlsterm" ]

narcotics control is an umlsterm, therapeutic is an umlsterm, physician is an umlsterm, time is an umlsterm, use is an umlsterm, narcotics is an umlsterm, control is an umlsterm, use is an umlsterm, narcotics is an umlsterm, conflicts is an umlsterm, physicians is an umlsterm, use is an umlsterm, opioids is an umlsterm, pain therapy is an umlsterm, opioids is an umlsterm, Narcotics is an umlsterm, Drug is an umlsterm

DerSchmerz.60100302.eng.abstr_task1

Sentence: Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act . Instructions: please typing these entity words according to sentence: narcotics control, therapeutic, physician, time, use, narcotics, control, use, narcotics, conflicts, physicians, use, opioids, pain therapy, opioids, Narcotics, Drug Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O" ]

Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act .

[ "Rules", "still", "valid", "today", "continue", "the", "tradition", "of", "state", "narcotics", "control", ",", "conceding", "therapeutic", "decisions", "to", "the", "physician", ",", "but", "at", "the", "same", "time", "allowing", "only", "restrictive", "use", "of", "narcotics", ".", "Legal", "control", "of", "medically", "indicated", "use", "of", "narcotics", "is", "burdened", "with", "conflicts", ".", "Recently", ",", "physicians", "have", "been", "given", "more", "scope", "in", "the", "use", "of", "strong", "opioids", "for", "pain", "therapy", ".", "Existing", "limits", "for", "a", "dose", "of", "opioids", "may", "be", "exceeded", "when", "necessary", ".", "However", ",", "there", "are", "still", "formal", "rules", "in", "the", "German", "Narcotics", "Drug", "Act", "." ]

[ "umlsterm" ]

narcotics control, therapeutic, physician, time, use, narcotics, control, use, narcotics, conflicts, physicians, use, opioids, pain therapy, opioids, Narcotics, Drug

DerSchmerz.60100302.eng.abstr_task2

Sentence: Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O" ]

Rules still valid today continue the tradition of state narcotics control , conceding therapeutic decisions to the physician , but at the same time allowing only restrictive use of narcotics . Legal control of medically indicated use of narcotics is burdened with conflicts . Recently , physicians have been given more scope in the use of strong opioids for pain therapy . Existing limits for a dose of opioids may be exceeded when necessary . However , there are still formal rules in the German Narcotics Drug Act .

[ "Rules", "still", "valid", "today", "continue", "the", "tradition", "of", "state", "narcotics", "control", ",", "conceding", "therapeutic", "decisions", "to", "the", "physician", ",", "but", "at", "the", "same", "time", "allowing", "only", "restrictive", "use", "of", "narcotics", ".", "Legal", "control", "of", "medically", "indicated", "use", "of", "narcotics", "is", "burdened", "with", "conflicts", ".", "Recently", ",", "physicians", "have", "been", "given", "more", "scope", "in", "the", "use", "of", "strong", "opioids", "for", "pain", "therapy", ".", "Existing", "limits", "for", "a", "dose", "of", "opioids", "may", "be", "exceeded", "when", "necessary", ".", "However", ",", "there", "are", "still", "formal", "rules", "in", "the", "German", "Narcotics", "Drug", "Act", "." ]

[ "umlsterm" ]

Uterus is an umlsterm, Endometrium is an umlsterm, Myometrium is an umlsterm, Ovar is an umlsterm, Reproduktion is an umlsterm, Peristaltik is an umlsterm, Spermientransport is an umlsterm, Muskelschichten is an umlsterm, Geburt is an umlsterm, Endometriose is an umlsterm, Adenomyosis is an umlsterm, Frauen is an umlsterm, Endometriose is an umlsterm, Myometrium is an umlsterm, Adenomyosis is an umlsterm

Reproduktionsmedizin.90150356.ger.abstr_task0

Sentence: Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri .

[ "Der", "menschliche", "Uterus", "setzt", "sich", "aus", "einer", "inneren", "paramesonephrischen", "Archimetra", "und", "einer", "aeusseren", "nicht", "-", "paramesonephrischen", "Neometra", "zusammen", ".", "Die", "Archimetra", "besteht", "aus", "dem", "Endometrium", "und", "dem", "Stratum", "subvasculare", "des", "Myometrium", "und", "erfuellt", "verschiedene", "vom", "Ovar", "gesteuerte", "Funktionen", "im", "fruehen", "Prozess", "der", "Reproduktion", "wie", "Aufbau", "des", "Endometriums", "fuer", "die", "Implantation", ",", "uterine", "Peristaltik", "fuer", "den", "gerichteten", "Spermientransport", "und", "die", "hohe", "fundale", "Implantation", "sowie", "die", "Infektabwehr", ".", "Die", "Neometra", "besteht", "aus", "den", "beiden", "aeusseren", "Muskelschichten", ",", "dem", "Stratum", "vasculare", "und", "supravasculare", ".", "Die", "wesentliche", "Funktion", "besteht", "im", "Aufbringen", "der", "Kraefte", "fuer", "die", "Geburt", ".", "Die", "Endometriose", "wird", "als", "Folge", "einer", "Adenomyosis", "oder", "deren", "Fruehmanifestationen", "und", "somit", "als", "eine", "Erkrankung", "der", "Archimetra", "angesehen", ".", "Dieses", "Konzept", "stuetzt", "sich", "auf", "spezifische", "Veraenderungen", "des", "eutopen", "Endometriums", "bei", "Frauen", "mit", "Endometriose", ",", "auf", "archimetrale", "Funktionsstoerungen", "wie", "Hyper-", "und", "Dysperistaltik", "sowie", "auf", "eine", "archimetrale", "Infiltration", "in", "das", "darunter", "liegende", "Myometrium", "mit", "dem", "Bild", "einer", "Adenomyosis", "uteri", "." ]

[ "umlsterm" ]

Uterus is an umlsterm, Endometrium is an umlsterm, Myometrium is an umlsterm, Ovar is an umlsterm, Reproduktion is an umlsterm, Peristaltik is an umlsterm, Spermientransport is an umlsterm, Muskelschichten is an umlsterm, Geburt is an umlsterm, Endometriose is an umlsterm, Adenomyosis is an umlsterm, Frauen is an umlsterm, Endometriose is an umlsterm, Myometrium is an umlsterm, Adenomyosis is an umlsterm

Reproduktionsmedizin.90150356.ger.abstr_task1

Sentence: Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri . Instructions: please typing these entity words according to sentence: Uterus, Endometrium, Myometrium, Ovar, Reproduktion, Peristaltik, Spermientransport, Muskelschichten, Geburt, Endometriose, Adenomyosis, Frauen, Endometriose, Myometrium, Adenomyosis Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri .

[ "Der", "menschliche", "Uterus", "setzt", "sich", "aus", "einer", "inneren", "paramesonephrischen", "Archimetra", "und", "einer", "aeusseren", "nicht", "-", "paramesonephrischen", "Neometra", "zusammen", ".", "Die", "Archimetra", "besteht", "aus", "dem", "Endometrium", "und", "dem", "Stratum", "subvasculare", "des", "Myometrium", "und", "erfuellt", "verschiedene", "vom", "Ovar", "gesteuerte", "Funktionen", "im", "fruehen", "Prozess", "der", "Reproduktion", "wie", "Aufbau", "des", "Endometriums", "fuer", "die", "Implantation", ",", "uterine", "Peristaltik", "fuer", "den", "gerichteten", "Spermientransport", "und", "die", "hohe", "fundale", "Implantation", "sowie", "die", "Infektabwehr", ".", "Die", "Neometra", "besteht", "aus", "den", "beiden", "aeusseren", "Muskelschichten", ",", "dem", "Stratum", "vasculare", "und", "supravasculare", ".", "Die", "wesentliche", "Funktion", "besteht", "im", "Aufbringen", "der", "Kraefte", "fuer", "die", "Geburt", ".", "Die", "Endometriose", "wird", "als", "Folge", "einer", "Adenomyosis", "oder", "deren", "Fruehmanifestationen", "und", "somit", "als", "eine", "Erkrankung", "der", "Archimetra", "angesehen", ".", "Dieses", "Konzept", "stuetzt", "sich", "auf", "spezifische", "Veraenderungen", "des", "eutopen", "Endometriums", "bei", "Frauen", "mit", "Endometriose", ",", "auf", "archimetrale", "Funktionsstoerungen", "wie", "Hyper-", "und", "Dysperistaltik", "sowie", "auf", "eine", "archimetrale", "Infiltration", "in", "das", "darunter", "liegende", "Myometrium", "mit", "dem", "Bild", "einer", "Adenomyosis", "uteri", "." ]

[ "umlsterm" ]

Uterus, Endometrium, Myometrium, Ovar, Reproduktion, Peristaltik, Spermientransport, Muskelschichten, Geburt, Endometriose, Adenomyosis, Frauen, Endometriose, Myometrium, Adenomyosis

Reproduktionsmedizin.90150356.ger.abstr_task2

Sentence: Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Der menschliche Uterus setzt sich aus einer inneren paramesonephrischen Archimetra und einer aeusseren nicht-paramesonephrischen Neometra zusammen . Die Archimetra besteht aus dem Endometrium und dem Stratum subvasculare des Myometrium und erfuellt verschiedene vom Ovar gesteuerte Funktionen im fruehen Prozess der Reproduktion wie Aufbau des Endometriums fuer die Implantation , uterine Peristaltik fuer den gerichteten Spermientransport und die hohe fundale Implantation sowie die Infektabwehr . Die Neometra besteht aus den beiden aeusseren Muskelschichten , dem Stratum vasculare und supravasculare . Die wesentliche Funktion besteht im Aufbringen der Kraefte fuer die Geburt . Die Endometriose wird als Folge einer Adenomyosis oder deren Fruehmanifestationen und somit als eine Erkrankung der Archimetra angesehen . Dieses Konzept stuetzt sich auf spezifische Veraenderungen des eutopen Endometriums bei Frauen mit Endometriose , auf archimetrale Funktionsstoerungen wie Hyper- und Dysperistaltik sowie auf eine archimetrale Infiltration in das darunter liegende Myometrium mit dem Bild einer Adenomyosis uteri .

[ "Der", "menschliche", "Uterus", "setzt", "sich", "aus", "einer", "inneren", "paramesonephrischen", "Archimetra", "und", "einer", "aeusseren", "nicht", "-", "paramesonephrischen", "Neometra", "zusammen", ".", "Die", "Archimetra", "besteht", "aus", "dem", "Endometrium", "und", "dem", "Stratum", "subvasculare", "des", "Myometrium", "und", "erfuellt", "verschiedene", "vom", "Ovar", "gesteuerte", "Funktionen", "im", "fruehen", "Prozess", "der", "Reproduktion", "wie", "Aufbau", "des", "Endometriums", "fuer", "die", "Implantation", ",", "uterine", "Peristaltik", "fuer", "den", "gerichteten", "Spermientransport", "und", "die", "hohe", "fundale", "Implantation", "sowie", "die", "Infektabwehr", ".", "Die", "Neometra", "besteht", "aus", "den", "beiden", "aeusseren", "Muskelschichten", ",", "dem", "Stratum", "vasculare", "und", "supravasculare", ".", "Die", "wesentliche", "Funktion", "besteht", "im", "Aufbringen", "der", "Kraefte", "fuer", "die", "Geburt", ".", "Die", "Endometriose", "wird", "als", "Folge", "einer", "Adenomyosis", "oder", "deren", "Fruehmanifestationen", "und", "somit", "als", "eine", "Erkrankung", "der", "Archimetra", "angesehen", ".", "Dieses", "Konzept", "stuetzt", "sich", "auf", "spezifische", "Veraenderungen", "des", "eutopen", "Endometriums", "bei", "Frauen", "mit", "Endometriose", ",", "auf", "archimetrale", "Funktionsstoerungen", "wie", "Hyper-", "und", "Dysperistaltik", "sowie", "auf", "eine", "archimetrale", "Infiltration", "in", "das", "darunter", "liegende", "Myometrium", "mit", "dem", "Bild", "einer", "Adenomyosis", "uteri", "." ]

[ "umlsterm" ]

coproporphyrinogen oxidase gene is a DNA_domain_or_region, erythroid and nonerythroid cells is a (AND cell_type cell_type)

77322_task0

Sentence: Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, (AND cell_type cell_type)

[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O" ]

Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells.

[ "Differential", "regulation", "of", "coproporphyrinogen", "oxidase", "gene", "between", "erythroid", "and", "nonerythroid", "cells", "." ]

[ "cell_type", "(AND cell_type cell_type)", "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "DNA_family_or_group", "protein_complex", "(AND cell_line cell_line)", "" ]

coproporphyrinogen oxidase gene is a DNA_domain_or_region, erythroid and nonerythroid cells is a (AND cell_type cell_type)

77322_task1

Sentence: Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Instructions: please typing these entity words according to sentence: coproporphyrinogen oxidase gene, erythroid and nonerythroid cells Options: DNA_domain_or_region, (AND cell_type cell_type)

[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O" ]

Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells.

[ "Differential", "regulation", "of", "coproporphyrinogen", "oxidase", "gene", "between", "erythroid", "and", "nonerythroid", "cells", "." ]

[ "cell_type", "(AND cell_type cell_type)", "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "DNA_family_or_group", "protein_complex", "(AND cell_line cell_line)", "" ]

coproporphyrinogen oxidase gene, erythroid and nonerythroid cells

77322_task2

Sentence: Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O" ]

Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells.

[ "Differential", "regulation", "of", "coproporphyrinogen", "oxidase", "gene", "between", "erythroid", "and", "nonerythroid", "cells", "." ]

[ "cell_type", "(AND cell_type cell_type)", "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "DNA_family_or_group", "protein_complex", "(AND cell_line cell_line)", "" ]

Patienten is an umlsterm, Tumors is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lymphknoten is an umlsterm, Gesamtkrankengut is an umlsterm, multivariaten Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lokalrezidivrate is an umlsterm, Rezidivs is an umlsterm

DerChirurg.70681023.ger.abstr_task0

Sentence: Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin .

[ "Zusammenfassung", ".", "Vom", "1", ".", "1", ".", "1985", "bis", "zum", "31", ".", "12", ".", "1995", "wurde", "bei", "386", "Patienten", "mit", "einem", "Rectumcarcinom", "im", "UICC", "-", "Stadium", "I", "-", "III", "nach", "konventionell", "chirurgischen", "Eingriffen", "und", "R0-Resektion", "des", "Tumors", "der", "Einfluss", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "auf", "Tumorstaging", "und", "Lokalrezidivrate", "retrospektiv", "untersucht", ".", "In", "der", "univariaten", "Analyse", "fanden", "wir", "einen", "signifikanten", "Zusammenhang", "zwischen", "der", "Zahl", "der", "dissezierten", "und", "der", "Zahl", "der", "befallenen", "Lymphknoten", ",", "und", "damit", "einhergehend", "eine", "signifikante", "Zunahme", "des", "UICC", "-", "Stadiums", "III", "(", "p", "=", "0,013", ")", "und", "der", "pTxpN2-Kategorie", "(", "p", "=", "0,000", ")", ".", "Eine", "signifikante", "Senkung", "der", "Lokalrezidivrate", "in", "Abhaengigkeit", "von", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "konnte", "nur", "fuer", "das", "UICC", "-", "Stadium", "I", "und", "II", "nachgewiesen", "werden", ".", "Im", "Gesamtkrankengut", "und", "in", "der", "multivariaten", "Analyse", "hatte", "die", "Zahl", "der", "dissezierten", "Lymphknoten", "keinen", "Einfluss", "auf", "die", "Lokalrezidivrate", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "die", "Senkung", "der", "Lokalrezidivrate", "im", "UICC", "-", "Stadium", "I", "und", "II", "nicht", "auf", "einen", "therapeutischen", "Effekt", ",", "sondern", "auf", "eine", "Stadienverschiebung", "im", "Rahmen", "eines", "exakteren", "Tumorstagings", "zurueckzufuehren", "ist", ".", "Dies", "weist", "auf", "den", "Einfluss", "anderer", "chirurgisch", "beeinflussbarer", "Faktoren", ",", "insbesondere", "die", "totale", "mesorectale", "Excision", "fuer", "die", "Entstehung", "eines", "locoregionaeren", "Rezidivs", "hin", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Tumors is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lymphknoten is an umlsterm, Gesamtkrankengut is an umlsterm, multivariaten Analyse is an umlsterm, Lymphknoten is an umlsterm, Lokalrezidivrate is an umlsterm, Lokalrezidivrate is an umlsterm, Rezidivs is an umlsterm

DerChirurg.70681023.ger.abstr_task1

Sentence: Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin . Instructions: please typing these entity words according to sentence: Patienten, Tumors, Lymphknoten, Lokalrezidivrate, Analyse, Lymphknoten, Lokalrezidivrate, Lymphknoten, Gesamtkrankengut, multivariaten Analyse, Lymphknoten, Lokalrezidivrate, Lokalrezidivrate, Rezidivs Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin .

[ "Zusammenfassung", ".", "Vom", "1", ".", "1", ".", "1985", "bis", "zum", "31", ".", "12", ".", "1995", "wurde", "bei", "386", "Patienten", "mit", "einem", "Rectumcarcinom", "im", "UICC", "-", "Stadium", "I", "-", "III", "nach", "konventionell", "chirurgischen", "Eingriffen", "und", "R0-Resektion", "des", "Tumors", "der", "Einfluss", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "auf", "Tumorstaging", "und", "Lokalrezidivrate", "retrospektiv", "untersucht", ".", "In", "der", "univariaten", "Analyse", "fanden", "wir", "einen", "signifikanten", "Zusammenhang", "zwischen", "der", "Zahl", "der", "dissezierten", "und", "der", "Zahl", "der", "befallenen", "Lymphknoten", ",", "und", "damit", "einhergehend", "eine", "signifikante", "Zunahme", "des", "UICC", "-", "Stadiums", "III", "(", "p", "=", "0,013", ")", "und", "der", "pTxpN2-Kategorie", "(", "p", "=", "0,000", ")", ".", "Eine", "signifikante", "Senkung", "der", "Lokalrezidivrate", "in", "Abhaengigkeit", "von", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "konnte", "nur", "fuer", "das", "UICC", "-", "Stadium", "I", "und", "II", "nachgewiesen", "werden", ".", "Im", "Gesamtkrankengut", "und", "in", "der", "multivariaten", "Analyse", "hatte", "die", "Zahl", "der", "dissezierten", "Lymphknoten", "keinen", "Einfluss", "auf", "die", "Lokalrezidivrate", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "die", "Senkung", "der", "Lokalrezidivrate", "im", "UICC", "-", "Stadium", "I", "und", "II", "nicht", "auf", "einen", "therapeutischen", "Effekt", ",", "sondern", "auf", "eine", "Stadienverschiebung", "im", "Rahmen", "eines", "exakteren", "Tumorstagings", "zurueckzufuehren", "ist", ".", "Dies", "weist", "auf", "den", "Einfluss", "anderer", "chirurgisch", "beeinflussbarer", "Faktoren", ",", "insbesondere", "die", "totale", "mesorectale", "Excision", "fuer", "die", "Entstehung", "eines", "locoregionaeren", "Rezidivs", "hin", "." ]

[ "umlsterm" ]

Patienten, Tumors, Lymphknoten, Lokalrezidivrate, Analyse, Lymphknoten, Lokalrezidivrate, Lymphknoten, Gesamtkrankengut, multivariaten Analyse, Lymphknoten, Lokalrezidivrate, Lokalrezidivrate, Rezidivs

DerChirurg.70681023.ger.abstr_task2

Sentence: Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Vom 1. 1. 1985 bis zum 31. 12. 1995 wurde bei 386 Patienten mit einem Rectumcarcinom im UICC-Stadium I-III nach konventionell chirurgischen Eingriffen und R0-Resektion des Tumors der Einfluss der Zahl der dissezierten Lymphknoten auf Tumorstaging und Lokalrezidivrate retrospektiv untersucht . In der univariaten Analyse fanden wir einen signifikanten Zusammenhang zwischen der Zahl der dissezierten und der Zahl der befallenen Lymphknoten , und damit einhergehend eine signifikante Zunahme des UICC-Stadiums III ( p = 0,013 ) und der pTxpN2-Kategorie ( p = 0,000 ) . Eine signifikante Senkung der Lokalrezidivrate in Abhaengigkeit von der Zahl der dissezierten Lymphknoten konnte nur fuer das UICC-Stadium I und II nachgewiesen werden . Im Gesamtkrankengut und in der multivariaten Analyse hatte die Zahl der dissezierten Lymphknoten keinen Einfluss auf die Lokalrezidivrate . Unsere Ergebnisse zeigen , dass die Senkung der Lokalrezidivrate im UICC-Stadium I und II nicht auf einen therapeutischen Effekt , sondern auf eine Stadienverschiebung im Rahmen eines exakteren Tumorstagings zurueckzufuehren ist . Dies weist auf den Einfluss anderer chirurgisch beeinflussbarer Faktoren , insbesondere die totale mesorectale Excision fuer die Entstehung eines locoregionaeren Rezidivs hin .

[ "Zusammenfassung", ".", "Vom", "1", ".", "1", ".", "1985", "bis", "zum", "31", ".", "12", ".", "1995", "wurde", "bei", "386", "Patienten", "mit", "einem", "Rectumcarcinom", "im", "UICC", "-", "Stadium", "I", "-", "III", "nach", "konventionell", "chirurgischen", "Eingriffen", "und", "R0-Resektion", "des", "Tumors", "der", "Einfluss", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "auf", "Tumorstaging", "und", "Lokalrezidivrate", "retrospektiv", "untersucht", ".", "In", "der", "univariaten", "Analyse", "fanden", "wir", "einen", "signifikanten", "Zusammenhang", "zwischen", "der", "Zahl", "der", "dissezierten", "und", "der", "Zahl", "der", "befallenen", "Lymphknoten", ",", "und", "damit", "einhergehend", "eine", "signifikante", "Zunahme", "des", "UICC", "-", "Stadiums", "III", "(", "p", "=", "0,013", ")", "und", "der", "pTxpN2-Kategorie", "(", "p", "=", "0,000", ")", ".", "Eine", "signifikante", "Senkung", "der", "Lokalrezidivrate", "in", "Abhaengigkeit", "von", "der", "Zahl", "der", "dissezierten", "Lymphknoten", "konnte", "nur", "fuer", "das", "UICC", "-", "Stadium", "I", "und", "II", "nachgewiesen", "werden", ".", "Im", "Gesamtkrankengut", "und", "in", "der", "multivariaten", "Analyse", "hatte", "die", "Zahl", "der", "dissezierten", "Lymphknoten", "keinen", "Einfluss", "auf", "die", "Lokalrezidivrate", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "die", "Senkung", "der", "Lokalrezidivrate", "im", "UICC", "-", "Stadium", "I", "und", "II", "nicht", "auf", "einen", "therapeutischen", "Effekt", ",", "sondern", "auf", "eine", "Stadienverschiebung", "im", "Rahmen", "eines", "exakteren", "Tumorstagings", "zurueckzufuehren", "ist", ".", "Dies", "weist", "auf", "den", "Einfluss", "anderer", "chirurgisch", "beeinflussbarer", "Faktoren", ",", "insbesondere", "die", "totale", "mesorectale", "Excision", "fuer", "die", "Entstehung", "eines", "locoregionaeren", "Rezidivs", "hin", "." ]

[ "umlsterm" ]

Group A streptococcus is a Organism, human is a Organism, emm49 GAS is a Organism, human is a Organism, GAS is a Organism, GAS is a Organism, human is a Organism, GAS is a Organism, non - invasive GAS is a Organism, invasive GAS is a Organism, human is a Organism, invasive GAS is a Organism, human is a Organism

67_task0

Sentence: Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism

[ "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O" ]

Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN.

[ "Results", "\n", "Group", "A", "streptococcus", "isolates", "from", "severe", "invasive", "infections", "is", "resistant", "to", "killing", "by", "human", "PMN", "To", "examine", "whether", "emm49", "GAS", "isolated", "from", "severe", "invasive", "infection", "might", "alter", "human", "PMN", "function", ",", "we", "performed", "phagocytosis", "assay", "in", "vitro", ".", "As", "non", "-", "opsonized", "GAS", "was", "resistant", "to", "the", "phagocytosis", "by", "PMN", "[", "14", "]", ",", "we", "opsonized", "GAS", "with", "human", "plasma", "in", "advance", "to", "the", "assay", ".", "As", "shown", "in", "Figure", "1A", ",", "there", "was", "no", "significant", "difference", "between", "GAS", "that", "were", "isolated", "from", "non", "-", "invasive", "and", "severe", "invasive", "infections", "in", "phagocytosis", "by", "PMN", "(", "p=0.5556", ")", ".", "However", ",", "as", "shown", "in", "Figure", "1B", ",", "in", "vitro", "killing", "assay", "revealed", "that", "PMN", "killed", "non", "-", "invasive", "GAS", ",", "resulting", "in", "15", "-", "42", "%", "of", "initial", "number", "of", "bacteria", ",", "but", "not", "invasive", "GAS", "(", "p=0.019", ")", ".", "The", "similar", "results", "were", "obtained", "when", "opsonized", "with", "either", "FCS", "or", "human", "serum", "regardless", "of", "complements", "immobilization", "(", "data", "not", "shown", ")", ".", "These", "results", "were", "common", "among", "all", "PMN", "donors", ".", "These", "data", "indicated", "that", "clinically", "isolated", "severe", "invasive", "GAS", "were", "phagocytosed", ",", "but", "escaped", "from", "killing", "by", "human", "PMN", ".", "\n" ]

[ "Organism", "Protein" ]

Group A streptococcus is a Organism, human is a Organism, emm49 GAS is a Organism, human is a Organism, GAS is a Organism, GAS is a Organism, human is a Organism, GAS is a Organism, non - invasive GAS is a Organism, invasive GAS is a Organism, human is a Organism, invasive GAS is a Organism, human is a Organism

67_task1

Sentence: Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN. Instructions: please typing these entity words according to sentence: Group A streptococcus, human, emm49 GAS, human, GAS, GAS, human, GAS, non - invasive GAS, invasive GAS, human, invasive GAS, human Options: Organism

[ "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O" ]

Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN.

[ "Results", "\n", "Group", "A", "streptococcus", "isolates", "from", "severe", "invasive", "infections", "is", "resistant", "to", "killing", "by", "human", "PMN", "To", "examine", "whether", "emm49", "GAS", "isolated", "from", "severe", "invasive", "infection", "might", "alter", "human", "PMN", "function", ",", "we", "performed", "phagocytosis", "assay", "in", "vitro", ".", "As", "non", "-", "opsonized", "GAS", "was", "resistant", "to", "the", "phagocytosis", "by", "PMN", "[", "14", "]", ",", "we", "opsonized", "GAS", "with", "human", "plasma", "in", "advance", "to", "the", "assay", ".", "As", "shown", "in", "Figure", "1A", ",", "there", "was", "no", "significant", "difference", "between", "GAS", "that", "were", "isolated", "from", "non", "-", "invasive", "and", "severe", "invasive", "infections", "in", "phagocytosis", "by", "PMN", "(", "p=0.5556", ")", ".", "However", ",", "as", "shown", "in", "Figure", "1B", ",", "in", "vitro", "killing", "assay", "revealed", "that", "PMN", "killed", "non", "-", "invasive", "GAS", ",", "resulting", "in", "15", "-", "42", "%", "of", "initial", "number", "of", "bacteria", ",", "but", "not", "invasive", "GAS", "(", "p=0.019", ")", ".", "The", "similar", "results", "were", "obtained", "when", "opsonized", "with", "either", "FCS", "or", "human", "serum", "regardless", "of", "complements", "immobilization", "(", "data", "not", "shown", ")", ".", "These", "results", "were", "common", "among", "all", "PMN", "donors", ".", "These", "data", "indicated", "that", "clinically", "isolated", "severe", "invasive", "GAS", "were", "phagocytosed", ",", "but", "escaped", "from", "killing", "by", "human", "PMN", ".", "\n" ]

[ "Organism", "Protein" ]

Group A streptococcus, human, emm49 GAS, human, GAS, GAS, human, GAS, non - invasive GAS, invasive GAS, human, invasive GAS, human

67_task2

Sentence: Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O" ]

Results Group A streptococcus isolates from severe invasive infections is resistant to killing by human PMN To examine whether emm49 GAS isolated from severe invasive infection might alter human PMN function, we performed phagocytosis assay in vitro. As non-opsonized GAS was resistant to the phagocytosis by PMN [14], we opsonized GAS with human plasma in advance to the assay. As shown in Figure 1A, there was no significant difference between GAS that were isolated from non-invasive and severe invasive infections in phagocytosis by PMN (p=0.5556). However, as shown in Figure 1B, in vitro killing assay revealed that PMN killed non-invasive GAS, resulting in 15-42% of initial number of bacteria, but not invasive GAS (p=0.019). The similar results were obtained when opsonized with either FCS or human serum regardless of complements immobilization (data not shown). These results were common among all PMN donors. These data indicated that clinically isolated severe invasive GAS were phagocytosed, but escaped from killing by human PMN.

[ "Results", "\n", "Group", "A", "streptococcus", "isolates", "from", "severe", "invasive", "infections", "is", "resistant", "to", "killing", "by", "human", "PMN", "To", "examine", "whether", "emm49", "GAS", "isolated", "from", "severe", "invasive", "infection", "might", "alter", "human", "PMN", "function", ",", "we", "performed", "phagocytosis", "assay", "in", "vitro", ".", "As", "non", "-", "opsonized", "GAS", "was", "resistant", "to", "the", "phagocytosis", "by", "PMN", "[", "14", "]", ",", "we", "opsonized", "GAS", "with", "human", "plasma", "in", "advance", "to", "the", "assay", ".", "As", "shown", "in", "Figure", "1A", ",", "there", "was", "no", "significant", "difference", "between", "GAS", "that", "were", "isolated", "from", "non", "-", "invasive", "and", "severe", "invasive", "infections", "in", "phagocytosis", "by", "PMN", "(", "p=0.5556", ")", ".", "However", ",", "as", "shown", "in", "Figure", "1B", ",", "in", "vitro", "killing", "assay", "revealed", "that", "PMN", "killed", "non", "-", "invasive", "GAS", ",", "resulting", "in", "15", "-", "42", "%", "of", "initial", "number", "of", "bacteria", ",", "but", "not", "invasive", "GAS", "(", "p=0.019", ")", ".", "The", "similar", "results", "were", "obtained", "when", "opsonized", "with", "either", "FCS", "or", "human", "serum", "regardless", "of", "complements", "immobilization", "(", "data", "not", "shown", ")", ".", "These", "results", "were", "common", "among", "all", "PMN", "donors", ".", "These", "data", "indicated", "that", "clinically", "isolated", "severe", "invasive", "GAS", "were", "phagocytosed", ",", "but", "escaped", "from", "killing", "by", "human", "PMN", ".", "\n" ]

[ "Organism", "Protein" ]

Clinical investigation is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, patients is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, patients is an umlsterm, proven is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, tumor is an umlsterm, stage is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, Histograph is an umlsterm, tumor is an umlsterm, hemoglobin concentration is an umlsterm, cells is an umlsterm, tumors is an umlsterm, cells is an umlsterm, relative is an umlsterm, frequency is an umlsterm, values is an umlsterm, hemoglobin concentration is an umlsterm, tumor is an umlsterm, association is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, hypoxia is an umlsterm, malignancy is an umlsterm, tumor is an umlsterm, cells is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, tumors is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, selection is an umlsterm, tumor is an umlsterm, cells is an umlsterm, malignant is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, research is an umlsterm

Strahlentherapie+Onkologie.01760475.eng.abstr_task0

Sentence: Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship .

[ "Clinical", "investigation", "of", "a", "potential", "relationship", "between", "the", "polarographically", "measured", "tumor", "oxygenation", "and", "the", "p53", "status", "in", "patients", "with", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", ".", "In", "99", "patients", "with", "mostly", "advanced", ",", "histologically", "proven", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "were", "estimated", "the", "classical", "tumor", "parameters", "(", "TNM", "stage", ",", "histological", "grading", ")", "the", "immunohistochemical", "p53-overexpression", "(", "DO-7", ")", "and", "the", "tumor", "oxygenation", "status", "(", "Eppendorf", "pO2", "Histograph", ")", ".", "The", "tumor", "volume", "and", "the", "hemoglobin", "concentration", "were", "evaluated", "simultaneously", ".", "No", "statistically", "significant", "difference", "could", "be", "detected", "between", "immunohistological", "p53-positive", "(", "p53", ">", "=", "10", "%", "stained", "cells", ")", "and", "p53-negative", "tumors", "(", "p53", "10", "%", "stained", "cells", ")", "regarding", "both", "the", "median", "pO2", "and", "the", "relative", "frequency", "of", "values", "=", "5", "mm", "Hg", ".", "Moreover", ",", "no", "statistically", "relevant", "differences", "could", "be", "seen", "between", "both", "p53-groups", "considering", "the", "hemoglobin", "concentration", ",", "the", "TNM", "stag", ",", "the", "histological", "grading", "and", "the", "tumor", "volume", ".", "Our", "data", "imply", "that", "there", "is", "no", "association", "between", "p53-overexpression", "and", "tumor", "hypoxia", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "this", "is", "not", "necessarily", "in", "contradiction", "to", "experimental", "or", "clinical", "data", "that", "confirmed", "a", "relationship", "between", "hypoxia", "and", "p53-mediated", "increased", "malignancy", "of", "tumor", "cells", "in", "other", "tumor", "entities", ".", "The", "comparable", "oxygenation", "status", "of", "p53-positive", "and", "p53-negative", "tumors", "in", "our", "study", "is", "associated", "with", "an", "analogous", "clinical", "tumor", "aggressiveness", "of", "both", "groups", ".", "That", "could", "be", "caused", "by", "hypoxia", "related", "but", "p53-independent", "selection", "of", "tumor", "cells", "with", "a", "more", "malignant", "phenotype", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "further", "research", "is", "needed", "to", "prove", "this", "possible", "relationship", "." ]

[ "umlsterm" ]

Clinical investigation is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, patients is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, patients is an umlsterm, proven is an umlsterm, squamous cell carcinoma is an umlsterm, head is an umlsterm, neck is an umlsterm, tumor is an umlsterm, stage is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, Histograph is an umlsterm, tumor is an umlsterm, hemoglobin concentration is an umlsterm, cells is an umlsterm, tumors is an umlsterm, cells is an umlsterm, relative is an umlsterm, frequency is an umlsterm, values is an umlsterm, hemoglobin concentration is an umlsterm, tumor is an umlsterm, association is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, hypoxia is an umlsterm, malignancy is an umlsterm, tumor is an umlsterm, cells is an umlsterm, tumor is an umlsterm, oxygenation is an umlsterm, tumors is an umlsterm, tumor is an umlsterm, hypoxia is an umlsterm, selection is an umlsterm, tumor is an umlsterm, cells is an umlsterm, malignant is an umlsterm, head is an umlsterm, neck is an umlsterm, carcinomas is an umlsterm, research is an umlsterm

Strahlentherapie+Onkologie.01760475.eng.abstr_task1

Sentence: Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship . Instructions: please typing these entity words according to sentence: Clinical investigation, tumor, oxygenation, patients, squamous cell carcinoma, head, neck, patients, proven, squamous cell carcinoma, head, neck, tumor, stage, tumor, oxygenation, Histograph, tumor, hemoglobin concentration, cells, tumors, cells, relative, frequency, values, hemoglobin concentration, tumor, association, tumor, hypoxia, head, neck, carcinomas, hypoxia, malignancy, tumor, cells, tumor, oxygenation, tumors, tumor, hypoxia, selection, tumor, cells, malignant, head, neck, carcinomas, research Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship .

[ "Clinical", "investigation", "of", "a", "potential", "relationship", "between", "the", "polarographically", "measured", "tumor", "oxygenation", "and", "the", "p53", "status", "in", "patients", "with", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", ".", "In", "99", "patients", "with", "mostly", "advanced", ",", "histologically", "proven", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "were", "estimated", "the", "classical", "tumor", "parameters", "(", "TNM", "stage", ",", "histological", "grading", ")", "the", "immunohistochemical", "p53-overexpression", "(", "DO-7", ")", "and", "the", "tumor", "oxygenation", "status", "(", "Eppendorf", "pO2", "Histograph", ")", ".", "The", "tumor", "volume", "and", "the", "hemoglobin", "concentration", "were", "evaluated", "simultaneously", ".", "No", "statistically", "significant", "difference", "could", "be", "detected", "between", "immunohistological", "p53-positive", "(", "p53", ">", "=", "10", "%", "stained", "cells", ")", "and", "p53-negative", "tumors", "(", "p53", "10", "%", "stained", "cells", ")", "regarding", "both", "the", "median", "pO2", "and", "the", "relative", "frequency", "of", "values", "=", "5", "mm", "Hg", ".", "Moreover", ",", "no", "statistically", "relevant", "differences", "could", "be", "seen", "between", "both", "p53-groups", "considering", "the", "hemoglobin", "concentration", ",", "the", "TNM", "stag", ",", "the", "histological", "grading", "and", "the", "tumor", "volume", ".", "Our", "data", "imply", "that", "there", "is", "no", "association", "between", "p53-overexpression", "and", "tumor", "hypoxia", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "this", "is", "not", "necessarily", "in", "contradiction", "to", "experimental", "or", "clinical", "data", "that", "confirmed", "a", "relationship", "between", "hypoxia", "and", "p53-mediated", "increased", "malignancy", "of", "tumor", "cells", "in", "other", "tumor", "entities", ".", "The", "comparable", "oxygenation", "status", "of", "p53-positive", "and", "p53-negative", "tumors", "in", "our", "study", "is", "associated", "with", "an", "analogous", "clinical", "tumor", "aggressiveness", "of", "both", "groups", ".", "That", "could", "be", "caused", "by", "hypoxia", "related", "but", "p53-independent", "selection", "of", "tumor", "cells", "with", "a", "more", "malignant", "phenotype", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "further", "research", "is", "needed", "to", "prove", "this", "possible", "relationship", "." ]

[ "umlsterm" ]

Clinical investigation, tumor, oxygenation, patients, squamous cell carcinoma, head, neck, patients, proven, squamous cell carcinoma, head, neck, tumor, stage, tumor, oxygenation, Histograph, tumor, hemoglobin concentration, cells, tumors, cells, relative, frequency, values, hemoglobin concentration, tumor, association, tumor, hypoxia, head, neck, carcinomas, hypoxia, malignancy, tumor, cells, tumor, oxygenation, tumors, tumor, hypoxia, selection, tumor, cells, malignant, head, neck, carcinomas, research

Strahlentherapie+Onkologie.01760475.eng.abstr_task2

Sentence: Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinical investigation of a potential relationship between the polarographically measured tumor oxygenation and the p53 status in patients with squamous cell carcinoma of the head and neck . In 99 patients with mostly advanced , histologically proven squamous cell carcinoma of the head and neck were estimated the classical tumor parameters ( TNM stage , histological grading ) the immunohistochemical p53-overexpression ( DO-7) and the tumor oxygenation status ( Eppendorf pO2 Histograph ) . The tumor volume and the hemoglobin concentration were evaluated simultaneously . No statistically significant difference could be detected between immunohistological p53-positive ( p53 > = 10% stained cells ) and p53-negative tumors ( p53 10% stained cells ) regarding both the median pO2 and the relative frequency of values = 5 mm Hg. Moreover , no statistically relevant differences could be seen between both p53-groups considering the hemoglobin concentration , the TNM stag , the histological grading and the tumor volume . Our data imply that there is no association between p53-overexpression and tumor hypoxia in head and neck carcinomas . However , this is not necessarily in contradiction to experimental or clinical data that confirmed a relationship between hypoxia and p53-mediated increased malignancy of tumor cells in other tumor entities . The comparable oxygenation status of p53-positive and p53-negative tumors in our study is associated with an analogous clinical tumor aggressiveness of both groups . That could be caused by hypoxia related but p53-independent selection of tumor cells with a more malignant phenotype in head and neck carcinomas . However , further research is needed to prove this possible relationship .

[ "Clinical", "investigation", "of", "a", "potential", "relationship", "between", "the", "polarographically", "measured", "tumor", "oxygenation", "and", "the", "p53", "status", "in", "patients", "with", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", ".", "In", "99", "patients", "with", "mostly", "advanced", ",", "histologically", "proven", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "were", "estimated", "the", "classical", "tumor", "parameters", "(", "TNM", "stage", ",", "histological", "grading", ")", "the", "immunohistochemical", "p53-overexpression", "(", "DO-7", ")", "and", "the", "tumor", "oxygenation", "status", "(", "Eppendorf", "pO2", "Histograph", ")", ".", "The", "tumor", "volume", "and", "the", "hemoglobin", "concentration", "were", "evaluated", "simultaneously", ".", "No", "statistically", "significant", "difference", "could", "be", "detected", "between", "immunohistological", "p53-positive", "(", "p53", ">", "=", "10", "%", "stained", "cells", ")", "and", "p53-negative", "tumors", "(", "p53", "10", "%", "stained", "cells", ")", "regarding", "both", "the", "median", "pO2", "and", "the", "relative", "frequency", "of", "values", "=", "5", "mm", "Hg", ".", "Moreover", ",", "no", "statistically", "relevant", "differences", "could", "be", "seen", "between", "both", "p53-groups", "considering", "the", "hemoglobin", "concentration", ",", "the", "TNM", "stag", ",", "the", "histological", "grading", "and", "the", "tumor", "volume", ".", "Our", "data", "imply", "that", "there", "is", "no", "association", "between", "p53-overexpression", "and", "tumor", "hypoxia", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "this", "is", "not", "necessarily", "in", "contradiction", "to", "experimental", "or", "clinical", "data", "that", "confirmed", "a", "relationship", "between", "hypoxia", "and", "p53-mediated", "increased", "malignancy", "of", "tumor", "cells", "in", "other", "tumor", "entities", ".", "The", "comparable", "oxygenation", "status", "of", "p53-positive", "and", "p53-negative", "tumors", "in", "our", "study", "is", "associated", "with", "an", "analogous", "clinical", "tumor", "aggressiveness", "of", "both", "groups", ".", "That", "could", "be", "caused", "by", "hypoxia", "related", "but", "p53-independent", "selection", "of", "tumor", "cells", "with", "a", "more", "malignant", "phenotype", "in", "head", "and", "neck", "carcinomas", ".", "However", ",", "further", "research", "is", "needed", "to", "prove", "this", "possible", "relationship", "." ]

[ "umlsterm" ]

vitamin D3 supplementation is a Intervention_Pharmacological, children and young adults is a Participant_Age, HIV : is a Outcome_Physical, placebo - controlled trial is a Intervention_Control, HIV - infected is a Participant_Condition, safety and efficacy is a Outcome_Other, 7000 IU vitamin D3 is a Intervention_Pharmacological, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status is a Outcome_Physical, HIV - infected subjects is a Participant_Condition, perinatally acquired HIV ( PHIV ) -infected subjects is a Participant_Condition, behaviorally acquired HIV ( BHIV ) -infected subjects is a Participant_Condition, 5.0 - 24.9 years is a Participant_Age, Safety is a Outcome_Other, 25 ( OH ) D - related parameters is a Outcome_Other, Fifty - eight subjects enrolled is a Participant_Sample-size, 67 % male is a Participant_Sex, 85 % African American is a Participant_Sample-size, 64 % is a Participant_Sample-size, 50 completed with no safety concerns is a Participant_Sample-size, Percentage of naive T - helper cells ( Th naive % ) is a Outcome_Physical, T - helper cells ( CD4 % ) is a Outcome_Physical, RNA viral load is a Outcome_Physical, in 25 ( OH ) D predicted RNA viral load is a Outcome_Physical, and CD4 % is a Outcome_Physical, increasing 25 ( OH ) is a Outcome_Physical, some clinically important HIV immune markers is a Outcome_Physical

66554_task0

Sentence: High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation .

[ "High", "-", "dose", "vitamin", "D3", "supplementation", "in", "children", "and", "young", "adults", "with", "HIV", ":", "a", "randomized", ",", "placebo", "-", "controlled", "trial", ".", "BACKGROUND", "Suboptimal", "vitamin", "D", "status", "is", "prevalent", "in", "HIV", "-", "infected", "patients", "and", "associated", "with", "increased", "risk", "of", "disease", "severity", "and", "morbidity", ".", "We", "aimed", "to", "determine", "12-month", "safety", "and", "efficacy", "of", "daily", "7000", "IU", "vitamin", "D3", "(", "vitD3", ")", "versus", "placebo", "to", "sustain", "increased", "serum", "25-hydroxyvitamin", "D", "(", "25", "(", "OH", ")", "D", ")", "and", "improve", "immune", "status", "in", "HIV", "-", "infected", "subjects", ".", "METHODS", "This", "was", "a", "double", "-", "blind", "trial", "of", "perinatally", "acquired", "HIV", "(", "PHIV", ")", "-infected", "subjects", "or", "behaviorally", "acquired", "HIV", "(", "BHIV", ")", "-infected", "subjects", "(", "5.0", "-", "24.9", "years", ")", ".", "Safety", ",", "25", "(", "OH", ")", "D", "-", "related", "parameters", "and", "immune", "status", "were", "assessed", "at", "baseline", ",", "3", ",", "6", "and", "12", "months", ".", "RESULTS", "Fifty", "-", "eight", "subjects", "enrolled", "(", "67", "%", "male", ",", "85", "%", "African", "American", "and", "64", "%", "BHIV", ")", "and", "50", "completed", "with", "no", "safety", "concerns", ".", "In", "unadjusted", "analyses", ",", "there", "were", "no", "differences", "between", "randomization", "groups", "at", "baseline", ";", "at", "3", ",", "6", "and", "12", "months", ",", "25", "(", "OH", ")", "D", "was", "higher", "with", "supplementation", "than", "baseline", "and", "higher", "than", "with", "placebo", "(", "P", "<", "0.05", ")", ".", "In", "adjusted", "mixed", "models", ",", "in", "the", "supplementation", "group", ",", "the", "fixed", "effect", "of", "25", "(", "OH", ")", "D", "was", "higher", "(", "P", "<", "0.001", ")", ".", "Percentage", "of", "naive", "T", "-", "helper", "cells", "(", "Th", "naive", "%", ")", "were", "significantly", "(", "P", "<", "0.01", ")", "and", "T", "-", "helper", "cells", "(", "CD4", "%", ")", "marginally", "(", "P", "<", "0.10", ")", "increased", "with", "supplementation", "in", "those", "taking", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", ",", "and", "RNA", "viral", "load", "was", "reduced", "(", "P", "≤", "0.05", ")", ".", "In", "exploratory", "linear", "models", ",", "change", "in", "25", "(", "OH", ")", "D", "predicted", "RNA", "viral", "load", "at", "3", "and", "12", "months", "and", "CD4", "%", "at", "3", "months", "(", "P", "<", "0.05", ")", ".", "CONCLUSIONS", "Daily", "7000", "IU", "vitD3", "for", "12", "months", "was", "safe", "in", "HIV", "-", "infected", "subjects", "and", "effective", "in", "increasing", "25", "(", "OH", ")", "D.", "Supplementation", "improved", "some", "clinically", "important", "HIV", "immune", "markers", "in", "subjects", "on", "HAART", ".", "Adjunct", "therapy", "with", "high", "-", "dose", ",", "daily", "vitD3", "for", "HIV", "-", "infected", "subjects", "and", "for", "those", "on", "/", "off", "HAART", "requires", "further", "investigation", "." ]

[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Sex" ]

vitamin D3 supplementation is a Intervention_Pharmacological, children and young adults is a Participant_Age, HIV : is a Outcome_Physical, placebo - controlled trial is a Intervention_Control, HIV - infected is a Participant_Condition, safety and efficacy is a Outcome_Other, 7000 IU vitamin D3 is a Intervention_Pharmacological, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status is a Outcome_Physical, HIV - infected subjects is a Participant_Condition, perinatally acquired HIV ( PHIV ) -infected subjects is a Participant_Condition, behaviorally acquired HIV ( BHIV ) -infected subjects is a Participant_Condition, 5.0 - 24.9 years is a Participant_Age, Safety is a Outcome_Other, 25 ( OH ) D - related parameters is a Outcome_Other, Fifty - eight subjects enrolled is a Participant_Sample-size, 67 % male is a Participant_Sex, 85 % African American is a Participant_Sample-size, 64 % is a Participant_Sample-size, 50 completed with no safety concerns is a Participant_Sample-size, Percentage of naive T - helper cells ( Th naive % ) is a Outcome_Physical, T - helper cells ( CD4 % ) is a Outcome_Physical, RNA viral load is a Outcome_Physical, in 25 ( OH ) D predicted RNA viral load is a Outcome_Physical, and CD4 % is a Outcome_Physical, increasing 25 ( OH ) is a Outcome_Physical, some clinically important HIV immune markers is a Outcome_Physical

66554_task1

Sentence: High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation . Instructions: please typing these entity words according to sentence: vitamin D3 supplementation, children and young adults, HIV :, placebo - controlled trial, HIV - infected, safety and efficacy, 7000 IU vitamin D3, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status, HIV - infected subjects, perinatally acquired HIV ( PHIV ) -infected subjects, behaviorally acquired HIV ( BHIV ) -infected subjects, 5.0 - 24.9 years, Safety, 25 ( OH ) D - related parameters, Fifty - eight subjects enrolled, 67 % male, 85 % African American, 64 %, 50 completed with no safety concerns, Percentage of naive T - helper cells ( Th naive % ), T - helper cells ( CD4 % ), RNA viral load, in 25 ( OH ) D predicted RNA viral load, and CD4 %, increasing 25 ( OH ), some clinically important HIV immune markers Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation .

[ "High", "-", "dose", "vitamin", "D3", "supplementation", "in", "children", "and", "young", "adults", "with", "HIV", ":", "a", "randomized", ",", "placebo", "-", "controlled", "trial", ".", "BACKGROUND", "Suboptimal", "vitamin", "D", "status", "is", "prevalent", "in", "HIV", "-", "infected", "patients", "and", "associated", "with", "increased", "risk", "of", "disease", "severity", "and", "morbidity", ".", "We", "aimed", "to", "determine", "12-month", "safety", "and", "efficacy", "of", "daily", "7000", "IU", "vitamin", "D3", "(", "vitD3", ")", "versus", "placebo", "to", "sustain", "increased", "serum", "25-hydroxyvitamin", "D", "(", "25", "(", "OH", ")", "D", ")", "and", "improve", "immune", "status", "in", "HIV", "-", "infected", "subjects", ".", "METHODS", "This", "was", "a", "double", "-", "blind", "trial", "of", "perinatally", "acquired", "HIV", "(", "PHIV", ")", "-infected", "subjects", "or", "behaviorally", "acquired", "HIV", "(", "BHIV", ")", "-infected", "subjects", "(", "5.0", "-", "24.9", "years", ")", ".", "Safety", ",", "25", "(", "OH", ")", "D", "-", "related", "parameters", "and", "immune", "status", "were", "assessed", "at", "baseline", ",", "3", ",", "6", "and", "12", "months", ".", "RESULTS", "Fifty", "-", "eight", "subjects", "enrolled", "(", "67", "%", "male", ",", "85", "%", "African", "American", "and", "64", "%", "BHIV", ")", "and", "50", "completed", "with", "no", "safety", "concerns", ".", "In", "unadjusted", "analyses", ",", "there", "were", "no", "differences", "between", "randomization", "groups", "at", "baseline", ";", "at", "3", ",", "6", "and", "12", "months", ",", "25", "(", "OH", ")", "D", "was", "higher", "with", "supplementation", "than", "baseline", "and", "higher", "than", "with", "placebo", "(", "P", "<", "0.05", ")", ".", "In", "adjusted", "mixed", "models", ",", "in", "the", "supplementation", "group", ",", "the", "fixed", "effect", "of", "25", "(", "OH", ")", "D", "was", "higher", "(", "P", "<", "0.001", ")", ".", "Percentage", "of", "naive", "T", "-", "helper", "cells", "(", "Th", "naive", "%", ")", "were", "significantly", "(", "P", "<", "0.01", ")", "and", "T", "-", "helper", "cells", "(", "CD4", "%", ")", "marginally", "(", "P", "<", "0.10", ")", "increased", "with", "supplementation", "in", "those", "taking", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", ",", "and", "RNA", "viral", "load", "was", "reduced", "(", "P", "≤", "0.05", ")", ".", "In", "exploratory", "linear", "models", ",", "change", "in", "25", "(", "OH", ")", "D", "predicted", "RNA", "viral", "load", "at", "3", "and", "12", "months", "and", "CD4", "%", "at", "3", "months", "(", "P", "<", "0.05", ")", ".", "CONCLUSIONS", "Daily", "7000", "IU", "vitD3", "for", "12", "months", "was", "safe", "in", "HIV", "-", "infected", "subjects", "and", "effective", "in", "increasing", "25", "(", "OH", ")", "D.", "Supplementation", "improved", "some", "clinically", "important", "HIV", "immune", "markers", "in", "subjects", "on", "HAART", ".", "Adjunct", "therapy", "with", "high", "-", "dose", ",", "daily", "vitD3", "for", "HIV", "-", "infected", "subjects", "and", "for", "those", "on", "/", "off", "HAART", "requires", "further", "investigation", "." ]

[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Sex" ]

vitamin D3 supplementation, children and young adults, HIV :, placebo - controlled trial, HIV - infected, safety and efficacy, 7000 IU vitamin D3, increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status, HIV - infected subjects, perinatally acquired HIV ( PHIV ) -infected subjects, behaviorally acquired HIV ( BHIV ) -infected subjects, 5.0 - 24.9 years, Safety, 25 ( OH ) D - related parameters, Fifty - eight subjects enrolled, 67 % male, 85 % African American, 64 %, 50 completed with no safety concerns, Percentage of naive T - helper cells ( Th naive % ), T - helper cells ( CD4 % ), RNA viral load, in 25 ( OH ) D predicted RNA viral load, and CD4 %, increasing 25 ( OH ), some clinically important HIV immune markers

66554_task2

Sentence: High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation .

[ "High", "-", "dose", "vitamin", "D3", "supplementation", "in", "children", "and", "young", "adults", "with", "HIV", ":", "a", "randomized", ",", "placebo", "-", "controlled", "trial", ".", "BACKGROUND", "Suboptimal", "vitamin", "D", "status", "is", "prevalent", "in", "HIV", "-", "infected", "patients", "and", "associated", "with", "increased", "risk", "of", "disease", "severity", "and", "morbidity", ".", "We", "aimed", "to", "determine", "12-month", "safety", "and", "efficacy", "of", "daily", "7000", "IU", "vitamin", "D3", "(", "vitD3", ")", "versus", "placebo", "to", "sustain", "increased", "serum", "25-hydroxyvitamin", "D", "(", "25", "(", "OH", ")", "D", ")", "and", "improve", "immune", "status", "in", "HIV", "-", "infected", "subjects", ".", "METHODS", "This", "was", "a", "double", "-", "blind", "trial", "of", "perinatally", "acquired", "HIV", "(", "PHIV", ")", "-infected", "subjects", "or", "behaviorally", "acquired", "HIV", "(", "BHIV", ")", "-infected", "subjects", "(", "5.0", "-", "24.9", "years", ")", ".", "Safety", ",", "25", "(", "OH", ")", "D", "-", "related", "parameters", "and", "immune", "status", "were", "assessed", "at", "baseline", ",", "3", ",", "6", "and", "12", "months", ".", "RESULTS", "Fifty", "-", "eight", "subjects", "enrolled", "(", "67", "%", "male", ",", "85", "%", "African", "American", "and", "64", "%", "BHIV", ")", "and", "50", "completed", "with", "no", "safety", "concerns", ".", "In", "unadjusted", "analyses", ",", "there", "were", "no", "differences", "between", "randomization", "groups", "at", "baseline", ";", "at", "3", ",", "6", "and", "12", "months", ",", "25", "(", "OH", ")", "D", "was", "higher", "with", "supplementation", "than", "baseline", "and", "higher", "than", "with", "placebo", "(", "P", "<", "0.05", ")", ".", "In", "adjusted", "mixed", "models", ",", "in", "the", "supplementation", "group", ",", "the", "fixed", "effect", "of", "25", "(", "OH", ")", "D", "was", "higher", "(", "P", "<", "0.001", ")", ".", "Percentage", "of", "naive", "T", "-", "helper", "cells", "(", "Th", "naive", "%", ")", "were", "significantly", "(", "P", "<", "0.01", ")", "and", "T", "-", "helper", "cells", "(", "CD4", "%", ")", "marginally", "(", "P", "<", "0.10", ")", "increased", "with", "supplementation", "in", "those", "taking", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", ",", "and", "RNA", "viral", "load", "was", "reduced", "(", "P", "≤", "0.05", ")", ".", "In", "exploratory", "linear", "models", ",", "change", "in", "25", "(", "OH", ")", "D", "predicted", "RNA", "viral", "load", "at", "3", "and", "12", "months", "and", "CD4", "%", "at", "3", "months", "(", "P", "<", "0.05", ")", ".", "CONCLUSIONS", "Daily", "7000", "IU", "vitD3", "for", "12", "months", "was", "safe", "in", "HIV", "-", "infected", "subjects", "and", "effective", "in", "increasing", "25", "(", "OH", ")", "D.", "Supplementation", "improved", "some", "clinically", "important", "HIV", "immune", "markers", "in", "subjects", "on", "HAART", ".", "Adjunct", "therapy", "with", "high", "-", "dose", ",", "daily", "vitD3", "for", "HIV", "-", "infected", "subjects", "and", "for", "those", "on", "/", "off", "HAART", "requires", "further", "investigation", "." ]

[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Sex" ]